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Background: Smoking cessation/quitting smoking is among the most important health-
promoting life changes a person can make, and is the most cost-effective disease prevention 
intervention available. Despite the benefits, many smokers have difficulty quitting using 
current smoking cessation options and the incidence of smoking relapse is high. Alternative 
treatments that are safe, effective, relatively inexpensive, and readily available are needed. 
Broad-spectrum micronutrient (minerals and vitamins) supplements are one such possible 
alternative. Research on the use of micronutrients in the treatment of substance 
dependence has existed for half a century. Investigations in to the use of micronutrients to 
relieve psychological symptoms has grown substantially in the past decade and has now 
been demonstrated in a number of trials. This thesis presents two randomised control trials 
to investigate whether a broad spectrum mineral vitamin formula supports smoking 
cessation. Aim Study One: Study one, a pilot trial, investigated if a broad-spectrum 
micronutrient formula supports withdrawal, smoking cessation, cigarette/day reduction and 
associated psychological symptoms. Methods: This pilot study was a single-case multiple-
baseline design with replication across participants (n=24), nested within an active 
treatment-placebo double-blind randomized trial. Following a baseline phase of one to 
three weeks when smoking history, daily cigarette consumption (cigarettes/day), 
withdrawal, and nicotine dependence were measured, 24 participants were randomized 
(12/group) to placebo or micronutrient conditions. A four-week pre-quit phase permitted 
titration up to 12 capsules/day and ensured the metabolic effects of the capsules were 
established before quitting. In the smoking cessation phase (12 weeks duration), 
participants registered with Quitline NZ (not including Nicotine Replacement Therapy 
(NRT)), read the Quit book, and continued to consume the 12/day micronutrient or placebo 
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capsules while attempting to quit smoking from a target quit day. Participants were counted 
as having a quit success if they were abstinent for ≥three days after their quit day. Quit 
success was established through self-report at study waypoints (4, 8, and 12 weeks post quit 
day). Abstinence was counted if a participant had not relapsed (≥three continuous days 
smoking) from their quit date to the end of the study waypoint. Daily withdrawal measures 
were taken at weeks 1-4, 8, and 12 post quit. Monthly withdrawal and psychological 
measures were completed at each study waypoint. Results: The results showed that median 
withdrawal scores were higher in the placebo group. Drop-out before making a quit attempt 
was lower in the micronutrient group (0 vs 4) and those taking micronutrients were more 
likely to make a quit attempt (11 (91.7%) vs 5 (41.7%); Odds Ratio (OR) = 15.4; 95% 
Confidence Interval (CI) [1.47, 160.98]) and be successful at quitting (≥ 3 days smoke-free) 
(10 (83.0)% vs 4 (33.3%); OR = 10.0; 95% CI [1.44,69.26]). The micronutrient group had a 
higher quit rate at four weeks (58.3%) compared to placebo (25.0%), this was not significant 
(χ2 (1, n= 24) = 2.74, P=0.10), and NNT=13. Aim Study Two: Study two, a fully-blinded 
randomised placebo-controlled trial was designed to further investigate the use of a broad-
spectrum micronutrient formula to assist with quitting smoking, reduction of cigarettes/day, 
withdrawal symptoms, and associated psychological symptoms. Methods: Following the 
baseline phase (one to two weeks) when smoking history, daily cigarette consumption 
(cigarettes/day), withdrawal, and nicotine dependence were measured participants (n=107) 
were randomised to placebo (n=50) or micronutrient conditions (n=57). A four-week pre-
quit phase permitted titration up to 12 capsules/day. During the quit phase participants 
were registered with a public Quitline (not including NRT), read the Quit book, and 
attempted to quit smoking on a target quit day while continuing to consume micronutrients 
or placebo for 12 weeks. Carbon monoxide levels and self-report confirmed continuous 
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abstinence at 4, 8, and 12 weeks post-quit. Results: Twenty-two (39%) participants in the 
micronutrient group and twenty-one (42%) in the placebo group completed the full trial. 
Micronutrient + Quitline and Placebo + Quitline groups did not differ on the primary 
outcome of continuous abstinence at 12-weeks post-quit day using intent-to-treat analysis; 
however, 28% of the micronutrient treated group had quit versus 18% for placebo 
(OR=1.78, 95%CI [0.71, 4.48]), with NNT=10. Comparison of cigarettes/day between 
micronutrient and placebo groups showed that those taking micronutrients reported 
reduced consumption throughout the trial, notably at pre-quit weeks one and four, and at 
quit phase week four. There were no serious adverse events, masking was successful and 
there were no substantive group differences in side effects or drop-out rate. Conclusion: 
The two studies presented are the first RCT’s investigating the impact of micronutrients on 
smoking reduction, finding that micronutrients support quit attempts, and reduced harm 
through reduction in number of cigarettes smoked relative to placebo. The small sample 
sizes and high drop-out rate limits confidence in the conclusions and generalizability of the 
results; however, micronutrients were shown to be comparable to other smoking cessation 
treatments but with fewer side effects. Future research using larger and longer trials 
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Chapter 1: Tobacco Smoking 
This thesis presents two randomised controlled trials (RCT; study one and two) investigating 
the effect of a broad-spectrum mineral-vitamin formula on smoking cessation outcomes, 
consumption of cigarettes, withdrawal and other psychological symptoms in adults who 
were current smokers. This introductory chapter will provide an outline of tobacco smoking, 
its prevalence, adverse health outcomes, and economic costs. Addiction, nicotine 
dependence, and withdrawal are also discussed. Furthermore, current standard smoking 
cessation interventions and at-risk populations for higher smoking prevalence and lower 
smoking cessation outcomes are outlined.  
1.1 Tobacco Smoking  
 Tobacco is a plant from the Solanaceae family within the Nicotiana genus and carries in 
its leaves quantities of an alkaloid called nicotine (Jiloha, 2010). Tobacco was initially used to 
treat various problems such as toothache and headache, and in the 18th century it began to 
be used recreationally (Thielen, Klus, & Müller, 2008). After harvesting and curing, tobacco 
leaves are manufactured into consumable products, the most common being cigarettes – a 
small quantity of tobacco wrapped in paper. Cigarette smoking, the most common method 
of tobacco consumption, is the practice of burning the tobacco inside a cigarette and 
inhaling the smoke (Thielen et al., 2008). With each puff of a lit cigarette a smoker draws 
tobacco smoke into their mouth and lungs, thus consuming a range of gases containing 
many different sized particles of approximately 4000-5000 different chemicals with nicotine 
the main chemically active and addictive component (Jiloha, 2010).  
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1.2 Prevalence of Tobacco Smoking 
The Global Burden of Disease study including 195 countries estimated in 2015 that 
the age-standardised prevalence of daily smoking was 25% in men and 5% in woman (95% 
CI 24, 26 and 5, 6 respectively) (Reitsma et al., 2017). The ten countries with the largest 
number of smokers together accounted for approximately 64% of the world's daily smokers. 
China, India, and Indonesia, the three leading countries in total number of male smokers, 
accounted for 52% of the world's male smokers in 2015. Conversely, the USA, China, and 
India, were the leading three countries in total number of female smokers, accounted for 
only approximately 27% of the world's female smokers. The prevalence of daily smokers in 
low Socio-Demographic Index (SDI) countries (29 countries) was 13% (range 7% to 22%) for 
men and 2% (range 1% to 7%) for woman in 2015. In low-to-middle SDI countries (30 
countries) 20% are daily smokers in men (range 1% to 48%) compared to 5% (range 0.4% to 
25%) in woman. Middle SDI countries (34 countries) had an average daily smoking 
prevalence of 24% in men (range 9% - 47%) and 4% (range 0.4% – 12%) in woman. High to 
middle SDI countries (55 countries) had a smoking prevalence of 24% in men and 10% in 
woman (ranges 5% to 44% and 1% to 44% respectively). High income countries (47 
countries) had a prevalence rate of 23% in men (range 4% - 46%) and 14% in woman (range 
2% to 25%) (Reitsma et al., 2017). Fifty-one countries and territories had significantly higher 
prevalence in smoking compared to the global average for men; these countries were 
mainly located in central and eastern Europe and southeast Asia. For women, 70 countries 
significantly exceeded the global average, largely located in western and central Europe 
(Reitsma et al., 2017).  
With increasing awareness of the adverse health effects of smoking and heightened 
anti-smoking campaigns, tobacco use has steadily decreased in many developed countries 
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over the past 20-30 years (Zheng et al., 2014). The global-age standardised prevalence of 
daily smoking has reduced significantly in both sexes decreasing by 29% (95% CI 26, 31) and 
34% (95% CI 30, 39), in men and women respectively, since 1990 (Reitsma et al., 2017). 
Thirteen countries (Australia, Brazil, China, Denmark, Dominican Republic, Iceland, Kenya, 
the Netherlands, New Zealand, Norway, Sweden, Switzerland, and the USA) recorded 
significant annualised rates of decline both between 1990 to 2015, suggesting sustained 
progress in tobacco control. Since 2005, 53 of 195 (27%) countries and territories recorded 
significant decreases in age-standardised prevalence of male daily smoking, whereas only 32 
(16%) recorded significant reductions for women. Nevertheless, Ng et al. (2014) who 
analysed data from 187 countries (38,315 observations) estimated that due to population 
growth the number of current smokers globally in 2014 had increased from 721 million to 
967 million since 1980 (Ng et al., 2014). 
New Zealand Smoking Prevalence 
 Aotearoa New Zealand (NZ) is a small, developed country that has had a long 
standing public health commitment to reducing smoking, not least because indigenous 
Māori have high rates of smoking and smoking-related death and disease (see 
www.health.govt.nz). A NZ Ministry of Health (Manatū Hauora) survey (approximately 
13,000 respondents) reported that 18% of NZ adults aged 15 years and over were current 
smokers in 2012-13, with current smokers defined as smoking more than 100 cigarettes in 
their lifetime and at the time of the survey smoking at least once a month1 (Ministry of 
Health, 2014). There were similar rates of current smoking across male and females (19% 
                                                        
1 There is a difference in definitions of a ‘current smoker’ between the two surveys of 1996/97 and 2012/13. 
The definition of ‘current smokers’ used in the 1996/97 NZHS is ‘those who reported that they smoked one or 
more cigarettes per day’ whereas the 2012/13 NZHS defines ‘current smokers’ as ‘those who have smoked 
more than 100 cigarettes in their lifetime and at the time of the survey were smoking at least once a month’. 
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and 16% respectively). The survey also reported that approximately 16% of adults (aged 15 
years and above) smoked daily (Ministry of Health, 2014).  
Current smoking rates in NZ are declining, with the prevalence falling significantly 
from 2006 (24%) to 2009 (21%), and again in 2012 (18%). However, the decline in smoking 
prevalence is occurring, at different rates among different population groups, with some 
declines slower than others. Individuals who identify as NZ European or Other showed a 
significant decline in tobacco smoking prevalence between 2006-07 and 2012-13. Those 
who identify as Māori, Asian, and Pacifica have also decreased in prevalence, but this is not 
statistically different from 2006-07. Māori continue to have the highest rates of smoking in 
NZ; around four in ten Māori adults (39%) were current smokers in 2012-13, a non-
significant change since 2006-07 (40%). Pacifica adults have the second highest prevalence 
in NZ with one in four (24%) identifying as current smokers in 2012-13, a non-significant 
decline since 2006-07 (26%) (Table 1.1) (Ministry of Health, 2014). Almost one in eight 
young people aged - 15–19 - years (13%) were current smokers in 2012/13. This represents 
a significant decline from the 2006/07 prevalence of one in five young people (20%). This 
age group 15–19 year olds showed the largest relative decline in current smoking 
prevalence (36%) between 2006 and 2012. In comparison, those aged 65–74 years and 25–
34 years showed 27% and 13% relative declines respectively between 2006 and 2012 









Table 1.1. Ethnic differences in prevalence of current smoking in NZ. 
Ethnic Group  2006/07 (%)  2012/13 (%) Relative % change  
Māori  42 39 -7 
Pacific 27 25 -9 
Asian 11 10 -10 
European/Other2 19 15 -18* 
Source: New Zealand Health Survey (Ministry of Health, 2014). *There is a statistically 
significant difference (p<0.05) between 2006 and 2012.  
 The Ministry of Health Survey (2014) revealed a gradient in smoking prevalence and 
neighbourhood deprivation, with 32% of smokers being from the most deprived areas 
compared to 13% in the least deprived. After adjusting for age, sex, and ethnic group, those 
who live in the most deprived areas are almost three times more likely to be smokers than 
people in the least deprived areas (Ministry of Health, 2014).  
Sex  
As discussed, there are large differences in smoking prevalence among males and 
females across countries. Women outlive men in all countries in the world, but men have a 
higher prevalence of smoking than women, and it is estimated that smoking-related deaths 
account for 40% to 60% of the gender mortality gap (McCartney, Mahmood, Leyland, Batty, 
& Hunt, 2011). The proportion of NZ females smoking in 2012 (16%) was significantly lower 
than the proportion of NZ males smoking (19%) (Ministry of Health, 2014). Conversely, there 
were significantly more Māori female smokers (42%) than Māori male smokers (37%) in 
2012/13 (Ministry of Health, 2014). Conversely, significantly more Asian males (16%) than 
Asian females (4.3%) were smokers.  
 
                                                        
2 Other includes individuals that do not identify with New Zealand European, Māori, Samoan, Cook Island 
Maori, Tongan, Niuean, Chinese, or Indian. 
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Mental health  
Tobacco use remains high in persons with mental illness (Centers for Disease Control 
and Prevention, 2013), with these individuals smoking at rates two to three times that of 
the general population (Dalton, Mellemkjær, Olsen, Mortensen, & Johansen, 2002; 
Lawrence, Mitrou, & Zubrick, 2009; Lê Cook et al., 2014; McClave, McKnight-Eily, Davis, & 
Dube, 2010). Mental illness is associated with higher levels of nicotine dependence, 
intensity of smoking, number of cigarettes smoked, greater withdrawal symptoms, and 
lower quit rates (Bowden, Miller, & Hiller, 2011; Gierisch, Bastian, Calhoun, McDuffie, & 
Williams, 2012; Lê Cook et al., 2014; Prochaska, Das, & Young-Wolff, 2017). The Ministry of 
Health survey revealed that almost a quarter (24%) of NZ smokers reported one or more 
diagnosed mental health conditions (depression, bipolar disorder, anxiety disorder, an 
alcohol-related disorder or a drug-related disorder) compared to 15% of non-smokers 
(Ministry of Health, 2014). People with mental health disorders have a life expectancy of 
eight years less than the general population and cigarette smoking may contribute to much 
of this difference (Tam, Warner, & Meza, 2016; Taylor et al., 2014).  
Many explanations for the high rate of tobacco use among people with mental 
illness have been proposed, including biological factors and psychosocial reasons such as a 
lack of social support, changes in cognitive functioning, anxiety, side effects of medications, 
and lack of coping skills (Ashton, Miller, Bowden, & Bertossa, 2010). The self-medication 
hypothesis posits that many smokers report that they smoke to alleviate emotional 
problems, and feelings of depression and anxiety, to stabilise mood, and for relaxation, as 
well as to relieve stress (Baker, Piper, McCarthy, Majeskie, & Fiore, 2004; Taylor et al., 
2014). Patients with mental illness may attribute greater benefits and reward value to 
smoking, may experience more difficult life circumstances compared to people without 
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mental illness, have higher levels of negative affect (referring to mood states marked by 
feeling angry, frustrated, irritable, sad, depressed, and distressed), and/or a relative lack of 
alternative rewards, all factors consistent with higher prevalence of smoking in these 
individuals (Ashton et al., 2010; Prochaska et al., 2017). Conversely, evidence also indicates 
that smoking may have a role in the aetiology of depression, anxiety, and schizophrenia, and 
is a gateway to problematic substance use (Prochaska et al., 2017). Therefore, bi-directional 
models maintain that smoking and psychiatric symptoms influence each other (Windle & 
Windle, 2001).  
1.3 Adverse health effects 
Smoking is associated with an array of adverse health effects, including an increased 
risk of cardiovascular disease, respiratory disease, stroke, hypertension, and cancer (Talhout 
et al., 2011; Yeomans et al., 2011). The primary reason for this is that smoking has a 
carcinogenic effect on tissues (Talhout et al., 2011; Valavanidis, Vlachogianni, & Fiotakis, 
2009). High rates of cancers in the mouth, pharynx, and lungs occur as these organs are 
directly exposed to the smoke. The oesophagus, stomach, and gut are not directly exposed 
to the smoke, but are exposed to the secretions of the mucous membranes from the mouth 
and pharynx as they are swallowed after smoking, leading to higher rates of cancers in these 
organs. Further, substances within tobacco smoke are absorbed from the lungs into the 
bloodstream and thus circulated to all parts of the body damaging many other organs and 
further contributing to whole-body adverse health events (Dreyer, Winther, Pukkala, & 
Andersen, 1997). 
Tobacco smoking is the leading cause of preventable premature mortality in the 
world (Banks et al., 2015; Polosa & Benowitz, 2011). Annually tobacco smoking and 
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exposure to second hand smoke causes approximately five million global deaths (Ng et al., 
2014; Polosa & Benowitz, 2011) with 4500-5000 occurring in NZ (Ministry of Health, 2014). 
The relative risks of adverse health effects and mortality associated with smoking increase 
with increased amounts of tobacco smoked per day. A large Australian cohort study (n=  
204, 953; aged ≥45 years) reported an adjusted relative risk (RR) for premature mortality of 
2.96 in all current smokers, with approximately a two-fold increase in mortality for people 
smoking 14 or fewer cigarettes/day and a four-fold increase in smokers who smoked 25 or 
more cigarettes per day compared to those who were never smokers (Banks et al., 2015). 
1.4 Economic Impact 
The economic impact of smoking is extensive, and a large amount of this cost is due to 
the loss of productivity over a smoker’s life, the adverse health effects (smoking-related 
illness and mortality), and attempts by governments to promote smoking cessation among 
smokers and to deter commencing smoking among non-smokers, especially adolescents 
(Ekpu & Brown, 2015; O'Dea, Thomson, Edwards, & Gifford, 2007). The World Bank 
estimates that approximately 15% of all health care expenditure in high income countries 
can be attributed to cigarette smoking (Feenstra, Hamberg-van Reenen, Hoogenveen, & 
Rutten-van Mölken, 2005; Parrott & Godfrey, 2004). Smoking also contributes considerable 
indirect costs to society and the non-smoking public, including the cost of second-hand 
smoking and costs to employers due to loss of productivity as a direct result of smoking-
related illness (Ekpu & Brown, 2015; Halpern, Shikiar, Rentz, & Khan, 2001) 
1.5 Nicotine Dependence 
Addiction (or substance dependence) is a complex disease marked by reduced 
capacity to control drug intake, regardless of the risks and other negative consequences 
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(Hyman & Malenka, 2001). Drugs of abuse produce their effects through a variety of 
mechanisms, but all of them recruit the natural reward pathways of the central nervous 
system (Joffe, Grueter, & Grueter, 2014) and increase dopamine release resulting in feelings 
of pleasure. Addictive substances create reinforcing feedback that is of a greater magnitude 
and duration than what is observed in response to natural events, and enhanced learning 
about a drug's positive experiences increases the likelihood of that drug being used again, 
with this effect magnified each time the drug is used (Torregrossa, Corlett, & Taylor, 2011). 
Addiction is a complex bio-behavioural phenomenon with causes and effects that range 
from molecular mechanisms to social interactions (Polosa & Benowitz, 2011), and as a 
chronic disease, is often characterised by a cyclical, relapse-laden progression through 
several phases of maladaptive behaviour (Joffe et al., 2014). 
Cigarette smoking expresses a major addiction (Hall, Humfleet, Reus, Muñoz, & Cullen, 
2015; Taggar et al., 2015). Approximately one third of those who ever try cigarettes will 
become addicted (Centers for Disease Control and Prevention, 2013), and the primary 
reason most smokers have difficulty quitting is because they become addicted to nicotine 
(West, Ussher, Evans, & Rashid, 2006). Nicotine is the primary active addictive component in 
tobacco (Lenoir, Tang, Woods, & Kiyatkin, 2013). Pure nicotine is a colourless, volatile, 
strongly alkaline liquid that turns pale yellow to dark brown when exposed to air, and is 
highly toxic and potentially lethal. It is chemically responsible for several physiological 
changes in the body. When a cigarette is lit and tobacco is burnt, nicotine volatilizes and is 
present in the smoke as free nicotine suspended on microscopic droplets of tar. Nicotine 
from tobacco smoke enters the blood stream through the lungs and is rapidly carried to 
different parts of the body; within seconds it crosses the blood-brain barrier and enters the 
brain (Jiloha, 2010; Polosa & Benowitz, 2011). There it binds to specific receptors in the 
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brain where it influences cerebral metabolism (Jiloha, 2010). Nicotine activates the same 
reward pathways as other addictive drugs such as cocaine and amphetamines, but to a 
lesser degree (Maritz & Mutemwa, 2012). Over time, nicotine use alters the properties of 
individual neurons, in particular those using acetylcholine as the neurotransmitter at 
synaptic junctions, and the neural circuits they participate in, and leads to complex states 
including dependence, tolerance, sensitization, craving, and withdrawal (Polosa & Benowitz, 
2011).  
Acetylcholine is involved in systems concerned with mental and physical arousal, 
learning and memory, and several aspects of emotion. Acetylcholine receptors respond to 
acetylcholine as they recognize the molecule by the position of two electrical charges, one 
positive and one negative. Nicotine has structural similarity to acetylcholine and this 
structural similarity makes nicotine molecules interact with acetylcholine receptors (Jiloha, 
2010). Unlike acetylcholine, nicotine remains bound to the receptor for much longer and 
consequently a proportion of receptors are desensitized. Repeated exposure to nicotine 
leads to an increase in the number of nicotine acetylcholine receptors (nAChRs), and the 
activation of nAChRs by nicotine can have a number of consequences in the recipient cells, 
such as the release of various other neurotransmitters including dopamine (Jiloha, 2010). 
Increases in the levels of dopamine and other neurotransmitters in the brain are responsible 
for the rewarding effects of nicotine (Maritz & Mutemwa, 2012). Nicotine not only causes 
damaging effects, it also leads to tolerance and addiction (Benowitz, 2008). Nicotine is also 
thought to be gateway drug to other drugs of abuse such as cannabis and alcohol (Jiloha, 
2010). 
The pharmacological basis of nicotine addiction can, therefore, be regarded as a 
combination of positive reinforcement (via the reward system) leading to enhancement of 
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mood or functioning, as well as negative reinforcement through escape/avoidance of 
negative consequences of prior drug use, especially relief from aversive withdrawal 
symptoms (Jiloha, 2010). Other reasons that motivate smoking are to alleviate emotional 
problems, to stabilise mood, for relaxation, to suppress appetite, and out of habit/boredom 
(Taylor et al., 2014).  
Nicotine dependence is a strong negative predictor for quit attempts and quit 
success; the more nicotine-dependent a smoker the less likely they are to attempt to quit or 
be successful at the quit (Li & Grigg, 2007; Taggar et al., 2015). There is no single definition 
of nicotine dependence and therefore no universal measure of it. However, two 
dependence measures are widely used, namely the Fagerström Test for Cigarette 
Dependence (FTCD) (Fagerstöm, 2011) and the two item Heaviness of Smoking Index (HSI) 
(Borland, Yong, O’Connor, Hyland, & Thompson, 2010). These measures have been 
biochemically validated and are widely used in tobacco smoking research (Taggar et al., 
2015).  
1.6 Cigarette/Nicotine Withdrawal  
Abrupt cessation/quitting or reduction of tobacco consumption and, therefore, of 
nicotine results in a withdrawal syndrome that primarily consists of negative affect and the 
emergence of aversive withdrawal symptoms (Piasecki, 2006). This negative affect and 
withdrawal leads to significant distress (Piper et al., 2011) and causes many smokers trying 
to quit to relapse, i.e., to resume smoking (West et al., 2006). Tobacco withdrawal 
symptoms are multi-dimensional and consist of several different types of symptoms (Javitz, 
Lerman, & Swan, 2012), but are all immediately relieved by smoking (Taylor et al., 2014).  
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Acute tobacco withdrawal usually begins within 24 hours of stopping or cutting down 
consumption, and peaks 1-4 days after abstinence, and lasts 2-4 weeks (American 
Psychiatric Association, 2013; Piasecki, 2006). The average pattern of withdrawal has 
considerable intra- and inter-individual variability, and each person responds somewhat 
differently when nicotine is withdrawn (Piasecki, 2006). Tobacco withdrawal symptoms 
listed in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) are: 1) 
irritability, frustration, or anger, 2) anxiety, 3) difficulty concentrating, 4) increased appetite, 
5) restlessness, 6) depressed mood, and 7) insomnia (American Psychiatric Association, 
2013). Clinical and anecdotal evidence reports other symptoms of withdrawal including: 
decreases in heart rate by 5-12 beats per minute, weight increases (of an average of 2-3 
kilograms over the first year after quitting), clinically significant mood changes (American 
Psychiatric Association, 2013; Hatsukami, Hughes, Pickens, & Svikis, 1984), craving for sweet 
and sugary food, impaired performance on tasks requiring vigilance, increases in 
constipation, coughing, dizziness, dreaming/nightmares, nausea, and a sore throat 
(American Psychiatric Association, 2013).  
Cigarette Craving  
The term craving refers to an intense desire or urge to smoke, and is not part of the 
DSM-5 criteria for tobacco withdrawal; however, it is considered to be an essential 
component of the withdrawal syndrome (Piasecki, 2006; Van Zundert, Ferguson, Shiffman, 
& Engels, 2012). Craving is one of the DSM-5 diagnostic criteria for tobacco use disorder 
(American Psychiatric Association, 2013) and may be one of the most sensitive predictors 
for continued smoking and of relapse (Piasecki, 2006; Van Zundert, Ferguson, et al., 2012). 
Craving typically shows a strong increase in the first week after quitting (Van Zundert, 
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Ferguson, et al., 2012) and decreases after a lengthy period of abstinence, but may never 
fully disappear (Piasecki, 2006). 
Positive or negative affective states (discussed in section 1.8) can trigger craving to 
smoke (Brewer et al., 2011) and upward variations in craving are associated with an 
increased risk of lapse and relapse of smoking (Taggar et al., 2015; Van Zundert, Ferguson, 
et al., 2012). Strong daily urges to smoke (craving) predict same day or next day relapse, 
even when baseline urge level is statistically controlled for (Van Zundert, Ferguson, et al., 
2012). Those who report less frequent urges to smoke and lower nicotine dependence are 
more likely to report abstinence at six months (Taggar et al., 2015). Craving is an important 
target for smoking cessation treatment; however, existing therapies may not assist those 
trying to quit manage craving adequately (Taggar et al., 2015).  
1.7 Smoking Cessation Interventions 
Smoking cessation/quitting smoking is among the most important health-promoting 
life changes a person can make (Bottorff et al., 2014), and is the most cost-effective disease 
prevention intervention available (Aubin et al., 2008). For instance, the leading cause of 
death from cigarette smoking is cardiovascular disease and quitting smoking has immediate 
cardiovascular benefits, reducing the risk of occurrence of coronary events to that of a non-
smoker within three years, and reducing mortality from a heart attack by up to 50% over 
three to five years (Prochaska & Hilton, 2012). Furthermore, those who have smoked 
cigarettes since early adulthood but stop at 30, 40, or 50 years of age gain approximately 10, 
9, and 6 years of life expectancy respectively, compared to those who continue to smoke 
(Jha & Peto, 2014). Other common reasons for people to want to quit smoking include the 
financial benefits, family, and lifestyle reasons (Ministry of Health, 2007).  
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Before reviewing specific smoking cessation interventions, a note on terminology is in 
order, since despite attempts to classify important outcomes in smoking cessation research, 
variations in the key definitions remain. In general, and in this thesis, the term lapse means 
a slip back to smoking after a period of abstinence. A lapse is an isolated event that is 
followed by the renewal of abstinence (Piasecki, 2006; Van Zundert, Ferguson, et al., 2012). 
A relapse refers to a period of several days (three or more) of continuous smoking after a 
period of abstinence or an attempt at abstinence (Brown, Lejuez, Kahler, Strong, & 
Zvolensky, 2005; Piasecki, 2006). Initiators of a lapse and relapse include withdrawal 
symptoms, negative affect, urge/craving for cigarettes, increases in alcohol consumption, 
the presence of other smokers, and being in situations where cigarettes are readily 
available. A lapse may also alleviate the withdrawal symptoms, and a lapse is therefore a 
major risk factor for relapse (Piasecki, 2006). Continuous abstinence requires an ex-smoker 
to be totally abstinent from smoking from a specified day (quit date) or after a specified 
grace period (up to two weeks after the target quit day) until a follow-up end point (a 
variable period specified study-by-study) to be counted as a treatment success. Most 
studies allow for isolated lapses without a relapse after cessation (Piasecki, 2006). Point 
prevalence is also used as a measure of prolonged abstinence; it is a measure of whether a 
person has had “even a puff” in a specific time-period prior to follow-up, typically the past 
seven days. Key endpoints/ follow-ups in clinical trials for determining treatment success 
are 3, 6, or 12 months after a quit date (Cinciripini et al., 2013; Piasecki, 2006; Walker et al., 
2011).  
Not all smokers will reach the gold standard goal of complete abstinence; therefore, 
reduction in the number of cigarettes/day is also frequently reported. Many smokers are 
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able to maintain smoking reductions after a relapse, and there is evidence to suggest that 
smoking reduction is associated with an increase in cessation rates in some (Broms, 
Korhonen, & Kaprio, 2008; Farkas, 1999; Lindson‐Hawley, Aveyard, & Hughes, 2012), but not 
other studies (Hughes, Cummings, & Hyland, 1999; Hughes, Lindgren, Connett, & Nides, 
2004; Meyer, Rumpf, Schumann, Hapke, & John, 2003). A Cochrane review of 10 RCTs 
(N=3760) concluded that neither reduction or abrupt quitting had superior abstinence rates, 
whether all studies were combined (RR 0.94, 95% Confidence Interval (CI) 0.79, 1.13), 
whether pharmacotherapy was used (RR 0.87, 95% CI 0.65, 1.22), or not (RR 0.97, 95% CI 
0.78, 1.21), whether studies included behavioural support (RR 0.87, 95% CI 0.64, 1.17) or 
self‐help therapy (RR 0.98, 95% CI 0.78, 1.23) (Lindson‐Hawley, Aveyard, & Hughes, 2012).  
Despite the known benefits, many smokers have difficulty quitting and the incidence 
of smoking relapse is high (Yeomans et al., 2011), with many smokers failing to attempt 
even 24 hours of continuous abstinence after quit date (Piasecki, 2006). Quitting smoking is 
a dynamic process often involving sequences of unsuccessful quit attempts before long-
term abstinence is achieved (Zvolensky, Stewart, Vujanovic, Gavric, & Steeves, 2009). To 
quit successfully requires both (i) making a quit attempt, and (ii) maintaining abstinence 
after that attempt. In general, effective smoking cessation treatments show an advantage 
over control treatments very soon after quit date, within the 3-10 day window when relapse 
is at its highest (American Psychiatric Association, 2013; Piasecki, 2006).  
NZ, as do many other Western countries, runs comprehensive tobacco control 
programmes to support smoking cessation, including annual increases in tax on tobacco, 
mass media campaigns to prompt quitting and reduce smoking initiation, restrictions on 
tobacco product marketing and sales, and extensive bans on smoking in indoor and some 
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outdoor environments (Glover, Fraser, & Nosa, 2012; Ng et al., 2014). The New Zealand 
Guidelines for Helping People to Quit Smoking (see www.health.govt.nz) provide updated 
guidance for smoking cessation support offered in NZ, including using free telephone 
counselling services and/or smoking cessation medications. The remainder of this chapter 
discusses current smoking cessation interventions, along with self-quitting (quitting without 
the support of any assistance or treatment).  
Self-quitting 
Many smokers attempt to quit smoking without any assistance or treatment, 
referred to as self-quitting (Chapman & MacKenzie, 2010; Piasecki, 2006). Rates of self-
quitting are declining due to the increase in smoking cessation medication and behavioural 
support, with approximately 50% of smokers who attempt to quit using a cessation aid 
(Smith et al., 2015). However, this means that half of quit attempters do not use an aid, and 
this is problematic as rates of success at self-quitting are low. Studies (seven studies, 
N=1677) suggest that approximately 80% of smokers who attempt to quit on their own 
relapse within the first month of abstinence, and only 3-5% of smokers (15 studies, N= 
>6955) remain abstinent at 6-12 months (Hughes, Keely, & Naud, 2003). A range of smoking 
cessation interventions are offered to decrease the level of self-quitters and increase global 
quit success and these are now discussed.  
Behavioural Interventions  
 Behavioural or psychological interventions to aid smoking cessation include self-help 
materials, brief therapist-delivered interventions, intensive counselling delivered on an 
individual basis or in a group, and any combinations of these approaches (Stead et al., 
2013). These interventions can be delivered in a face-to-face, internet, mobile phone, 
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and/or telephone format. Lancaster and Stead (2017) reviewed the effect of intensive one 
to one behavioural interventions on smoking cessation delivered by specialist counsellors. 
They found that individual counselling was more effective than a minimal contact control 
(brief advice, usual care, or provision of self‐help materials) when pharmacotherapy was not 
offered to any participants (RR 1.57, 95% CI 1.40, 1.77; 27 studies, N= 11,100). Furthermore, 
there was evidence for a benefit of intensive counselling when all participants received 
pharmacotherapy (NRT; RR 1.24, 95% CI 1.01, 1.51; 6 studies, N=2662). There was also a 
small benefit of more intensive counselling compared to brief counselling (RR 1.29, 95% CI 
1.09, 1.53; 11 studies, N=2920) (Lancaster & Stead, 2017).  
Quit lines  
Telephone counselling services (quit lines) for smoking cessation, are an easily 
accessible and effective treatment delivery method (Toll et al., 2015), and are available in 
many countries in the world through state and/or national health plans (Wadland et al., 
2007). The support offered by quit lines typically includes mailed materials, recorded 
messages, call-back counselling, and some quit lines, including NZ, provide free or 
discounted nicotine replacement therapy (NRT) (Cummins, Bailey, Campbell, Koon-Kirby, & 
Zhu, 2007; Stead, Perera, & Lancaster, 2007). Proactive telephone support for smoking 
cessation increases long-term (conventionally 12-months) abstinence rates, and including 
telephone support with medication interventions increases abstinence rates compared to 
medication alone (McRobbie et al., 2008). A Cochrane review pooled nine-trials (N >24,000) 
among smokers who contacted quit lines, and found that quit rates were higher in those 
who received multiple sessions of proactive counselling (participants were called back) 
reported a RR of 1.37 (95% CI 1.26, 1.50). Fifty-one trials (N =30,246) were reviewed to test 
the effect of telephone counselling for people who had not called a quit line, some of whom 
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might not have been actively planning to quit. The results suggested a modest benefit of 
proactive telephone counselling (RR 1.27, 95% CI 1.20, 1.36) (Stead, Hartmann‐Boyce, 
Perera, & Lancaster, 2013). Furthermore, twelve studies (N =30,182) compared an 
intervention involving multisession (>five sessions) proactive telephone counselling with a 
control condition that provided self-help materials or brief counselling at a single call. The 
results showed evidence of a benefit from the additional support (RR 1.38, 95% CI 1.28, 
1.49) when compared to brief support (Stead et al., 2013). The results suggest that rates 
abstinence are increased with more intensive telephone support when compared to brief 
support (one or two calls).  
Quitline NZ is a free quit smoking telephone helpline launched in 1999 by the NZ 
Ministry of Health. Callers can request a quit pack containing practical quit-smoking advice 
and information including the Quitbook, register on the Quitline programme for ongoing 
advice and support, and get exchange vouchers (Quitcards) for a four to eight week supply 
of subsidised (NZ$5) NRT (patches, gum, lozenges). Borland et al. (2012) reported that 12% 
of quitters in NZ used Quitline between 2011-12, and this was the highest rate of quit line 
use out of the 15 countries (Australia, Canada, China, France, Germany, Ireland, Malaysia, 
Mexico, Netherlands, New Zealand, South Korea, Thailand, UK, Uruguay and USA, N= 
24,523) in the International Tobacco Control Policy Evaluation Project (ITC), versus 
approximately 10% in Australia, 9% in the USA, 6% in UK (Borland et al., 2012). In 2014 the 
Ministry of Health reported that Quitline was used by one in six (16%) recent quit 
attempters (Ministry of Health, 2014). 
Four week self-report continuous abstinence rates for all callers using Quitline NZ 
were reported to be 30% in 2013 (n= 1251) (Quitline NZ, 2013). Research using Quitline 
usual care as a control group in NZ adults reported three-month continuous abstinence 
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rates of 21% and 26% (Walker et al., 2011; Walker et al., 2012) and six-month rates of 15-
19% (n=551, n= 704, n=705 respectively) (Bullen et al., 2010; Walker et al., 2011; Walker et 
al., 2012). Biochemical confirmation (Walker et al., 2011) or not (Bullen et al., 2010; Walker 
et al., 2012) did not appear to effect abstinence rates. Borland and colleagues randomised 
1578 adult Australian smokers to receive self-help materials, computer-generated advice, or 
computer generated advice plus telephone counselling (via Quit Victoria, an Australian 
Quitline). At the three-month follow-up they reported a point-prevalence rate post-
randomization of 21% (chi squared = 17; p<0.001) versus 12% for the control groups (not 
biochemically confirmed). However 24% of this group purchased and used NRT during their 
quit attempt (Borland, Balmford, Segan, Livingston, & Owen, 2003). A meta-analysis of 10 
RCTs (N = 8225) using telephone counselling (Mottillo et al., 2009) reported an odds ratio 
(OR) of quitting of 1.58 (95% CI 1.15, 2.29) for telephone counselling compared to a control 
group at 6 and 12 month follow-ups. 
Aukati Kai Paipa 
Aukati Kai Paipa is a smoking cessation approach developed by Māori for Māori and 
is predominately delivered by Māori health organisations as well as hospital and community 
based clinics. It is whanāu-focused (family-focused), operating in a whanāu setting utilising 
strong local ties, and adopts a holistic approach to health. NRT is typically combined with 
support. Support consists of a Māori approach to health addressing all elements of 
wellbeing, and regular follow-up (McRobbie et al., 2008). A pilot programme, primarily 
targeting Māori woman (aged 18 and over; n = >3200) and their whanāu provided free NRT 
in the form of patches or gum, and counselling delivered by Māori quit coaches over a 
period of up to 12-months. They reported positive results for Aukati Kai Paipa with a six-
month self-reported point-prevalence quit rate of 26% and 12-month point-prevalence quit 
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rate of 23% (Ministry of Health, 2003). The cost of delivering Aukati Kai Paipa was calculated 
to be approximately $4310 to $5715 per person (Ministry of Health, 2003).  
Mobile phone-based interventions 
 The International Telecommunications Union estimated that there were more than 
seven billion mobile subscriptions in 2015, approximately 96.8 per 100 inhabitants of the 
world. Mobile phones are increasingly useful for health information and healthcare delivery 
around the world, and text messaging has been used for health service appointment 
reminders, preventive activities, and medication adherence (Free et al., 2013). Smoking 
cessation services are using mobile phones to deliver support, particularly in conjunction 
with other services (Abroms, Whittaker, Free, Van Alstyne, & Schindler-Ruwisch, 2015). 
Whittaker and colleagues reviewed the current research on the use of mobile phones in 
smoking cessation to determine whether mobile phone-based smoking cessation 
interventions increase cessation in people who want to quit (Whittaker, McRobbie, Bullen, 
Rodgers, & Gu, 2016). They included randomised and quasi-randomised trials, with 
participants of any age who wanted to quit smoking. Twelve studies (N =11, 885), of which 
the majority used text messaging, were analysed using their most rigorous six month data, 
some studies providing continuous abstinence measures or repeated measures of point 
prevalence, others only providing seven-day point prevalence. The pooled RR was 1.67 (95% 
CI 1.46, 1.90) supporting the use of mobile-based interventions when compared to usual 
care. The evidence supports the beneficial impact of using mobile phone-based smoking 
cessation interventions. However, it should be noted that the majority of the included 
studies used text messaging in high-income countries with good tobacco control policies. 
Caution should be taken when generalising the efficacy outside of this type of intervention 
(text messaging) and context (high income countries) (Whittaker et al., 2016).  
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Internet-based interventions  
 The internet has the potential to deliver behaviour change interventions (Japuntich 
et al., 2011). The Internet can be accessed in people's homes, on their phones, in libraries 
and through other public access points, such as Internet cafes and information kiosks. It is 
available all day every day, including in areas where there are limited resources for a 
smoking cessation clinic (e.g., some rural or deprived areas and low‐income countries). 
Internet-based interventions can also be individualised similarly to that of one‐to‐one 
counselling (Muñoz et al., 2006), and therefore have a lot of potential to be used for 
smoking cessation interventions. 
 Taylor et al. (2017) reviewed 67 RCTs that investigated any type of smoking cessation 
internet intervention, with no exclusions based on age or gender. Eight trials (N =6786) 
compared a tailored and interactive internet intervention compared to a non-active control 
in adults for abstinence at six-months. Results showed an effect in favour of the internet-
based intervention (RR 1.15, 95% CI 1.01, 1.30). Five trials (N =3806) compared a non-
tailored internet-based intervention to an active control. The pooled effect favoured the 
control; however, the results were not statistically significant with the CI crossing the null 
(RR 0.92, 95% CI 0.78, 1.09). Five studies evaluated an internet programme plus behavioural 
support compared to a non‐active control (N =2334). These studies indicated a positive 
effect of the intervention (RR 1.69, 95% CI 1.30, 2.18). Four studies evaluated the Internet 
plus behavioural support compared to active control. None of the studies detected a 
difference between trial arms (RR 1.00, 95% CI 0.84, 1.18, N =2769). Seven studies 
compared an interactive or tailored internet intervention, or both, to an Internet 
intervention that was not tailored/interactive. Pooled results favoured the interactive or 
tailored programme, but the estimate crossed the null (RR 1.10, 95% CI 0.99, 1.22, N = 
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14,623). Three studies compared tailored with non‐tailored internet‐based messages, 
compared to non‐tailored messages. The tailored + non-tailored messages produced higher 
cessation rates compared to control, but the estimate crossed the null (RR 1.17, 95% CI 
0.97, 1.41, N =4040). Taylor and colleagues concluded that internet-based interventions that 
were interactive and tailored to individual responses led to higher quit rates than usual care, 
however the results should be interpreted with caution due to some of the pooled results 
not showing a significant difference to the control groups.  
Incentives  
 Material or financial incentives are widely used in an attempt to precipitate or 
reinforce behaviour change, including smoking cessation (Cahill, Hartmann-Boyce, & Perera, 
2015). Previous research has shown that providing financial incentives can increase 
enrolment in to smoking cessation programmes (Volpp et al., 2006, Hennrikus et al., 2002, 
Donnatelle, Prows, Champeau, & Hudson., 2000). Cahill and colleagues (2015) reviewed 
RCTs allocating adults in workplaces, groups within workplaces, or communities to receive 
incentives to quit smoking versus controls. The incentives included lottery tickets or prize 
draws, cash payments, vouchers for goods and groceries, and in six trials the recovery of 
money deposited by those taking part. The OR for quitting with incentives at the longest 
follow‐up (six months or more) compared with controls was 1.42 (95% CI 1.19, 1.69; 17 
trials; N =7715). However only three studies demonstrated significantly higher quit rates 
beyond six-months post receiving the incentives versus controls (Cahill, Hartmann-Boyce, & 
Perera, 2015). Recently, Lasser, Quintilani, & Truong (2017) conducted a RCT with 352 adults 
randomised to usual care or patient navigation and financial incentives, delivered over six 
months. At 12-months post-randomization 11.9% of the navigation + financial incentives 
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group had quit smoking versus 2.3% of the control (OR 5.8, 95% CI 1.9, 17.1). Therefore, 
based on the current research it appears as though incentives boost smoking cessation 
while they are in place, with limited research that they may lead to improvements six-
months post incentives.  
Pharmacotherapy Interventions  
Pharmacotherapies (i.e., the consumption by an individual of a specific drug or drug 
combination sanctioned by the health system) are often presumed to work by the drug 
induced reduction of withdrawal symptoms (Piasecki, 2006). More than 50% of quit 
attempters in high-income countries (Australia, Canada, United Kingdom and United States) 
sought pharmacotherapy in 2007 to support a quit attempt and less than 30% in NZ 
(Borland et al., 2012). Pharmacotherapy smoking cessation interventions are discussed 
below.   
Nicotine Replacement Therapy (NRT) 
NRT is the most common medication used to assist smoking cessation (Polosa & 
Benowitz, 2011). There are six commonly used NRT products (patches, gum, sublingual 
tablets, inhalers, lozenges, and nasal spray) (McRobbie et al., 2008) but the nicotine patch is 
the most commonly used (Piper et al., 2009). Differences between the formulations from 
NRT (e.g., lozenges vs gum) could influence withdrawal symptoms or the urge to smoke, but 
there is little evidence that one nicotine product is more effective than another (Polosa & 
Benowitz, 2011). Combination NRT (using two simultaneously) is associated with higher 
abstinence rates than single NRT use (Cahill et al., 2014; Stead, Perera, Bullen, Mant, & 
Lancaster, 2008). It is recommended that NRT should be used for 8 to 12 weeks, but heavily 
dependent smokers and those finding it hard to quit may need to use it for longer 
(McRobbie et al., 2008).  
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 NRT’s mechanism of action is to partially replace the nicotine that was acquired 
through tobacco smoking, and this aids smoking cessation by weakening the reinforcing 
effects of nicotine, reducing the severity of withdrawal and craving (Polosa & Benowitz, 
2011). NRT does not completely remove withdrawal symptoms because the delivery of NRT 
nicotine differs from the rapid and high levels of nicotine achieved through tobacco smoking 
(Benowitz, 1993).  
NRT approximately doubles the chance of achieving long-term abstinence (Polosa & 
Benowitz, 2011). A recent Cochrane review analysed 133 trials with 64,640 participants 
comparing any type of NRT to a placebo or a non-NRT control group. The RR for any form of 
NRT relative to control was 1.55 (95% CI 1.49, 1.61) (Hartmann‐Boyce, Chepkin, Ye, Bullen, 
& Lancaster, 2018). The OR reported by another Cochrane review for NRT compared to 
placebo (quit rate 17% versus 10%) was 1.84 (95% CI 1.71, 1.99; 150 studies; N >51,000) at a 
six-months post-quit (Cahill et al., 2014). Wu, Wilson, Dimoulas, and Mills (2006) analysed 
70 trials that compared NRT to controls at 1 year and found an OR of 1.7 (95% 1.6, 1.9, 
N=28,343). The results were consistent when examining all placebo-controlled trials (49 
RCTs, N =25,512, OR 1.8, 95% CI 1.6, 2.0), NRT gum (33 RCTs, N =12,245, OR 1.60, 95% CI 
1.4, 1.9) or patch (23 RCTs, N =11,108, OR 1.6, 95% CI 1.4, 1.9). NRT also reduced smoking at 
3 months (59 RCTs, N  =25,294, OR 1.99, 95% CI, 1.8–2.2). 
NRT is considered safe for most patients, with a relatively low rate of discontinuation 
because of adverse events. Wu and colleagues analysed 70 placebo controlled-trials using 
NRT (N =28,343). Although there was inadequate information for pooling they found that 
the following adverse events were reported significantly more often in the NRT group: 
mouth and throat irritation, skin irritation, nausea/vomiting, coughing, hiccoughs, 
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dyspepsia, watering of eyes, headaches, heart palpations, sneezing, sleep disturbances and 
dream abnormalities, insomnia, rhinitis, vertigo, taste disturbances, and muscle aches (Wu 
et al., 2006). Hartmann-Boyce et al., (2018) reported that adverse events from using NRT 
were related to the type of product, and include skin irritation from patches and irritation to 
the inside of the mouth from gum and tablets. Attempts to quantitatively analyse the 
incidence of various adverse effects were hindered by variation in reporting the nature, 
timing, and duration of symptoms. The odds ratio (OR) of chest pains or palpitations for any 
form of NRT relative to control was 1.88 (95% CI 1.37, 2.57, 15 trials, N =11,074); however, 
chest pains and palpitations were rare in both groups and serious adverse events were 
extremely rare. Warnings for NRT include a history of myocardial infarction within six weeks 
of starting, uncontrolled hypertension, severe cardiac dysrhythmia, unstable angina, and 
pregnancy (McRobbie et al., 2008; Polosa & Benowitz, 2011). Despite these warnings, NRT is 
reported to be safe in smokers with cardiovascular problems. Furthermore, there is little to 
no withdrawal discomfort when patients discontinue NRT (Polosa & Benowitz, 2011).   
Bupropion Hydrochloride  
Bupropion hydrochloride (bupropion) was initially developed and marketed as an 
antidepressant medication and was later found to be effective as a smoking cessation aid 
and marketed as Zyban or Wellbutrin (Cinciripini et al., 2013). There are three mechanisms 
suggested by which antidepressants may support smoking cessation. First, nicotine 
withdrawal may produce depressive symptoms or precipitate a major depressive episode, 
and antidepressants may relieve these symptoms. Secondly, nicotine may have 
antidepressant effects that maintain smoking and anti-depressant medication may 
substitute for this. Lastly, some antidepressants may act on specific neural pathways or 
receptors underlying cigarette addiction (Hughes, Stead, Hartmann-Boyce, Cahill, & 
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Lancaster, 2014). Whatever the specific mechanism, bupropion acts to reduce severity of 
withdrawal symptoms, and may also have other actions to help smokers quit (McRobbie et 
al., 2008). Among possible mechanisms of action, bupropion is a weak inhibitor of the 
neuronal uptake of norepinephrine and dopamine (Hurt et al., 1997). Further, the method 
of action of bupropion involves inhibition of neuronal reuptake of dopamine and a weak 
nicotinic acetylcholine receptor antagonist effect (less dopamine release) and this may play 
a role in the reported reduction in severity of nicotine cravings and withdrawal symptoms 
(Cinciripini et al., 2013; Polosa & Benowitz, 2011). Physicians recommend taking bupropion 
hydrochloride one week before quitting allowing accumulation of blood levels of bupropion 
hydrochloride and its active metabolites (Polosa & Benowitz, 2011). 
Hughes and colleagues (2014) concluded that there was high quality evidence that 
when used as the sole pharmacotherapy, bupropion significantly increased smoking 
cessation (44 trials, N =13,728, RR 1.62, 95% CI 1.49, 1.76) (Hughes et al., 2014). 
Furthermore Cahill et al., (2014) showed an OR for bupropion versus placebo of 1.82 (95% CI 
1.60, 2.06; 45 trials, N =12,097). A meta-analysis of 11 trials using bupropion reported an OR 
of 2.13 (95% CI 1.72, 2.64; N =5148) at three months and two trials reported an OR of 1.56 
(95% CI 1.20, 2.21; N =548) at one-year when compared to placebo-control groups (Wu et 
al., 2006). There was insufficient evidence that adding bupropion (12 trials, N =3487, RR 1.2, 
95% CI 0.9, 1.5) to NRT provides additional long-term benefits over NRT alone (Hughes et al., 
2014). Anthenelli et al. (2016) in a double-blind study randomised adult smokers to receive 
either varenicline (n=1005), bupropion (n=1001), nicotine patch (n=1013), or placebo 
(n=1009) for 12-weeks. Of the total sample 4028 were from a non-psychiatric cohort and 
4116 from a psychiatric cohort (met DSM-IV criteria for a psychiatric disorder). They 
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reported that those receiving bupropion achieved higher abstinence rates than those on 
placebo (OR 2.1, 95% CI 1.8, 2.5).  
Common reported adverse side effects while taking bupropion include insomnia (30-
40% of patients) and dry mouth (approximately 10%) (Hughes et al., 2014). Other adverse 
events reported significantly more in bupropion groups compared to placebo are 
gastrointestinal upset, and constipation (Wu et al., 2006). Rates of discontinuation because 
of adverse events range from 7% - 12% (Polosa & Benowitz, 2011). The prescribing 
information for bupropion also carries a ‘black box’ warning that antidepressants can 
increase the  risk of suicidal ideation and behaviour in people with certain psychiatric 
disorders (Polosa & Benowitz, 2011). Hughes and colleagues’ review did not detect a 
significant increase in the rate of serious adverse events amongst participants taking 
bupropion, although the 95% CI narrowly missed statistical significance (33 trials, N =9631, 
RR 1.30, 95% CI 1.00, 1.69). There is a risk of about 1 in 1000 of seizures associated with 
bupropion use. Bupropion has been associated with suicide risk, but whether this is causal is 
unclear (Hughes et al., 2014). Anthenelli et al. (2016) did not report any differences between 
groups for neuropsychiatric events and reported the most frequent adverse side effect in 
the bupropion group to be insomnia (12%). A serious adverse event meta-analysis of the 
bupropion studies demonstrated no increase in neuropsychiatric or cardiovascular events 
compared to placebo (Cahill et al., 2014).  
Other antidepressants   
A Cochrane review assessed the safety and efficacy of other antidepressant 
medications to aid smoking cessation (Hughes et al., 2014). These medications included 
doxepin; fluoxetine; imipramine; lazabemide; moclobemide; nortriptyline; paroxetine; S-
Adenosyl-L-Methionine (SAMe); selegiline; sertraline; St. John’s wort; tryptophan; 
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venlafaxine; and zimeledine. There was moderate quality evidence, limited by a small 
number of trials and participants, that nortriptyline significantly increased cessation when 
used as the sole pharmacotherapy (six trials, N =975, RR 2.03, 95% CI 1.48, 2.78). There was 
insufficient evidence that adding nortriptyline (4 trials, N =1644, RR 1.21, 95% CI 0.94, 1.55) 
to NRT provides additional long-term benefits over NRT alone. Cahill and colleagues (2014) 
reviewed 10 studies (N =2,194) that investigated the efficacy of nortriptyline. They found 
that nortriptyline increased the chance of quitting (RR 2.03; 95% CI 1.48, 2.78). Nortriptyline 
has the potential for side effects, including dry mouth, constipation, nausea, and sedation, 
and it can be dangerous in overdose (Hughes et al., 2014). but none have been seen in the 
few trials completed.  
A Cochrane review by Hughes and colleagues (2014) reported that there was no 
evidence of a significant effect for selective serotonin reuptake inhibitors (SSRIs) on their 
own for smoking cessation when compared to controls (RR 0.93, 95% CI 0.71, 1.22, N = 
1594; 2 trials fluoxetine, 1 paroxetine, 1 sertraline) or in conjunction with NRT (3 trials of 
fluoxetine, N =466, RR 0.70, 95% CI 0.64, 1.82). Significant differences were also not 
reported for monomine oxidase inhibitors (RR 1.29, 95% CI 0.93, 1.79, N =827; 1 trial 
moclobemide, 5 trials selegiline), the atypical antidepressant venlafaxine (1 trial, N =147, RR 
1.22, 95% CI 0.64, 2.32), the herbal therapy St John’s wort (hypericum; 2 trials, N =261, RR 
0.81, 95% CI 0.26, 2.53), or the dietary supplement SAMe (1 trial, N =120, RR 0.70, 95% CI 
0.24, 2.07) (Hughes et al., 2014). 
Varenicline tartrate 
Varenicline tartrate (varenicline) marketed as Champix or Chantix, was launched in 
2006 (Polosa & Benowitz, 2011) after it was approved for marketing as a pharmacological 
aid for smoking cessation (Ware et al., 2013). Varenicline is a partial agonist selective for 
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α4β2 nAChRs (Polosa & Benowitz, 2011; Ware et al., 2013) with dual effects; these are partial 
stimulation of nAChRs without creating the full effect of nicotine, and blocking the nAChRs, 
which prevents nicotine reaching the receptors (Polosa & Benowitz, 2011) (i.e., it reduces 
the severity of withdrawal and simultaneously reduces the rewarding effects of nicotine). 
Varenicline inhibits the surges of dopamine release that are believed to be responsible for 
the reinforcement and reward associated with tobacco use (Prochaska & Hilton, 2012). 
These effects provide relief from craving and withdrawal symptoms (Polosa & Benowitz, 
2011).  
Two RCTs reported that after one-year, healthy smokers had approximately 2.5 
greater odds of quitting with varenicline compared to placebo, and 1.7 times greater odds 
compared to bupropion (Gonzales et al., 2006; Jorenby et al., 2006). Cahill, Lindson-Hawley, 
Thomas, Fanshawe, & Lancaster (2016) reviewed 39 trials that investigated the use of 
varenicline. The RR for abstinence at six months or longer for varenicline compared to 
placebo was 2.24 (95% CI 2.06, 2.43, 27 trials, N =12,625). The pooled RR for varenicline 
compared to bupropion at six months was 1.39 (95% CI 1.25 to 1.54, 5 trials; N =5877) and 
the RR was 1.25 (95% CI 1.14 to 1.37, 8 trials, N =6264) for varenicline versus NRT (Cahill et 
al., 2016). A Cochrane review reported an OR of 2.88 (95% CI 2.40 to 3.47, 24 trials; N = 
4,102) for varenicline compared to placebo (quit rate 28% versus 12%) at a follow-up of six-
months (Cahill et al., 2014). Varenicline was also shown to be superior to both NRT (OR 1.57, 
95% CI 1.29 to 1.91) and to bupropion (OR 1.59, 95% CI 1.29 to 1.96) (Cahill et al., 2014). Wu 
et al. (2006) pooled four trials to compare the effect of varenicline versus placebo and 
increased odds of quitting using varenicline were reported at one-year (OR 2.96, 95% CI 
2.12, 4.12) and at three months (OR 3.75, 95% CI 2.12, 4.12). Pooled results from four trials 
comparing bupropion to varenicline showed significantly lower quitting with bupropion than 
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with varenicline (N =1810, RR 0.68, 95% CI 0.56 to 0.83) (Hughes et al., 2014). Anthenelli et 
al. (2016) reported that varenicline-treated participants achieved higher abstinence rates 
than those on placebo (OR 3.61, 95% CI 3·07, 4.24), nicotine patch (OR 1.68, 95% CI 1.46, 
1.93), and bupropion (OR 1.75, 95% CI 1.52, 2.01).   
McKee et al. (2011) conducted a meta-analysis of 17 double-blind RCTs to examine 
the sex differences in the efficacy of varenicline for smoking cessation (n=6710, 34% 
females). For those who were randomised to placebo, women were more than 30% less 
likely to quit when compared to men (point-prevalence OR 1.3, 95% CI 1.1, 1.6 and 
continuous abstinence OR 1.4, 95% CI 1.0, 1.8). For those who used varenicline, similar rates 
of abstinence for men and women were reported at six months post quit day. However, the 
effect size for varenicline was significantly larger for women than for men when sex was 
included as a moderator in the analysis. Varenicline was 46%, 34%, and 31% more effective 
for women in point-prevalence at 12 weeks, continuous abstinence at 12, and 24 weeks 
respectively. No differences in abstinence rates were found between men and women at 
the one year follow-up. Therefore, the meta-analysis concluded that varenicline was more 
effective for women for short and intermediate outcomes, and it may have potential in 
supporting to reduce the sex disparity in rates of smoking cessation.  
The most common side effects reported from varenicline are nausea, insomnia, 
gastrointestinal upsets, and headache (Polosa & Benowitz, 2011; Wu et al., 2006). 
Varenicline has been associated with an increased risk of sleep disorders, abnormal dreams, 
depression, and fatigue (Thomas, Martin, Knipe, Higgins, & Gunnell, 2015). Anthenelli and 
colleagues reported that the overall incidence of neuropsychiatric adverse events was 
similar across the four treatment groups (varenicline, bupropion, nicotine patch, and 
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placebo), ranging from 3.7% to 4.5% (Anthenelli et al., 2016). The most common adverse 
event in the varenicline was nausea (25%) (Anthenelli et al., 2016).  
Unlike other pharmacotherapies, varenicline is associated with gradually increasing 
cessation rates over 12 weeks of treatment, presumably due to the antagonism of nicotine 
resulting in reduced satisfaction from smoking (Polosa & Benowitz, 2011).  A meta-analysis 
of 14 varenicline RCTs found no difference between varenicline and placebo for the 
outcome of serious adverse events; however, there was one incident of suicidal ideation in a 
varenicline group that was considered to be varenicline-related (Cahill et al., 2014). Thomas 
et al. (2015) reported through a meta-analysis (39 RCTs, N =10,761) that participants 
prescribed varenicline compared to placebo had no increased risk of suicide or attempted 
suicide, suicidal ideation, depression or death, however, varenicline was associated with an 
increased risk of sleep disorders (OR 1.63, 95% CI 1.29 to 2.07), insomnia (OR 1.56, 95% CI 
1.36 to 1.78), abnormal dreams (OR 2.38, 95% CI 2.05 to 2.77), and fatigue (OR 1.28, 95% CI 
1.06 to 1.55) but a reduced risk of anxiety (OR 0.75, 95% CI 0.61 to 0.93). Singh and 
colleagues conducted a meta-analysis (14 RCTs, N=8216) of the safety of varenicline in 
regards to cardiovascular events and concluded that the varenicline increased the risk of 
serious adverse events by 72% (OR=1.72, 95% CI 1.09, 2.71) (Singh, Loke, Spangler, & 
Furberg, 2011). Prochaska and Hilton (2012) conducted a meta-analysis of all published RCT 
of varenicline and found that there was no significant differences in serious adverse 
cardiovascular events between placebo and varenicline within 30 days of discontinuation. 
Thus, there remain unresolved questions about the safety of varenicline, with the majority 
of research reporting no increase in adverse effects. Further research is needed to 




 Cytisine was developed as a treatment for cigarette dependence in Bulgaria in the 
1960’s and is a partial agonist that binds to the nicotinic acetylcholine receptor (Cahill et al.,  
2016; Walker et al., 2014). There is also heightened interest in cytisine in New Zealand, 
where it is found in the seeds of the native Kowhai tree, widely used in traditional Māori 
healing (Cahill et al., 2016). Cahill and colleagues pooled the results from two trials of 
cytisine (N =937) and found that more participants taking cytisine quit smoking when 
compared with placebo (RR= 3.98, 95% CI 2.01, 7.87) (Cahill et al., 2016). Furthermore, 
Walker and colleagues (2014) compared cytisine with NRT in 1310 people using an open-
label, noninferiority trial in NZ. At one month abstinence from smoking was reported for 
40% who received cytisine and 21% who received NRT (RR 1.3, 95% CI 1.1, 1.5). They also 
found that more people quit using cytisine at six months (22% versus 15%; RR 1.4, 95% CI 
1.1, 1.8) (Walker et al., 2014). In pre-specified analyses conducted according to sex Walker 
and colleagues reported significantly higher one-month continuous abstinence in women 
when compared to men (RR 1.55 (95% CI 1.26, 1.90) versus RR 1.05 (95% CI 0.84, 1.30), 
p=0.011). The cytisine trials analysed by Cahill et al., (2016) did not identify more adverse 
events in the intervention group when compared to controls, but self-reported adverse 
events over 6 months occurred more frequently in the cytisine group (288 events among 
204 participants) than in the group receiving NRT (174 events among 134 participants). 
Adverse events were primarily nausea, vomiting and sleep disorders (Walker et al., 2014).  
Combined pharmacotherapy and behavioural interventions  
 Many clinical practice guidelines recommend that healthcare providers should offer 
people who want to quit smoking both behavioural support interventions and 
pharmacotherapy on the basis that they will have an additive, combined effect (Stead, 
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Koilpillai, & Lancaster, 2015). Stead and colleagues (2016) reviewed trials that combined 
pharmacotherapy (including NRT, varenicline, bupropion, cytisine, or nortriptyline) with 
behavioural support (tailored materials, brief advice, in person or telephone counselling) 
and compared the outcomes against a control group that received either usual care or a 
brief cessation component (i.e., advice to quit but no other behavioural support or 
medication common to the intervention). Based on 52 studies there was evidence for a 
benefit of combined pharmacotherapy and behavioural treatment compared to usual care, 
brief advice, or less intensive behavioural support (RR 1.83, 95% CI 1.68, 1.98; N =19,488). 
The pooled estimates for the efficacy of 43 trials that recruited participant’s in healthcare 
settings (RR 1.97, 95% CI 1.79, 2.18; N =13863) was higher than the eight trials recruiting 
from community based recruitment (RR 1.53, 95% CI 1.33, 1.76; N =4906) (Stead, Koilpillai, 
Fanshawe, & Lancaster, 2016).  
 Stead and colleagues (2015) reviewed 47 studies (N >18,000) to evaluate the effect 
of increasing the intensity of behavioural support for people using smoking cessation 
medication compared to either treatment alone. All but four studies provided more than 
four sessions of support. Most trials used NRT. There was evidence of a small but 
statistically significant benefit for intensive support combined with pharmacotherapy (RR 
1.2, 95% CI 1.1, 1.2), with no statistical difference between NRT and bupropion. No 
significant effects for nortriptyline (two trials) and varenicline (one trial) combined with 
behavioural support were shown. This suggests that increasing the intensity of behavioural 
support with the aid of pharmacotherapy for people trying to make a quit attempt typically 
leads to a small increase in the proportion that are abstinent at 12 months (Stead, Koilpillai, 




Electronic cigarettes (e-cigarettes) are battery-powered electronic devices that heat 
a solution of humectants, nicotine (in most cases), and flavourings (in many cases), to 
deliver an aerosol that the user inhales (Kalkhoran & Glantz, 2016) and no tobacco is 
necessary for it to operate. Most e-cigarette users report using them in an attempt to stop 
smoking, with fewer than 1% of never-smokers using them regularly (Brose et al., 2015).  
A meta-analysis reported on 15 cohort studies (N =24,496), three cross sectional 
studies (N =15,625) and two clinical trials (N =757) assessing smoking cessation in e-
cigarette users compared to control groups and reported 28% lower odds (OR=0.7, 95% CI 
0.6, 0.9) of smoking cessation among those who used or had used e-cigarettes (Kalkhoran & 
Glantz, 2016). Bullen and colleagues (2016) conducted a Cochrane review to investigate the 
safety and efficacy of using e-cigarettes to help people achieve smoking abstinence. They 
reviewed three RCTS, two of which compared nicotine e-cigarettes to non-nicotine e-
cigarettes (N =662). The results showed that participants using a nicotine e-cigarettes were 
more likely to have abstained from smoking for at least six months compared with 
participants using placebo e-cigarettes (RR 2.3, 95% CI 1.1, 5.0; placebo 4% versus e-
cigarette 9%). One study compared e-cigarettes to NRT (nicotine patch) found no significant 
difference in six‐month abstinence rates, but the confidence intervals do not rule out a 
clinically important difference (RR 1.26, 95% CI 0.68, 2.34; N = 584) (Bullen et al., 2013). 
Further RCTs that compare e-cigarettes to other forms of smoking cessation will determine 
the safety and efficacy of these devices as a smoking cessation intervention long-term 




Of the 24 included studies involving e-cigarettes (three RCTs and 21 cohort studies) 
in the Cochrane review, none reported serious adverse events considered to be related to 
the use of e-cigarettes (follow-up up to two years). The most frequently reported adverse 
side effects were mouth and throat irritation, of which most disappeared over time (Bullen 
et al., 2016).  
Costs of smoking cessation interventions  
Due to the differences in effect sizes based on the current body of literature it is 
difficult to obtain reliable estimates of current cost effectiveness for current smoking 
cessation interventions. However, the approximate cost of smoking cessation interventions 
deserves mention. Based on calculations from the 2012 WHO study of 126 countries the 
approximate cost per person attempting to quit of the following pharmacotherapies are 
estimated as: NRT = NZ$2.50 to $12.40/day, varenicline = NZ$7.20/day, bupropion = 
NZ$3.40-$7.90/day, cytisine = $1.00 to $1.50/day, and nortriptyline $1.40/day (World 
Health Organization, 2013). Cytisine and nortriptyline are considerably cheaper in 
comparison to other smoking cessation options. Therefore there may be potential for these 
treatments to be used more in countries with lower average incomes and where smoking 
cessation programmes are not supported by insurance plans or by a national health service 
(Cahill et al., 2016). Furthermore, in many regions, it may be considerably cheaper to 
continue smoking than to embark upon a course of pharmacotherapy for smoking 
cessation. In 2011 in China a packet of cigarette cost between USD $0.15 and USD $0.73, 
compared with a course of NRT (USD $230), bupropion (USD $123), or varenicline (USD 
$327). Similarly, a pack of 20 cigarettes in India costs around USD $1.10, compared with USD 
$150 for a course of NRT, USD $100 for bupropion and USD $200 for varenicline. Cytisine is 
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currently available in Poland for the equivalent of USD $15 for a course of treatment, and in 
Russia for the equivalent of USD $6 as an over‐the‐counter medication. 
1.8 Differences in Smoking Cessation Outcomes  
 
Rates of smoking cessation are not linear across all individuals, with significant 
differences observed across gender and between people with and without mental illness. 
These differences are discussed below.  
Sex 
As mentioned there are large differences in smoking prevalence among males and 
females across countries, with men generally having a higher prevalence of smoking than 
women (McCartney et al., 2011). However, clinical trials report that women are less likely to 
successfully quit smoking than men, with no difference reported in the number of quit 
attempts (Bohadana, Nilsson, Rasmussen, & Martinet, 2003; Collins et al., 2004; Smith et al., 
2015). A double-blind RCT examined whether the male versus female smoking cessation 
outcome was influenced by baseline smoking rates when participants (196 men and 204 
women) were randomised to receive different combinations of NRT therapy. Men had 
significantly higher FTCD scores at baseline (6.4 versus 6.0, p=0.02) and women had higher 
behavioural dependence (Glover–Nilsson Smoking Behavioural Questionnaire 1.27 versus 
1.06, p<0.001). They reported significant differences in continuous abstinence rates (p<0.05) 
with men more likely to quit than women regardless of treatment group and quit rates of 
42.3% vs. 30.9% at 12 weeks, 30.1% vs. 17.6% at 6 months, and 23.0% vs. 10.8% at 12 
months (Bohadana et al., 2003). This observed difference was supported by Collins et al. 
(2004) who randomised 314 women and 241 men to receive 10 weeks of bupropion or a 
placebo control. They reported an end of treatment quit rate (10 weeks post-
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randomization) of 51% in men versus 40% in woman (chi squared = 6.56, p=0.01), and a six 
month post-randomization quit rate of 31.5% in men and 22.3% in women (chi squared = 
12.79, p=0.0004). Smith and colleagues analysed data from the International Tobacco 
Control Four Country Survey conducted in the UK, USA, Canada, and Australia to examine 
gender differences in smoking cessation among 8,904 participants. Among those who made 
a quit attempt, women had 31% lower odds of successfully quitting smoking than men at a 
30-day follow-up (OR = 0.7, 95% CI 0.5, 0.9), despite no significant gender difference in the 
likelihood of making a quit attempt (Smith et al., 2015). The NZ Ministry of Health reported 
that NZ males were more likely than females (62% vs 54%) to have quit for at least a week, 
after adjusting for age differences (Ministry of Health, 2014).  
Possible explanations for the sex difference in smoking cessation outcomes include 
women’s greater concern about weight gain, possibly greater difficulty with negative mood 
associated with quitting, and greater need for social support during a quit attempt 
(Bohadana et al., 2003). Women are more likely to report the use of smoking cessation 
medication than men (Smith et al., 2015), therefore the difference in cessation outcomes 
favouring males is clinically meaningful in regards to how we continue to develop smoking 
cessation aids, since it clearly suggests that smoking cessation programmes need to reflect 
these known sex differences.    
Mental Illness 
Most smokers, both with and without mental illness, report that they want to quit 
but continue to smoke as it provides them with perceived mental health benefits (Taylor et 
al., 2014). In contrast, individuals with mental illness also often report a fear that quitting 
will increase their symptoms; fortunately, most people do not experience an increase in 
psychiatric symptoms specific to their illness when they stop smoking (McRobbie et al., 
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2008). Persons with mental illness may encounter greater difficulty with tobacco cessation 
(Addington, El-Guebaly, Campbell, Hodgins, & Addington, 1998; Lasser et al., 2000; Ziedonis 
& George, 1997) and more intensive smoking cessation interventions appear to be 
beneficial for this population, including multi-session support and medication (McRobbie et 
al., 2008). Further research to identify interventions to address mechanisms specific to 
people with mental illness should be a priority for tobacco control policy (Lê Cook et al., 
2014). Despite the higher use of cigarettes and the potential challenge of quitting smoking 
for individuals with a mental illness, their motivation to quit is high and comparable with the 
general population (Acton, Prochaska, Kaplan, Small, & Hall, 2001; Nahvi, Richter, Li, Modali, 
& Arnsten, 2006; Prochaska et al., 2017; Prochaska, Fletcher, Hall, & Hall, 2006). 
1.9 Mood and Tobacco Smoking 
Negative affect, referring to mood states marked by feeling angry, frustrated, 
irritable, sad, depressed, and distressed, is widely believed to be a motive for smoking and 
may explain some of the aforementioned differences in smoking cessation in those with 
mental illness; however, the relationship between the two is complex (Piasecki, 2006). 
Positive affect refers to mood states of feeling happy, joyful, pleased, and of enjoyment 
(Diener & Emmons, 1985). Greater depressive symptoms and low positive affect prior to a 
quit attempt, and negative changes in depressive symptoms and positive affect following 
quitting are associated with poor smoking cessation outcomes (Kahler et al., 2015). Nicotine 
dependence is a complex process, developed in part from the formation of associative 
memories of both positive (e.g., after a good meal) and negative (e.g., feeling stressed) 
affective states (Brewer et al., 2011). Thus, cues that are judged positive or negative can 
induce positive or negative affective states and trigger craving to smoke.  
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Smokers learn to connect negative affect relief to smoking through repeated 
experience. Negative affect becomes a conditioned cue to smoke, understood cognitively as 
an expectancy (e.g., “cigarettes help me deal with anxiety and worry”) (Weinberger & 
McKee, 2012) and experiential confirmation of the expectancy functions as a (negative) 
reinforcement for smoking. Therefore, smokers commonly report a desire for relief from 
negative affect as a chief reason for smoking, and often attribute relapses to acute negative 
affect (Piasecki, 2006). Many studies have demonstrated a positive association between 
tobacco use and depressive disorders (Edwards, Maes, Pedersen, & Kendler, 2011), 
suggesting that the risk of major depression increases with increasing levels of nicotine 
dependence, or vice versa (Edwards et al., 2011). Negative affect or depressed mood is also 
considered a hallmark of nicotine withdrawal, and increases in negative affect after quitting 
appear in both adults and adolescents (Van Zundert, Ferguson, et al., 2012).   
1.10 Alcohol and Tobacco Smoking 
Nicotine and alcohol are two addictive drugs that have significant impact on public 
health; they are both prevalent and lead to significant health risks (Berg, Piper, Smith, Fiore, 
& Jorenby, 2015). Furthermore, alcohol and nicotine abuse are the largest type of 
polysubstance abuse reported (Van Skike et al., 2016). Approximately 40% of NZ smokers 
have drinking patterns that are considered potentially hazardous (alcohol consumption that 
carries a risk of harming the drinker's physical or mental health), compared to 14% of non-
smokers (Ministry of Health, 2014). Estimates based on clinical samples of adults with 
alcohol use disorders have revealed that 50-95% are current smokers (Van Skike et al., 2016; 
Van Zundert, Kuntsche, & Engels, 2012). Analysis of data from 1376 respondents of the NZ 
Health Survey revealed that High Alcohol Use Disorders Identification Test (AUDIT) scores (8 
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or more) are associated with smoking, especially in people that are younger, male, and 
Māori (Wilson, Weerasekera, Kahler, Borland, & Edwards, 2012). Relative to non-smokers, 
tobacco smokers are more likely to binge drink, consume two times more alcohol, and are 
10-14 times more likely to have an alcohol use disorder (Van Skike et al., 2016). Higher 
levels of alcohol intake are associated with higher levels of smoking and are also associated 
with lower rates of quitting (Wilson et al., 2012). Lapse and relapse are strongly associated 
with alcohol use, as smokers report a higher craving to smoke and more enjoyment of their 
cigarette when drinking compared to not drinking (Van Zundert, Kuntsche, et al., 2012).  
Evidence suggests that alcohol consumption decreases after a smoking quit attempt. 
Karlamangla, Zhou, Reuben, Greendale, and Moore (2006) found that smoking cessation 
was associated with a lower probability of heavy drinking (RR= 3.4, 95% CI 2.8, 4.0) 
compared to no change in smoking habits in US adults. Berg et al. (2015) followed 1301 
participants daily for two weeks prior and after a quit attempt. They reported that 
participants significantly decreased their alcohol intake post-quit, with mean pre-quit 
alcohol use at 0.73 (Standard Deviation (SD) = 0.9, range 0-4.3) drinks per day; excluding the 
482 non-drinking participants the average was 1.16 (SD =0.9, range 0.1-4.29) drinks per day. 
The average post-quit alcohol consumption was 0.6 (SD =0.88, range 0-6.6) drinks per day; 
excluding those who did not drink at all, average alcohol use post-quit was 0.95 (SD =0.94, 
range 0.1-6.6) drinks per day. For the whole sample there was a significant reduction in 
drinks per day at two weeks post-quit when compared to baseline (t(1300) =6.98, p<0.001) 
and for the sample that excluded non-drinkers (t(697) =6.87, p<0.001).  
The risk of mortality increases with combined use of tobacco and alcohol (Toll et al., 
2015), therefore it is important to consider combining the effort to reduce both alcohol 
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intake and smoking (Van Skike et al., 2016). Previous research has found that adding alcohol 
interventions to smoking cessation treatment improved quit rates among hazardous 
drinkers (Kahler et al., 2015). Wilson et al. (2012) suggested that the NZ Government could 
consider potential benefits for advancing tobacco control via cost effective and evidence-
based interventions that reduce alcohol related harm, and consider additional funding 
support for health services to allow them to address heavy drinking and smoking cessation 
together.   
As mentioned above, on the balance of evidence, varenicline appears to currently be 
the most efficacious treatment for smoking cessation. There is also evidence to support the 
use of varenicline to support decreasing alcohol consumption. Mitchell and colleagues 
(2012) reported a double-blind study that randomized 99 participants to receive varenicline 
or placebo for 12 weeks. Participants were eligible if they smoked 10 or more cigarettes and 
consumed ≥7 for women or ≥14 for men alcoholic drinks per week. They reported significant 
difference in cigarettes per week for those in the varenicline group versus the placebo group 
from weeks 3 to 11 (χ2 = 182.23, p < 0.001). There was also a significant difference in drinks 
per week between completers in the varenicline and placebo groups from weeks 3 to 11 
(χ2 = 35.32, p < 0.001) (Mitchell, Teague, Kayser, Bartlett, & Fields, 2012). Litten et al. (2014) 
in a double-blind study randomised 200 adults meeting criteria for alcohol dependence to 
receive either varenicline or placebo and a computerized behavioural intervention for 13 
weeks. The varenicline group had significantly lower weekly percent of heavy drinking days 
(37.9 versus 48.4, p=0.03, Cohen’s d=0.31), drinks per day (4.4 versus 5.3, p=0.03, Cohen’s 
d=0.29), drinks per drinking day (5.8 versus 6.8, p=0.03, Cohen’s d=0.26), and alcohol craving 
(8.2 versus 9.0, p=0.01, Cohen’s d=0.33) when compared to placebo. The varenicline group 
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also reported smoking fewer cigarettes per day compared to placebo (7.4 versus 11.7, 
p=0.002, Cohen’s d=0.73) (Litten et al., 2013). 
Hurt and colleagues investigated the use of varenicline in adults, who smoked an 
average of 10 or more cigarettes per day, and had alcohol dependence or abuse as assessed 
by the Mini-International Neuropsychiatric Interview and the physician investigator, were 
currently drinking, and interested in quitting smoking. Participants were randomly assigned 
to varenicline (n=16) or placebo (n=17) for 12-weeks, with follow-up at six months. The 7-
day point prevalence smoking abstinence rate at the end of treatment (12 weeks) was 
significantly higher in the varenicline than the placebo group (n=7 (44%) vs n=1 (6%); p 
=0.01). Prolonged smoking abstinence was also significantly higher with varenicline than 
placebo at end of treatment (n=6 (38%) vs n=1 (6%); p =0.03). At the end of study (24 
weeks), the 7-day point prevalence smoking abstinence rate (n=5 [31%] vs 0%; p =0.02) and 
prolonged smoking abstinence (n=4 (25%) vs 0%; p=0.04) were both significantly higher with 
varenicline than with placebo. Over the first 16 days after the target quit date, nicotine 
craving was significantly lower in those receiving varenicline than placebo (average 
difference, −1.79; 95% CI 2.59, 0.99; p< .001). At the end of treatment, average drinks per 
drinking day was significantly lower with varenicline than placebo (mean (SD), 5.7 (3.9) vs 
9.0 (5.3); treatment effect estimate, −2.8; 90% CI −6.6, −1.0). At the end of study, the 
average drinks per drinking day was also significantly lower in the varenicline group than the 
placebo group (mean (SD), 5.0 (3.8) vs 7.6 (4.3); treatment effect estimate, −2.3; 90% CI 






Cigarette smoking is the practice of burning tobacco contained in a cigarette and 
inhaling the smoke. Approximately 20% of the global population (>15 years) and 18% of the 
NZ population are current smokers. Overall the prevalence of cigarette smoking is 
decreasing, but not equally across all ethnic groups, genders, and nationalities. Smoking is 
associated with an array of adverse health effects, but individuals continue to smoke 
because nicotine contained in tobacco smoke is highly addictive and causes an adverse 
withdrawal syndrome upon cessation.  
 Current smoking cessation interventions include counselling, NRT, and 
pharmacotherapy, singly and in combination, but many smokers still do not quit with such 
treatments. Furthermore, the cost per person per day of these treatments varies widely 
among countries and health systems, and the ratio of the costs of these different 
treatments, with their different levels of efficacy,  to the benefits of quitting are hard to 
typify. In NZ, Quitline provides free telephone counselling and supplies a prescription for 
two months of heavily subsidised NRT. NRT doubles an individual’s chance of staying smoke 
free long-term. Other pharmacotherapies (varenicline and bupropion), achieve quitting and 
abstinence rates equal to or exceeding NRT but many smokers (>70%) do not successfully 
quit even with such treatments. Pharmacotherapy can be expensive, requires medical 
prescription and supervision, and may have problematic side effects. Alternative treatments 
that are safe, effective, relatively inexpensive, and readily available are needed. Broad-
spectrum micronutrients (minerals and vitamins) supplements are one such possible 
alternative, and mineral and vitamin supplements for the treatment of psychiatric 
symptoms and addictions are discussed in Chapter 2.   
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Chapter 2: Broad-spectrum Micronutrients  
Researchers, public health authorities, and consumers will continue to seek treatments for 
smoking cessation because of its high prevalence and the adverse health effects it causes. 
This chapter provides an overview of one such alternative, namely broad-spectrum 
micronutrient supplementation, and why it may be applicable to this population. Research 
on the use of micronutrients in the treatment of substance dependence has existed for half 
a century, and investigations in to the use of micronutrients to relieve psychological 
symptoms has grown substantially in the past decade and has now been demonstrated in a 
number of trials. This chapter will review the literature on the use of micronutrients as a 
treatment of substance dependence, and to relieve associated psychological symptoms in 
adults. This will be followed by a discussion of potential mechanisms of action for the 
therapeutic effect of micronutrients on mental health.  
2.1 Micronutrients  
Micronutrients are conventionally considered to include vitamins, minerals, amino 
acids, and antioxidants and have a primary function in human metabolism, the maintenance 
of health, and the prevention of disease (Ames, 1998). Adequate intakes of micronutrients 
are essential in maintaining the body’s homeostasis, and its physiological functioning for 
normal growth and development. At least 30 micronutrients are essential to the body’s 
functioning and cannot be synthesised by the body, making intake via dietary sources 
critical (Shergill-Bonner, 2013).  
Although the human brain only accounts for 2 to 2.7% of body weight, it requires 
25% of the body’s primary energy supply (glucose) and 19% of the blood supply at rest, and 
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this increases by 50% and 51% respectively in response to cerebral activity (Haller, 2005). 
The brain is dependent on a stable supply of both glucose and oxygen for the maintenance 
of cellular integrity and information processing. In addition to the high requirements of 
glucose and oxygen, the brain also requires a range of micronutrients for metabolism and 
chemical transmission (Sinn & Howe, 2008). Micronutrients are involved in many aspects of 
brain function, from the global functions such as energy metabolism, to more specific 
functions, for example being the co-enzymes for neurotransmitter functioning (Haller, 
2005). Every neurotransmitter goes through many metabolic steps to ensure synthesis, 
reuptake, and breakdown, each of these steps requires an enzyme - a biological catalyst – 
and enzyme function and synthesis are dependent on multiple co-enzymes. Co-enzymes 
include a variety of vitamins and minerals. Availability of the co-enzymes may limit the rate 
at which neurotransmitter synthesis and other critical brain metabolism is carried out 
(Kennedy et al., 2010). 
Unfortunately, a significant proportion of the world’s population suffers from 
micronutrient deficiencies, particularly in developing societies where low dietary intake of 
micronutrients is common among most of the population (Schlebusch et al., 2000). 
Alleviating deficiencies through diet or supplementation is likely to lead to major 
improvements in general health and an increase in longevity, at a low cost (Ames, 1998).  
Supplementation is a term used to describe the ingestion of micronutrients usually in 
the form of pills, capsules, or syrups, independently of normal food consumption, and has 
the advantage of being able to supply an optimal amount of specific micronutrients to the 
body (Allen, De Benoist, Dary, & Hurrell, 2006). Recommended daily intakes (RDI) of 
micronutrients in the normal diet and upper limits (UL) have been formulated from 
observational studies in healthy populations and laboratory estimates of tissue and blood 
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status to assist with determining the optimal ingestion of extra nutrients (Shergill-Bonner, 
2013). The RDI is defined by the Australian Government (2005) as “the average daily dietary 
intake level that is sufficient to meet the nutrient requirements of nearly all (97-98 percent) 
the healthy individuals in a particular life stage and gender group” and the UL is “the highest 
average daily nutrient intake level likely to pose no adverse health effects to almost all 
individuals in the general population”. Variations in recommendations may occur due to 
different methods used to assess requirements, different age, sex, the presence of chronic 
disease, pregnancy, or specific dietary conditions (Shergill-Bonner, 2013). However, as 
intake increases above the UL the potential risk of adverse effects increases (Australian 
Government, 2005).  
Recent research has demonstrated the efficacy of micronutrient supplementation 
above the RDI but below the UL as beneficial in the treatment of various psychological 
symptoms (Kimball, Mirhosseini, & Rucklidge, 2018; Lothian, Blampied, & Rucklidge, 2016; 
Rucklidge, Eggleston, Johnstone, Darling, & Frampton, 2017; Sole, Rucklidge, & Blampied, 
2017). The remainder of this chapter will review research investigating the use 
micronutrient treatments in adults for substance dependence and psychological symptoms 
that are often associated with cigarette smoking. It will then consider the potential 
physiological mechanisms that support a micronutrient treatment approach in the 
treatment of psychological symptoms.   
2.2 Micronutrients and substance dependence 
 The lifestyle of addiction often corresponds with diet neglect and the tendency to 
consume foods high in sugars, and low in proteins, vitamins, and minerals. Numerous 
studies have reported on the adverse effects of alcohol, illicit drug use, and cigarette 
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smoking on nutritional status (Albert, Butters, Rogers, Pressman, & Geller, 1982; Alkerwi et 
al., 2017; Cowan & Devine, 2008; Elnimr, Hashem, & Assar, 1996; Islam, Hossain, & Ahsan, 
2001; Lumeng & Li, 1974; Prayurahong, Migasena, Pongpaew, Vudhivai, & Busapathumrong, 
1991; van den Berg, van der Gaag, & Hendriks, 2002). Over half a century of research has 
provided a strong biological rationale for the use of nutrients in the treatment of substance 
dependence. The literature includes numerous case reports and pilot studies (Beasley et al., 
1991; Libby & Stone, 1978; Mathews-Larson & Parker, 1987; Scher, Rice, Kim, DiCamelli, & 
O'Connor, 1976; Smith, 1974), alongside a group of controlled studies, suggesting that high 
dose micronutrient interventions can improve abstinence rates and withdrawal symptoms. 
This section includes a summary of the trials in the investigation of a micronutrient 
treatment on withdrawal.  
Free and Sanders (1978) conducted a six-month pilot study investigating the use of 
high dose ascorbic acid (vitamin C) in the treatment of narcotic drug withdrawal symptoms 
in adults. At the point of intake, participants were able to choose to be in one of three 
groups; 186 participants received medications for symptom relief, 30 received high dose 
ascorbic acid alone, and 11 received a combination of ascorbic acid and medications. At the 
end of the six-month protocol, results showed that the ascorbic acid procedure was more 
effective than the medications in alleviating narcotic withdrawal symptoms, and that the 
combination of both showed the greatest reduction in symptoms. With an average of 2 
symptoms reported in the ascorbic acid group (6.5 at baseline), 1 in the combination group, 
(9 at baseline), and 6.5 in the symptomatic medication group (6.5 at baseline). The results 
should be interpreted with caution as no qualitative analyses were provided.   
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Guenther (1983) randomised 50 male adult participants to receive 63 days of 
conventional therapy for alcohol dependence and 55 to a combination therapy 
(conventional treatment + diet modifications, vitamin and mineral supplements, and 
nutrition education classes). At the six-month discharge the groups did not differ in 
measures of anxiety, depression, or general health (p>0.05). However, 38% of the group 
receiving conventional therapy remained abstinent, compared to 81% of the group receiving 
nutritional and conventional therapy combined, this difference was statistically significant 
(z=4.28, p<0.001).   
 Replogle and Eicke (1989) investigated the use of micronutrients to reduce 
depression and anxiety during alcohol detox. They randomised 44 male participants, who 
had been voluntarily admitted to a residential alcohol program to receive 21 days of 
micronutrients (vitamin C, niacin, vitamin B6, vitamin E) or placebo capsules. There were no 
group differences in measures of depression. However, the micronutrient group showed 
significant reductions in anxiety when compared to the placebo group at the end of the 21-
day detox. Participants in the micronutrient group significantly (p<0.05) decreased by 11 
and 3 points in the State Anxiety Index and State Trait Index respectively, versus no 
decrease and an increase of 1 in the placebo group.  
In the 1980s, Blum and colleagues (1988) conducted the first known double-blind 
RCT, using nutritional formulas containing amino acids, minerals, and vitamins (they 
referred to these as “neuronutrients” or “neuroadaptagens”) to treat cocaine addiction 
(Blum et al., 1988). They randomised participants to three groups: Tropamine (n=24; five 
amino acids, 12 vitamins and minerals), SAAVE (n=14; five amino acids and vitamin B6), or a 
control (n=16; no supplement), during a 30-day inpatient cocaine detox. They reported a 
significant differences (p =0.014) in both drop-out against medical advice in participants 
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randomised to the Tropamine (1/24, 4.2%) formula compared to SAAVE (4/14, 28.6%) and 
control (6/16, 37.5%) at the 30-day follow-up (Blum et al., 1988). They also reported that 
the Tropamine group scored the lowest on the Drug Hunger Index at each follow-up when 
compared to SAAVE and control, with significant differences reported during the first 10 
days of treatment for Tropamine and SAAVE compared to control (Student-Newman-Kuels 
multiple comparison statistics p=0.015 and p=0.007). Treatment staff and physicians also 
qualitatively reported that the patients randomised to Tropamine and SAAVE displayed 
decreases in agitation, outside focus, and drug hunger/craving after as early as five days on 
the treatment. The beneficial effects of SAAVE and Tropamine was supported in research by 
Brown, Blum, and Trachtenberg (1990) who demonstrated that 10-weeks of SAAVE and 
Tropamine significantly reduced relapse rates and enhanced recovery in 30 driving-under-
the-influence offenders with either alcohol or cocaine related problems. Follow-up on both 
SAAVE and Tropamine groups after 10 months revealed a 73% and 53% overall recovery 
rate, respectively.  
Another study administered Ascorbic acid (vitamin C) and vitamin E combined with 
conventional medication to 40 participants with heroin addiction and compared their 
withdrawal syndrome to 30 participants who received conventional medication-alone. They 
found that more participants in the control group (57%) expressed a withdrawal syndrome 
classified as major compared to the vitamin-treated group (17%, chi-squared 15.5, p<0.005) 
(Evangelou et al., 2000).  
2.3 Cigarette Smoking and Micronutrients  
The adverse effects of smoking on nutritional status are well-documented in the 
smoking cessation literature (Alkerwi et al., 2017), however there is limited research that 
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has investigated the manipulation of diet or the use of micronutrients to support smoking 
cessation. The remainder of this section reviews studies that have reported on the beneficial 
effects of micronutrients to reduce withdrawal symptoms and promote cessation from 
smoking.  
Tryptophan, an amino acid, may have antidepressant properties because it increases 
levels of serotonin (Hughes, Stead, & Lancaster, 2007). Bowen, Spring, and Fox (1991) 
hypothesized that tryptophan’s serotonin enhancing action, in conjunction with high 
carbohydrate diet might relieve the negative effects of nicotine withdrawal. Participants 
(n=16) received tryptophan and were instructed to follow a high carbohydrate diet + low 
protein diet, and were compared to participants (n=15) who received placebo pills and 
instructions to follow a low carbohydrate diet. Participants in both groups also received 
two-hour weekly group therapy sessions. Two weeks after their quit date, 75% (12/16) of 
those receiving tryptophan and high carbohydrate instructions were abstinent versus 47% 
(7/15) of the placebo and low carbohydrate diet group, although this difference was not 
statistically significant (p >0.05) (Bowen et al., 1991). These data suggest that a serotonin-
enhancing substance shows promise for use as an addition to existing smoking cessation 
interventions.   
One case study (Harrison, Rucklidge, & Blampied, 2013) used a single case reversal 
(off-on- -off) design to investigate a broad-spectrum micronutrient formula in the treatment 
of ADHD symptoms in an adult. They documented on-off control of psychological symptoms 
as micronutrients were consumed (for 10 and 16 weeks) or withdrawn (for 10 weeks), and 
simultaneous on-off craving and decreases in the use of cannabis and cigarettes, despite the 
addictions not directly being targeted in the treatment protocol. During both “on” phases, 
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the participant quit cigarettes while taking the micronutrients. This case study used 
EMPowerplus, a 36-ingredient vitamin-mineral formula, and one of the most researched 
multi-ingredient formula for the treatment of psychiatric disorders (Harrison et al., 2013). 
This study is the first study reporting on the use of a broad-spectrum micronutrient to 
support smoking cessation.  
In summary, the existing body of literature tentatively suggests that micronutrient 
treatment improves psychological functioning, reduces withdrawal symptoms, enhances 
program retention, and increases the chance of remaining abstinent when trying to quit 
drugs and cigarette smoking. The research investigating the outcomes of using 
micronutrients to assist with becoming abstinent from addictive substances and cigarette 
smoking is limited due to small sample sizes, limited control groups, and blinding. Additional 
large RCT studies are warranted. Nevertheless, withdrawal from smoking is associated with 
numerous adverse psychological symptoms, some of which have been relieved with 
micronutrient supplementation and this is discussed in the next two sections of this chapter.    
2.4 Single micronutrient interventions for psychological symptoms  
Many researchers have investigated the use of single nutrients (e.g., folate, zinc, 
vitamin D) for the treatment of psychological symptoms (Haller, 2005; Kaplan & Leung, 
2011). This single nutrient approach has produced some promising results, although 
symptom improvements are often modest (see; Popper, Kaplan, and Rucklidge (2017) for a 
review). This modest symptom improvement is not surprising as most nutrient risk factors 
for psychological symptoms are related to a combination of nutrients (Kaplan, Crawford, 
Field, & Simpson, 2007). Humans have evolved to need many nutrients in combination for a 
variety of functions, and no single nutrient appears to show more therapeutic potential than 
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any other (Kaplan et al., 2007), therefore, a more efficacious treatment for psychological 
symptoms may be one containing a broad-spectrum of micronutrients.   
2.5 Multi-ingredient micronutrient interventions for psychological symptoms  
Over the last decade there has been a considerable amount of research conducted 
investigating the use of multi-ingredient/broad-spectrum micronutrient formulas for the 
treatment of psychological symptoms. Below is a review of RCTs using micronutrient 
supplements for a range of symptoms that are often associated with withdrawal from 
nicotine and cigarette smoking, suggesting that the use of a broad-spectrum micronutrient 
is a reasonable approach to take to address the psychological symptoms associated with 
nicotine withdrawal.   
Mood Symptoms 
As discussed above, quitting or reducing cigarette smoking can result in withdrawal 
symptoms that consist of negative affect or low mood (Piasecki, 2006), and this can trigger 
cravings to smoke (Brewer et al., 2011). Poor mood has been associated with a deficiency of 
a number of essential vitamins and minerals (Harris et al., 2011). Benton, Haller, and Fordy 
(1995) randomized 209 young (17-27 years) healthy university students to take either a high 
dose of nine vitamins (A, thiamine, riboflavin, B6, B12, C, E, folic acid, and niacin) or a 
placebo for one year under a double blind procedure. At the end of the 12 months female 
participants (n=99) reported significant improvements in scores on the General Health 
Questionnaire (Gender x Treatment X Time interaction (F(3,354)=2.81, p<0.05) when 
compared to placebo, with males (n=110) showing no significant difference (p>0.05). 
Female participants taking the vitamins reported feeling “more composed” (gender x 
treatment x time interaction F(3,348) = 2.65, p<0.05) on the Profile of Mood States when 
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compared to the females taking the placebo capsules, with no significant difference in 
males. All participants taking the vitamin formula reported themselves as feeling “more 
agreeable” on the POMs when compared to taking the placebo (treatment x time 
interaction F(3,348)=3.18, p<0.02).  
A double-blind RCT randomized 225 hospitalized elderly patients suffering from 
various acute illnesses to receive six-weeks of a micronutrient formula containing 12 
vitamins (A, C, D, E, B1, B2, B6, B12, folic acid, niacin, biotin and pantothenic acid) and 11 
minerals (potassium, magnesium, calcium, phosphorous, chloride, iron, zinc, iodine, copper, 
manganese and selenium) or treatment as usual (TAU; normal hospital diet) (Gariballa & 
Forster, 2007). The patients who received a micronutrient formula displayed significantly 
(repeated measures analysis adjusting for baseline depression scores p=0.021) fewer signs 
of depression on a 15-item geriatric depression scale compared to the TAU group, with a 
mean group difference of 1.35 (95% CI, 0.43, 2.27). The positive effect of the supplement on 
depressive symptoms was seen in all patients including those with no symptoms of 
depression, mild depression, and severe depression.  
Gosney, Hammond, Shenkin, and Allsup (2008) conducted a double-blinded RCT 
examining the effect of a micronutrient supplement (selenium, folate, and vitamin C) on 
mood symptoms in 73 nursing home patients over the age of 60. Among those with 
abnormal Hospital Anxiety and Depression Scale (HADS) depression scores at baseline (≥8), 
those in the active treatment group showed a significant increase in selenium levels 
(t(9)=2.94, p= 0.009) and a significant decrease in depression scores (Wilcoxon signed ranks 
test Z =2.15; p= 0.016) after 8 weeks. However, in the placebo group, selenium levels were 
unchanged (t(6)=0.24, p = 0.41) and HAD depression scores did not show significant change 
(Wilcoxon Z = 1.02, p= 0.15) (Gosney et al., 2008). 
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Kennedy et al. (2010) assessed the cognitive and mood effects of a high dose B-
complex vitamin and mineral supplement (Berrocca™) compared to placebo in 215 healthy 
males in a placebo-controlled, double-blind, parallel groups trial. At the end of the 33-day 
treatment period participants who received the vitamin/mineral formula had significantly 
greater improvements in ratings of stress (F(1205)= 5.24, p<0.05) and general health 
(F(1205)= 4.52, p<0.05) as compared to those who received the placebo. Overall trends of 
mood scores (Profile of Mood States) also improved, however, narrowly failed to reach a 
statistically significant difference compared to placebo (F(1196)= 3.77, p=0.054). However, 
analysis of the mood subscales showed a significant increase in self-reported ‘vigour’ ratings 
(F(1196)= 6.03, p<0.05).  
Harris and colleagues randomised 50 healthy men aged 50 to 69 years to a high dose 
multivitamin, mineral, and herbal supplement (Ulitivite™) or a placebo for eight weeks 
(Harris et al., 2011). They reported a significant group difference in the General Health 
Questionnaire scores (t(47)=2.51, p=0.016) and alertness scores on the visual analogue 
mood scale (t(47)= 2.2, p=0.03), with the change in the multi vitamin group being higher 
than the placebo group. There was also a significant treatment effect x time for the total 
Depression Anxiety Stress Scale-42 (DASS-42) score (z=2.1, p=0.03), revealing significant 
symptom reductions in the multivitamin group.  
Sarris et al. (2012) asked semi-structured, open ended questions to explore the 
subjective experience of taking a once-daily multivitamin (Swisse Ultivite; n=55) compared 
to placebo (n=59) in a 16-week double-blind, randomised, placebo-controlled, parallel 
groups trial. In response to a question asking participants about any positive effects of the 
treatment, more participants in the micronutrient group (60%) qualitatively reported at 
least one positive experience compared to those in the placebo group (51%). The two main 
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statistically significant themes identified in the multivitamin group over the placebo group 
were an increase in energy and mental alertness (p= 0.022), and an increase in mood and 
mental/emotional wellbeing (p= 0.027) (Sarris et al., 2012).  
Lewis et al. (2013) evaluated the efficacy of a vitamin B complex (Max Stress B) for 
improving depressive and anxiety symptoms using the Beck Depression and Anxiety 
Inventories (BDI and BAI). They randomised 60 adults who had a diagnosis of major 
depression or another form of depressive disorder to receive the vitamin B complex or a 
placebo control (double-blinded). Results revealed that both groups showed significant 
improvements in BDI and BAI scores from baseline to a 60-day follow-up. The vitamin B 
complex group showed greater improvements in BAI (mean difference 4.2 versus 3.4); 
however, the change was not significant (p>0.05). Conversely, the placebo group showed 
greater improvements in BDI, with both groups showing a significant improvement (mean 
difference 7.5 versus 7.9, p<0.05). However, the participants who received the vitamin B 
complex achieved a more continuous decrease throughout the 30 to 60-day study protocol, 
with the placebo showing no improvement.   
Research suggests that there is a correlation between impaired B-vitamin 
metabolism and elevated homocysteine levels, leading to a heightened risk of depressive 
disorders (Mech & Farah, 2016). Mutations or minor variations in the genes coding for B-
vitamin metabolism can lead to deficient co-enzyme production and lower than optimal 
levels of neurotransmitters (e.g., serotonin, norepinephrine, and dopamine) (Mitchell, 
Conus, & Kaput, 2014). The most common of these gene polymorphisms are the 
methylenetetrahydrofolate reductase (MTHFR) variants (Mech & Farah, 2016). Mech and 
Farah (2016) randomised participants with major depressive disorder and were positive for 
MTHFR polymorphism to receive either a placebo (n=160) or a broad-spectrum 
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micronutrient (three forms of vitamin B9, thiamine, magnesium, and zinc) in a double-blind 
study. They demonstrated that those in the micronutrient group decreased in homocysteine 
levels (Cohen’s d effect size = 0.88) compared to an increase in the placebo group. The 
micronutrient group was also scored significantly lower on the Montgomery-Asberg 
Depression Rating Scale at the eight-week follow-up when compared to placebo (Cohen’s d 
effect size = 0.81) (Mech & Farah, 2016).    
In summary, there is now a substantial body of research that supports the use of 
micronutrient supplements to improve mood symptoms. However, this research relies 
heavily on the use of B-vitamin complexes and mean differences are not always consistently 
statistically significant. Furthermore, there is a lack of RCTs with clinical samples, diminishing 
the generality of the results. Further research in to the use of a broad-spectrum 
micronutrient for the treatment of mood symptoms is needed, in particular with large 
sample sizes (or more replications), long term follow-ups, and recruitment of clinical 
samples.  
Stress and anxiety  
As also noted above, many smokers report that they smoke to alleviate feelings of 
anxiety and to relieve stress (Taylor et al., 2014). Stress is a person’s physiological, 
psychological, and behavioural response when seeking to adapt to internal and/or external 
pressures associated with change. Deficiencies in micronutrients can result in a diminished 
ability to cope with stress, and during times of high stress, essential micronutrients become 
depleted because of dietary increased demand for basic nutrients (Schlebusch et al., 2000). 
Furthermore, stress-related behaviours (e.g., cigarette smoking, alcohol consumption, poor 
nutritional habits, excessive caffeine intake) and symptoms of these behaviours (e.g. 
withdrawal and anxiety) have a negative effect on micronutrient status (Huskisson, Maggini, 
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& Ruf, 2007), and may compromise stress management mechanisms. Multiple RCTs have 
demonstrated the use of micronutrient supplements for the reduction of stress and anxiety 
symptoms.  
 Carroll, Ring, Suter, and Willemsen (2000) investigated the effects of a vitamin and 
mineral supplement (Berocca™) on psychological well-being. They double-blind randomized 
80 healthy adult males (18-42 years), to take either the micronutrient supplement or a 
placebo for 28 days. The micronutrient supplement resulted in consistent and significant 
increases in the General Health Questionnaire (2.1 score increase, F(1,74)=4.1, p<0.05) 
compared to decreases in the placebo group (1.2 score decrease). They also reported 
reductions in anxiety (1.1 score decrease, F(1,73)= 3.9, p=0.05) and perceived stress (1.3 
score decrease, F(1,74)= 6.2, p<0.05) compared to an increase in placebo groups (0.2 and 
1.9 score increase for anxiety and stress respectively). The group receiving the supplement 
also reported being less tired (F(1,73)=3.5, p=0.06) and more able to concentrate (F(1,73)= 
7.49, p<0.05) following treatment compared to the placebo group (Carroll et al., 2000).  
Schlebusch et al. (2000) conducted a double-blind RCT with 300 adults with high 
stress levels across two centres in South Africa, to examine the effects of a taking a 
micronutrient formula (Berocca™) compared to a placebo for 30-days on stress. Although 
both groups showed improvements, the micronutrient group showed more pre-to-post 
improvements (decreases) in the Berocca Stress Index (20.6 versus 15.6, p=0.03), the 
Hamilton Anxiety Rating Scale (6.74 versus 4.60, p=0.01), and the Psychological General 
Wellbeing Schedule (16.4 versus 11.7, p=0.01) (Schlebusch et al., 2000).  
A small body of research has also examined the use of micronutrients to support 
psychological symptoms following natural disasters. Rucklidge, Johnstone, Harrison, and 
Boggis (2011) followed 16 adults with ADHD who were taking a broad-spectrum 
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micronutrient (EMPowerplus) following a magnitude 7.1 earthquake in Christchurch NZ that 
caused property damage and on-going disruption to services such as water, power and 
sewage, compared to a group of adults with ADHD (n=17) who were not taking the 
micronutrients. Before the earthquake, the two groups did not differ in measures of 
depression, anxiety, and stress. However, at two -weeks post-earthquake the micronutrient, 
but not the control group, reported significantly less depression (percentage decrease from 
baseline 66.6%, Cohen’s d =0.73, versus 30.2%, Cohen’s d =0.45), anxiety (76.3%, Cohen’s d 
=0.84, versus 12.9%, Cohen’s d =0.11) and stress (55.1%, Cohen’s d =1.00, versus 8.6% 
Cohen’s d =0.16). Five months after the initial 7.1 earthquake, Christchurch experienced a 
devastating 6.3 magnitude aftershock, which killed 185 people and caused widespread 
destruction to the City. Subsequently, Rucklidge et al. (2012) randomised 91 adults who had 
heightened psychological symptoms (depression, anxiety, stress, trauma symptoms) at 
three-five months post-earthquake to either two doses (four capsules or eight capsules) of a 
broad-spectrum micronutrient (CNE™) or a high dose vitamin B complex (Berocca 
Performance™; one pill/day). A non-randomized control group (n=25) also completed 
questionnaires. All three treatment groups experienced significant decreases in 
psychological symptoms over the four weeks of the trial (p<0.001). However, participants 
taking the higher dose of CNE™ reported significantly greater improvement in mood, 
anxiety, and energy (p<0.05). The CNE™ group were more likely to report being “much” to 
“very much” improved (52% versus 17%) and more likely to continue taking CNE post-trial 
(OR=5.2, p<0.05) compared to the Berocca™ group. In 2013, there was a devastating flood 
in southern Alberta, Canada. Subsequently, Kaplan, Rucklidge, Romijn, and Dolph (2015) 
randomised 56 participants with heightened levels of depression, anxiety, or stress to one of 
three groups; Vitamin D (one pill/day), a Vitamin B-complex (one pill/day), or a broad-
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spectrum micronutrient formula (four capsules/day). At the end of the six-week trial, 
participants taking the B-complex and the broad-spectrum micronutrient showed 
significantly greater reductions in stress and anxiety compared to those consuming Vitamin 
D, with large between group effect sizes (Cohen’s d range 0.76 to 1.08). Thus, the current 
research supports the use of micronutrients to alleviate stress and anxiety symptoms. This 
may be particularly important in times of withdrawal and learning new behaviour post-
quitting.  
Insomnia  
 Sleep is essential to human functioning (Lothian et al., 2016) and insomnia (difficulty 
sleeping) is a core smoking withdrawal symptom. There are no known RCTs that have 
investigated the use of nutrient supplements to treat insomnia (See Appendix I for fuller 
explanation of single case designs). However, one recent multiple-baseline open label study 
investigated the use of a broad-spectrum micronutrient (Daily Self Defence) in 17 adults 
diagnosed with insomnia. Throughout the eight week trial, consumption of the 
micronutrient formula resulted in improvements in insomnia symptoms (Cohen’s d =3.45), 
mood (Cohen’s d =1.33), stress (Cohen’s d =2.53), and anxiety (Cohen’s d =1.36), with large 
effect sizes observed in the reduction of mean insomnia severity ratings (Lothian et al., 
2016). This research suggests that micronutrients can improve sleep, mood, stress, and 
anxiety symptoms, but further single-case replications and larger sample RCTs are needed 
to investigate the efficacy of micronutrients to improve insomnia over a placebo control.  
Irritability  
Currently, there are no RCTs investigating the use of broad-spectrum micronutrients 
in the reduction of irritability in adults. However, there is research supporting the use of 
micronutrients to reduce antisocial behaviors. Gesch, Hammond, Hampson, Eves, and 
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Crowder (2002) gave 231 adult prisoners adequate (in terms of established nutritional 
norms) intakes of vitamins, minerals, and essential fatty acids (26 ingredients) or a placebo 
(in a double-blind study) and compared disciplinary offences before and after 
supplementation. The group receiving the nutritional supplement showed a reduction from 
baseline in their rate of offending by 35%, whereas the group receiving placebo only showed 
a 7% reduction (p<0.001), and those receiving the nutritional supplement committed an 
average of 26% (95% CI 16.3, 53.9) fewer offences compared to those receiving 
placebo(p<0.001) (Gesch et al., 2002). This study was replicated in detail by Zaalberg, 
Nijman, Bulten, Stroosma, and Van Der Staak (2010), where 221 prisoners (aged 18 to 25 
years) received nutritional supplementation that was virtually identical to Gesch and 
colleagues’ formulation or placebo for 1 to 3 months. Findings were comparable to Gesch 
and colleagues’, with a 34% decrease in staff-reported incidents of aggressive and rule-
breaking behaviours (mainly alcohol or drug use) in the group receiving nutritional 
supplementation, compared with a 14% increase (p=0.017) in the placebo group. Other 
assessments however reported no significant reductions in aggressiveness and psychiatric 
symptoms.  
Cost of Daily Essential Nutrients  
 Due to the variety in combinations of nutrients used in the studies discussed it is 
difficult to report on the cost of the formulas studied. However, the cost of the broad-
spectrum micronutrient used in the current research – Daily Essential Nutrients (DEN) – at 
12 capsules/day is NZ$4.71 per day. With cigarettes in NZ costing an average of NZ$1.26 
per/cigarette (see www.smokefree.co.nz), DEN is more cost-effective for any quitter who 
has smoked at least four cigarettes per day, or for an individual who cuts down to no more 
than four cigarettes per day. Furthermore, it is assumed (more controlled research is 
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required to confirm) that DEN (or other nutritional supplement) will only need to be taken 
during the initial weeks of the quit attempt. Thereafter, the financial benefits of not smoking 
will not be offset by the cost of the supplement. 
The research reviewed in this section supports the use of multiple micronutrient 
formulas to facilitate the reduction of some of the psychological symptoms that are 
associated with smoking withdrawal symptoms. A logical next step in this discussion is to 
review the potential mechanisms of action for the therapeutic effect of micronutrient 
supplements on psychological symptoms.  
2.6 Physiological mechanisms of the beneficial effect of micronutrients on psychological 
symptoms and withdrawal 
The mechanisms of action for the beneficial effects of broad-spectrum 
micronutrients assisting with psychological symptoms, including withdrawal and becoming 
abstinent from addictive drugs are not fully known. Many theories have been proposed as 
to why micronutrients might effect change on psychological symptoms. Reviewed here are 
potential mechanisms of positive effects of nutrient supplementation on psychological 
symptoms and withdrawal, including the effect of smoking on nutritional status, reducing 
inflammation in the gastrointestinal (GI) tract and oxidative stress, correcting mitochondria 
dysfunction and inborn errors of metabolism, and addressing deficient methylation 
processes. These mechanisms are not mutually exclusive or exhaustive; they may be 
completely compatible and explain co-existing pathways by which vitamins and mineral 
influence the psychological symptoms of withdrawal and support one to achieve abstinence.  
Cigarette smoking nutritional implications 
 The effects of cigarette smoking on a variety of adverse diseases and health 
outcomes is well-documented (see chapter one); however, smoking also causes direct 
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effects on levels of macro- and micronutrients in the body (Preston, 1991). As discussed in 
chapter one, tobacco smoke contains numerous compounds and gases, many of which are 
oxidants. Antioxidants constitute vitamins, minerals, fibres, fatty acids, and amino acids 
(Pisoschi & Pop, 2015) (e.g. Vitamin E, vitamin C, B-carotene and selenium), and are involved 
in cellular anti-oxidant defence systems. Smoking has been shown to lower the level of 
vitamin C and B-carotene, and cadmium found in tobacco decreases the bioavailability of 
selenium. Tobacco smoke also acts antagonistically to zinc. Vitamin E may be at suboptimal 
levels in the tissues of smokers. Furthermore, compounds from tobacco smoke have been 
shown to reduce levels of several B-vitamins (Preston, 1991). The nutritional status of 
smokers may be further compromised by an inadequate diet (Dallongeville, Marecaux, 
Fruchart, & Amouyel, 1998; Traber, Van Der Vliet, Reznick, & Cross, 2000). Imbalances in 
nutrients may have a role in many of the pathological conditions attributed to smoking and 
withdrawal symptoms upon cessation. Taken together, the research suggests that smokers 
have both lower intakes of antioxidants and are exposed to increased oxidative stress.  
The microbiome and inflammation 
 It would be hard to consider any mechanisms of the beneficial effects of 
micronutrients on functioning, without first considering that at least 90% of the cells in and 
on our bodies are microbial cells, predominantly bacteria. These cells make up our 
microbiome (also known as the gut flora, microflora and microbiota). Microbial cells have a 
variety of functions: to protect the intestinal barrier defence system, digest food, extract 
nutrients that we need, and synthesize these nutrients (Kaplan, Rucklidge, Romijn, & 
McLeod, 2015). Most of these microbial cells reside in the GI tract. The GI tract is an organ 
system that takes in food, digests it to absorb nutrients, and expels the remaining waste 
(Ouwehand, Isolauri, & Salminen, 2002).  
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Any imbalance in gut bacteria, termed dysbiosis, can have various negative 
consequences for the host, such as an over-growth of already-present microorganisms, a 
decrease in the production of short chain fatty acids, an increased susceptibility to intestinal 
pathogens, and can be a pre-disposing factor for the translocation of bacteria from the 
intestines to the interior of the body (Bailey et al., 2011). This translocation of bacteria is 
often referred to as “leaky gut”. Leaky gut stimulates the immune system and causes 
inflammation (Bailey et al., 2011; Maes et al., 2013).  
Depression is associated with increased activation of inflammatory responses (Berk 
et al., 2013) and the increased production of proinflammatory cytokines (Dowlati et al., 
2010). Pro-inflammatory cytokines can also contribute directly to the development of 
depressive symptoms (Dantzer, 2012; Dietrich-Muszalska et al., 2012), leading to the debate 
of whether inflammation causes depression, or depression causes inflammation. 
Longitudinal data suggests that this relationship is complex, with depression sometimes 
preceding elevations of inflammation biomarkers, or the opposite - the biomarker elevation 
precedes the onset of depression (Dantzer, 2012). Inflammatory processes have also been 
demonstrated in bipolar disorder (Hamdani, Tamouza, & Leboyer, 2012) and psychosis 
(Borovcanin et al., 2012). 
Increases in the inflammatory response can make one more susceptible to stress 
(Bailey et al., 2011), a common withdrawal response after cessation from smoking. This 
relationship is also a complex one, as stress exposure significantly changes the structure of 
bacteria in the gut, further aggravating any initial stress response (Bailey et al., 2011; 
Knowles, Nelson, & Palombo, 2008). Gut dysbiosis can be caused by a variety of other 
mechanisms including the use of broad-spectrum antibiotics, a poor diet, the modern very 
clean environment, the innate act of breathing (Kaplan, Rucklidge, Romijn, & McLeod, 
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2015), and notably for this research, cigarette smoking. Cigarette smoke and nicotine causes 
an increase in inflammatory cells in the colon and inflammation in the GI tract due to 
oxidative stress (Cope & Heatley, 1992; Lei et al., 2015; Verschuere, De Smet, Allais, & 
Cuvelier, 2012).  
In summary, inflammation can negatively affect brain function and exacerbate 
psychological symptoms. The association between dysbiosis and inflammatory activation is 
a robust one, but there are many potential causative agents for chronic activation. A regular 
smoker may already have higher levels of gut dysbiosis and inflammation due to increased 
oxidative stress, and this is likely to be exacerbated upon the stressful event of quitting and 
the subsequent withdrawal.  
Oxidative Stress 
Oxidative stress happens in even the most balanced body systems. It occurs because 
normal metabolism (i.e., the innate act of breathing) generates reactive chemical molecules 
that are pro-inflammatory, called reactive oxygen species (ROS). Through the promotion of 
oxidation, the ROS govern cellular signalling, which then stimulates inflammatory processes 
(Lei et al., 2015). Inflammatory responses are what enable us to fight infection, and they 
trigger ROS in the process of that fight. It would be a mistake to categorize inflammation 
and oxidative stress as harmful, given that both are an essential part of a balanced system 
and enable us to maintain health in the face of infection (Kaplan, Rucklidge, Romijn, & 
McLeod, 2015).  
Oxidative stress and ROS-induced damage, however, are also relevant to 
psychological symptoms. Stress can elevate oxidative stress and in turn ROS, and this can 
damage cell structures (Mitochondria, DNA, RNA, and proteins) (Kaplan, Rucklidge, Romijn, 
& McLeod, 2015). ROS-induced damage can contribute to programmed cell death 
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(apoptosis), neurodegenerative diseases such as Alzheimer’s and Huntington’s, and is also 
relevant to mental disorders (Lei et al., 2015). Elevations in biomarkers for oxidative stress 
have been reported for many different types of mental disorders, including ADHD (Ceylan, 
Sener, Bayraktar, & Kavutcu, 2012), bipolar disorder (Andreazza et al., 2008), schizophrenia 
(Dietrich-Muszalska et al., 2012) and as mentioned, in cigarette smokers. Inflammation 
influences oxidative stress, and both are inevitable consequences of normal metabolism, 
(Lei et al., 2015) therefore the next logical question is, what influences oxidative stress? For 
the answer to this question we need to discuss the mitochondria. 
Mitochondria and Mental Health 
Mitochondria are cellular organelles which have a fundamental function of 
producing the bodies energy source adenosine triphosphate (ATP) (Gardner & Boles, 2011), 
and have evolved in humans to manage inflammation and oxidative stress (Kaplan, 
Rucklidge, Romijn, & McLeod, 2015). Mitochondria possess their own genome and 
Deoxyribonucleic acid (DNA), namely mtDNA, this is small and only accounts for 0.3% of 
total cellular DNA. The mtDNA encodes enzymes that are involved in two processes 
(electron transport chain and Krebs cycle) that produce ATP. Many cofactors required for 
proper enzymatic function in the Krebs cycle and electron transport chain are dependent on 
the availability of dietary nutrients. The electron transport chain is efficient in generating 
energy but requires oxygen to do so, and errors in reactions involving oxygen can generate 
ROS. ROS can damage mitochondria and cause DNA mutations. The mtDNA is particularly 
susceptible to ROS-induced damage due to its proximity to the electron transport chain. 
Furthermore, mtDNA has less efficient repair and protective systems than nuclei DNA, which 
results in mutations accumulating at a rate 10 to 16 times faster than nuclei DNA (Gardner & 
86 
 
Boles, 2011). Mutations in mtDNA affect enzyme functioning, decreasing energy production, 
and causes mitochondrial disease and dysfunction. 
Mitochondrial disorders result in decreased production of cellular energy (ATP) and 
the management of oxidative stress and inflammation (Harrison et al., 2013). All tissues in 
the body are dependent on the electron transport chain process, and mitochondria are in all 
our cells, therefore mitochondria dysfunction can affect virtually every organ and system in 
the body (Gardner & Boles, 2011). Given that brain tissue requires high levels of ATP for 
metabolism, and the susceptibility of mtDNA to oxidative stress and mutation, it is not 
surprising that investigators are proposing that mitochondrial dysfunction is a causal 
pathway to consider in mental disorders. Research has demonstrated that ATP production is 
compromised in bipolar disorder (Young, 2007), ADHD (Russell et al., 2006), autism 
spectrum disorder (Rossignol & Frye, 2012), and depression (Gardner & Boles, 2011). When 
all steps of cellular metabolism and energy production are combined for consideration, it 
appears as if virtually all known minerals, vitamin, amino acids, and essential fatty acids are 
involved (Kaplan, Rucklidge, Romijn, & McLeod, 2015). For that reason, it is reasonable to 
consider using a broad spectrum of nutrients to optimize mitochondrial function, and 
subsequently increase energy production and decrease oxidative stress and inflammation.  
Inborn errors of metabolism  
Another potential mechanism pathway that deserves mention are inborn errors in 
metabolism, as they may reduce neurotransmitter functioning and contribute to 
psychological symptoms in idiosyncratic ways. Inborn errors of metabolism are a group of 
disorders each of which results from deficient activity of a single enzyme in a metabolic 
pathway (El-Hattab, 2015). Inborn errors in metabolism can have many detrimental effects 
on the brain, including reducing co-enzyme reactions and neurotransmitter functioning 
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(Kaplan et al., 2007). At least one third of all gene mutations result in the corresponding 
enzyme having a decreased binding affinity for the co-enzyme (Ames, Elson-Schwab, & 
Silver, 2002). Approximately 50 human genetic diseases that are due to defective enzymes 
can be remedied by the supplementation of high doses of the vitamin or mineral 
component of the corresponding co-enzyme, which partially restores enzymatic activity 
(Ames et al., 2002). It is possible that brain imbalances, for example psychological symptoms 
and withdrawal, represent the same type of dysfunction and can be remedied in the same 
way. That is, psychological and withdrawal symptoms are the result of decreased co-
enzymes being available for optimal neurotransmitter functioning, and the individual 
requires higher (perhaps pharmacological) amounts of micronutrients for normal metabolic 
functioning to be restored (Kaplan et al., 2007). Micronutrient treatment should 
theoretically provide the brain with sufficient co-enzymes, so that even enzymes with 
considerably reduced activity in metabolism can become supersaturated with the necessary 
co-enzymes and near-normal function is restored (Harrison et al., 2013).  
Deficient methylation processes 
 Methylation reactions represent another interface between nutrients and genetic 
expression. Methylation is simple in terms of mechanism - it is the process of adding a 
methyl group to a molecule; however, it has huge and complex impacts on physiological 
functioning (Kaplan et al., 2007). There are hundreds of methylation processes: they switch 
on genes, activate enzymes, and regulate the amount of proteins generated by genes. DNA 
transcription cannot occur without methylation, nor can the synthesis of neurotransmitters 
(Kaplan et al., 2007).  
Several studies have suggested that low levels of methylation are associated with 
depression, fatigue, autism spectrum disorder, and other neurological diseases (Botez, 
88 
 
Young, Bachevalier, & Gauthier, 1979; Bottiglieri et al., 2000; Ciernia & LaSalle, 2016; 
Jakovcevski & Akbarian, 2012; Kato & Iwamoto, 2014; Mischoulon & Fava, 2002; Schmidt et 
al., 2012; Stuffrein-Roberts, Joyce, & Kennedy, 2008). Evidence also suggests that 
psychological stress impairs methylation processes, resulting in altered availability of 
micronutrients for neurotransmitter synthesis and function (Kaplan et al., 2007; Yang et al., 
2006).  
Furthermore, the impact of cigarette smoking can persist for extended periods 
following cessation, and may involve changes in DNA methylation. Wan et al. (2012) 
analysed genome-wide methylation data (n=1434) and identified 15 sites that were 
significantly associated with cigarette smoking, suggesting the existence of site-specific 
methylation changes in response to smoking, which may contribute to the long-term risks 
associated with cigarette smoking that persist after abstinence.  
Nutrition plays an important role in methylation, as many dietary micronutrients 
such as folate and vitamin B12 are important methyl donors and co-factors, therefore an 
inadequate supply of micronutrients can disrupt methylation (Scott, Molloy, Kennedy, 
Kennedy, & Weir, 1994; Stevens, Rucklidge, & Kennedy, 2017). Supplementation with 
micronutrients during the stress of withdrawal may correct deficiencies and increase the 
supply of methyl donors restoring adequate methylation (Stevens et al., 2017), moderating 
the stress of withdrawal.  
Conclusion  
 The mechanisms reviewed in this section represent a summary of the current body 
of research for understanding the use of micronutrients to reduce withdrawal and improve 
psychological functioning. A variety of broad-spectrum micronutrient formulas have been 
researched, making the comparisons across studies challenging. It is unclear if one formula 
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can be replaced by another and produce the same or similar effects. Despite this, the 
research is generally consistent that micronutrient combinations are beneficial for 
psychological functioning and withdrawal symptoms. None of the aforementioned studies 
have investigated the efficacy and safety of the use of high dose micronutrient formulas 
long-term. Further research using large sample RCT double-blind designs with reported 
effect size measures and long-term follow-up are needed, particularly in the area of 
micronutrient and addiction research. 
There are multiple pathways to consider for the use of micronutrients to support 
psychological functioning during withdrawal, and these pathways may occur in isolation or 
simultaneously. Further research in the field of nutritional psychiatry is needed to resolve 
these questions, however, the beneficial effects of micronutrients may well contribute to 
optimizing brain functioning during and after withdrawal. Any insufficiency in the neural 
availability of critical enzymes and co-factors, perhaps exacerbated by nutritional 
deficiencies, illness, injuries, lifestyle, stress, and individual differences in metabolic 
efficiency, may be particularly significant when coping with stress and withdrawal symptoms 
and while learning new patterns of behaviour post-quitting.  
2.7 Rationale and Aim of Current Research 
Current tobacco cessation products increase the chance of quitting. However, 
relapse rates for quit attempters remain high. Treatments that are safe, effective, relatively 
inexpensive, and readily available are needed, either on their own or in conjunction to other 
treatments. A small body of literature shows potential for the use of micronutrients to be 
used as a treatment for substance dependence. Further investigation into the effects of 
broad-spectrum micronutrients for the treatment of smoking cessation will provide a 
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clearer picture of this relationship. The current research aims to investigate the efficacy and 
safety of a broad-spectrum micronutrient to support smoking cessation in adults who want 
to quit smoking. The studies were designed so that, first, any effects of the broad spectrum 
micronutrient on smoking per se was assessed prior to the quit attempt, and second, there 






















Chapter 3: Study 1: Mineral-Vitamin Treatment for Smoking Cessation: A 
Pilot Double-Blind Randomised Placebo-Controlled Trial 
The following chapter presents a pilot study investigating a smoking cessation 
treatment involving the consumption of a broad-spectrum mineral-vitamin formula, Daily 
Essential Nutrients (DEN; see Appendix II for ingredient list and the dose used in this study 
and compared with the recommended dietary allowance), in conjunction with Quitline NZ 
support and advice. DEN is similar to the formula used by Harrison et al. (2013) (i.e., 
EMPowerplus), and is one of the most studied micronutrient formulas. Simpson et al. (2011) 
assembled the data from both published and unpublished studies of EMP+ and found no 
abnormalities in the blood tests or clinically meaningful negative outcomes due to toxicity. 
Minor, transitory adverse events, were identified, namely headaches and gastrointestinal 
problems (Simpson et al., 2011). However, they acknowledge that, although the results 
support the safety and tolerability of taking EMP+ on its own, combining the formula with 
psychiatric medications may result in complex interactions and should be monitored closely 
(Simpson et al., 2011; Popper, 2001). 
Aims and Hypotheses 
Based upon the tentative theory outlined in the previous chapter explaining how 
micronutrient supplementation may improve brain function, and on the limited research 
supporting the use of nutritional supplements to relieve withdrawal symptoms and assist 
with quitting addictive drugs, I hypothesised as follows: 
1) The intensity of withdrawal symptoms following a quit attempt would be less for the 
micronutrient + Quitline group compared to the placebo + Quitline group, and the 
intensity of withdrawal would predict likelihood of and/or time to relapse.  
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2) Participants randomized to the micronutrient + Quitline intervention would be more 
likely to succeed in making an initial quit attempt and be more likely to have 
remained quit at each study waypoint compared to placebo + Quitline.  
3) Psychological symptoms of some or all of depression, anxiety sensitivity, stress, and 
negative mood would increase during a quit attempt, but the magnitude of this 
increase would be less for the micronutrient + Quitline group compared to the 
placebo + Quitline group.  
3.1 Method 
Design  
This pilot study was a single-case multiple-baseline design with replication across 
participants, nested within an active treatment-placebo double-blind randomized trial. 
Participants are randomised to a baseline phase of one, two, or three weeks, followed by a 
four-week pre-quit micronutrient or placebo phase, and then a 12 week micronutrient + 
Quitline or placebo + Quitline phase. A single-case design was selected for this study 
following the recommendation of Blampied (2013) that such designs should be used in the 
early stages of investigation of novel treatments, before any RCT’s are conducted. Blampied 
(2013) argued that single-subject research is ideal for exploring novel questions, since it is 
truly experimental and can document causal relationships between independent and 
dependent variables. Single-case designs typically involve multiple participants in a single 
study (Horner et al., 2005), but without the demand for the large numbers of participants 
needed in group-based RCT research designs (Blampied, 2013), thus reducing the risks 
associated with exposure of participants to novel treatments while sparing the allocation of 




Inclusion criteria were that participants be adults ≥18 years old, current smokers of 
≥three cigarettes/day for the previous 12 months, not currently engaged in smoking 
cessation, not on psychoactive medication four weeks prior to baseline, and able to come in 
to the University of Canterbury approximately every four weeks for meetings. Exclusion 
criteria were being under 18 years old, taking psychiatric medication in the four weeks prior 
to baseline (combining the formula with psychiatric medications may result in complex 
interactions and should be monitored closely (Simpson et al., 2011; Popper, 2001)), any 
illness needing concurrent treatment and/or that may affect participation in the study, and 
being pregnant or breastfeeding (See Consolidated Standards of Reporting Trials (CONSORT) 
diagram; Figure 3.1).  
Recruitment 
Participants were recruited in Canterbury, New Zealand, through advertising on 
posters at local businesses and posts on social media (Mental Health and Nutrition Research 
Group’s Facebook page) from June 2013 until December 2014. Advertising referred 
potential participants to a website (http://bit.ly/UCnutritionresearch) where they could 
access information about the study (including the information sheet, see Appendix III), the 
contact details of the researchers, and a link to an online eligibility screening survey 
developed using Qualtrics (http://www.qualtrics.com). The survey contained a summary of 
the study, demographic information questions (see measures section), previous and current 
smoking information, history of mental illness, and questions on past and current 
psychoactive medication use. If a participant was not eligible to participate they were 




The micronutrient formula was supplied gratis by NutraTek Health Innovation Inc 
(Raymond, Alberta, Canada). It is a broad-spectrum micronutrient formula for oral 
administration, containing 17 minerals, 13 vitamins, four amino acids, and four 
antioxidants/botanicals (see Appendix I). The contents of the pills were independently 
tested by SupraNaturals in March 2016 and all quality control samples processed yielded 
acceptable results. All capsules were used within the expiry date, with no compromise in 
potency. The placebo formula (also supplied gratis by NutraTek Health Innovations Inc) 
included a small amount of riboflavin to mimic the urine colour associated with taking 
micronutrients (see Appendix I). The placebo has demonstrated effective masking in a 
recent study (Rucklidge, Eggleston, Johnstone, Darling, & Frampton, 2018). Both capsules 
were identical in appearance. At the completion of baseline participants were given a four-
week supply of placebo or micronutrient capsules, in plain containers with their name, 
participant number, date received, and date to start taking the capsules on the container. 
Participants titrated up to the full dose of 12 capsules/day (in routine use, NutraTek Health 
Innovation Inc recommends consuming between 12-15 capsules/day to enhance mental and 
physical well-being) over seven days, taking four capsules three times daily with food and 
plenty of water for the remainder of the trial. Based on previous clinical experience, 
expectation was that participants would typically experience a slow and gradual effect from 
the capsules within four weeks, therefore the pre-quit phase ensured that the metabolic 
effects of the micronutrients were established before quitting was attempted, and 
permitted any effects of the micronutrients or placebo alone on smoking and related 




A printed copy of the Quit Book was supplied to all participants and read through 
with the researcher before their quit attempt. The Quit Book (see; www.quit.org.nz) 
explains each step of Quitline’s five step program; 1) Set a Quit date, 2) Know your reasons 
for quitting, 3) Know your triggers, 5) Stay Quit. Step 4, the use of NRT, was removed for this 
study. The first day of the quit phase was the participant’s target quit day, a day where they 
attempted to stop smoking. Participants continued to consume 12 capsules/day during the 
quit phase, receiving a four-week supply at each study waypoint meeting (weeks 4, 8, and 
12 post-quit day).The participant was instructed to contact Quitline if they had a cigarette 
(lapse), no other behavioural support was provided. The quit phase intervention for this 
study was micronutrient + Quitline or placebo + Quitline for 12 weeks; however, for ease to 
the reader the two groups are referred to as micronutrient and placebo. At the end of the 
quit phase participants came to the laboratory to complete study waypoint questionnaires, 
hand in left over capsules, discuss that Quitline can continue to support them, and receive 
advice on how to purchase the capsules commercially should they wish to continue taking 
them. Participants were informed as to their randomly allocated condition at the end of 
data analysis and the plain English summary of the results (with further results sent on 
request).   
Randomisation, allocation, and blinding 
An independent research assistant randomly assigned participants to a baseline of 
one, two, or three weeks and in a 1:1 ratio to micronutrient or placebo capsules with 
www.randomization.com using block randomisation (blocks of four). Opaque envelopes 
labelled with a participant number contained the specified baseline length for each 
participant. The envelopes were opened and the blind for baseline length was broken after 
the participant consented to take part in the study. A collaborating pharmacist received a 
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list of participant numbers with their associated randomised condition allocation, but the 
randomisation sequence was concealed from all researchers involved in the study until the 
end of data analyses. All capsules (i.e., containing micronutrient or placebo) were pre-
packaged by the pharmacist in plain containers and labelled with the participant number. A 
sealed envelope was contained within each pill package only to be opened in an emergency 
(e.g., the participant’s health deteriorated significantly), permitting the blind to be broken in 
an emergency for only that one participant. A separate randomization sheet labelled with A 
and B groups (micronutrient or placebo) was kept by a research assistant and at the end of 
data collection this list was given to the researcher (PR) to permit analysis of the results.  
Concomitant medication  
 Non-psychiatric medications (e.g., oral contraceptives, antidiabetic drugs, and 
statins) were allowed case-by-case. 
Withdrawal criteria  
Participants were able to withdraw voluntarily from the study or the primary 
investigator may discontinue a participant from the study. The primary investigator may 
discontinue or withdraw a participant from the study for the following reasons: pregnancy, 
an adverse event associated with the intervention, medical condition(s) or other situation(s) 
occur such that continued participation in the study would not be in the best interest of the 
participant, and if the participant meets exclusion criteria (either newly developed or not 
previously recognised). A participant is considered lost to follow-up if he or she fails to 
return for a scheduled visit and is unable to be contacted by researchers (after three 
attempts on mobile, email, and phone call). If participants wanted to stop their participation 
they were asked to come in to the University to complete study way-point questionnaires. 
Relapse from smoking (≥three days smoking) signalled the end of participation in the study, 
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participants were asked to complete study waypoint questionnaires and were 
recommended to contact Quitline NZ for advice.  
Baseline assessments  
Meetings (approximately one hour) with each individual participant were held at the 
University of Canterbury Mental Health and Nutrition Research laboratory in the Psychology 
Department. At the baseline meeting participants were given a full description of the study, 
and had an opportunity to ask any questions before giving written consent (Appendix IV). At 
the end of consent participants received their participant number and baseline length (one, 
two, or three weeks), and used a computer in the laboratory to complete baseline 
questionnaires through Qualtrics. After the questionnaires were completed using Qualtrics 
participants received instructions to complete the daily diary (Figure 3.2) every day for their 
assigned baseline (one, two, or three weeks). This phase provided baseline assessments 
(discussed below) of cigarettes/day, withdrawal symptoms, nicotine dependence, and 
psychological health and well-being, and any baseline occurrence of side effects potentially 
associated with the consumption of micronutrients. 
Demographic information. Participant’s age, gender, and ethnicity were obtained at 
baseline.  
Smoking History. Participants reported the age they first puffed a cigarette and began 
regular smoking, and how many times they had attempted to quit smoking (for more than 
24 hours). 
Fagerström Test for Cigarette Dependence (FTCD). The FTCD is a six-item questionnaire that 
assessed baseline levels of cigarette dependence, with scores ranging from zero (least 
dependent) to 10 (most dependent) (Fagerström, 2011; Horner et al., 2005). A score of six 
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or higher is recognised as establishing cigarette dependence and a score of seven or higher 
as high dependence (Yeomans et al., 2011); Cronbach’s alpha=0.64 (Pomerleau, Carton, 
Lutzke, Flessland, & Pomerleau, 1994). 
Mood and Physical Symptoms Scale (MPSS). The MPSS measures symptoms of withdrawal 
and was completed using the daily diary (Figure 3.2) during the baseline phase (1,2, or 3 
weeks). The core items of the MPSS consist of five single-item ratings of depressed mood, 
irritability, restlessness, hunger, and poor concentration. All items are rated on a five-point 
scale from applying  “not at all” to “extremely”, with the total score ranging from 0-25. In 
addition to these five ratings, the MPSS contains two six-point sub-scales (0-5) to measure 
time spent craving cigarettes and strength of the cravings. The MPSS only uses one item to 
assess each withdrawal symptom keeping the scale as brief as possible and suitable for the 
daily self-report diary; Cronbach’s alpha=0.78 (West & Hajek, 2004).   
Cigarettes/day. For the baseline phase participants recorded any cigarette smoking (a 
cigarette is lit and at least one puff taken) in the daily diary (Figure 3.2).  
Date:  
Please record the amount of cigarettes you inhale (even 













  Please show for each of the items how you have been feeling 
     over the past 24 hours (circle one number for each item). 
                         Not at all   Slightly   Somewhat  Very  Extremely 
    Depressed                1              2                3            4             5  
    Irritable                     1              2                3            4             5 
    Restless                     1              2                3            4             5 
    Hungry                       1              2                3            4             5 
    Poor concentration 1              2                3            4             5 
 
    How much of the time have you felt the urge to smoke in the   
    past 24 hours? (circle one number). 
         All the  Almost all  A lot of the    Some of   A little of    Not at  
         time     the time       time               the time    the time      all  
            5             4               3                      2                   1           0  
 
       How strong have the urges been? (circle one number).  
        Extremely strong    Very strong   Strong   Moderate   Slight   No urges 
                   5                                4               3                 2              1            0  
Figure 3.1. Daily Diary given to the participants for use throughout the trial.  
Depression Anxiety Stress Scale-21 (DASS-21). DASS-21 is a 21-item questionnaire consisting 
of three self-report scales designed to measure negative emotional states of depression, 
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anxiety, and stress (Lovibond & Lovibond, 1995). Participants used a four-point severity 
scale to rate the extent to which they have experienced each state in the week prior to 
baseline. Each of the three DASS-21 sub-scales contain seven items, and scores for 
depression, anxiety, and stress subscales were calculated by summing all the scores for 
relevant items and doubling the outcome to align with DASS-42 scores (range 0-42). 
Cronbach’s alpha scores = 0.88 for depression, 0.82 for anxiety, and 0.90 for stress (Henry & 
Crawford, 2005).  
Anxiety Sensitivity Index (ASI). The ASI is a 16-item measure developed to assess a person’s 
beliefs about the social and somatic consequences of anxiety symptoms. These beliefs 
contribute to fear learning, avoidance behaviour, and anxiety disorders. Participants self-
reported how much each item was consistent with their usual way of thinking in the two 
weeks prior to baseline from zero (very little) to four (very much). Total scores range from 0-
64; Cronbach’s alpha= 0.71-0.75 (Reiss, Peterson, Gursky, & McNally, 1986).   
Diener and Emmons Mood Form (DEMF). Positive and negative affect/mood were assessed 
at baseline using the nine items of the DEMF. The sum of four specified items gives a 
positive affect score (DEMF-P) and the sum of the remaining five gives a negative affect 
score (DEMF-N); Cronbach’s alpha= 0.89 for DEMF-P and 0.84 for DEMF-N (Diener & 
Emmons, 1985).   
Side effects. Participants were asked about presence/absence of side-effects potentially 
associated with the consumption of nutrients (e.g., headache, nausea, stomach aches, dry 
mouth) and to report any other possible effects/concerns. These were followed up and 
monitored by the researcher (PR). 
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Primary outcome  
 
Minnesota Nicotine Withdrawal Scale- short form (MNWS). Changes in scores on the MNWS 
at each study waypoint provided the primary outcome measures. The MNWS-short form 
measures withdrawal symptoms of craving, irritability, anxiety, difficulty concentrating, 
restlessness, increased appetite/weight gain, depression, and insomnia by rating each 
symptom from zero (not present) to four (severe). The sum of the eight scores gives an 
overall rating of withdrawal symptoms severity (range 0-32). The MNWS has been validated 
in multiple smoking cessation studies (Donny et al., 2015; Ebbert et al., 2014; Zvolensky et 
al., 2009); Cronbach’s alpha= >0.8 (Toll, O'Malley, McKee, Salovey, & Krishnan-Sarin, 2007). 
Participants completed the MNWS-short form at baseline, at the end of the pre-quit four 
week phase (pre-quit four weeks), and at 4, 8, and 12 weeks post target quit day during the 
smoking cessation phase.  
Secondary outcomes 
  
Mood and Physical Symptoms Scale (MPSS). Participants monitored changes in daily 
withdrawal symptoms via the MPSS using their daily diary in weeks 1-4, 8, and 12 of the quit 
phase.    
Cigarettes use. For the first and last week of the pre-quitting phase participants recorded 
any cigarette smoking in the daily diary (Figure 3.2). A participant was counted as having a 
quit attempt if they quit smoking for ≥24 hours, and a quit success if they were abstinent for 
≥three days after their quit day. Participants reported cigarette use/lapse during the quit 
phase by using the daily diary (weeks 1-4, 8 and 12), by contacting the researcher through 
email or text (on weeks that did not require completion of daily diary), or by self-report at 
study waypoint meetings. Smoking relapse was monitored with self-report (not 
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biochemically confirmed) at each meeting, “Have you had a cigarette in the past four 
weeks?”, participants were instructed to contact the researcher if they smoked for three 
days in a row throughout the quit phase, this counted as a relapse. Continuous abstinence 
(quit rate) was defined counted if a person did not relapse from the target quit day to the 
specified study waypoint.   
Psychological measures. Changes in psychological symptoms during the pre-quit and quit 
phase were measured using the DASS-42, ASI, and DEMF. Participants completed the 
questionnaires at each study waypoint using Qualtrics computer software.  
Side effects. Participants were asked about presence/absence of side-effects at each study 
waypoint. Any reported side effects were followed up and monitored by the researcher 
(PR). If any adverse effects were reported they would have been discussed with the 
consultant psychiatrist (Prof. Mulder) to determine whether further investigation was 
required. Prof. Rucklidge was consulted on all aspects of the project, and was aware of any 
foreseeable risks. The trial would of been terminated if serious adverse effects known to be 
caused by the nutrients occurred.  
Compliance to capsule intake. Capsules were counted at the end of the study for the four 
weeks prior to each study waypoint. If a participant consumed ≥80% of their capsules they 
adhered to capsule protocol. 
Sample Size 
In a single-case multiple-baseline design with replication across participants the 
minimum number of phase repetitions needed to meet the standard advanced by Horner et 
al. (2005) is three, but four or more is recognized as desirable (Kratochwill et al., 2010). With 
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12 replications per study arm (24 participants in total), this project more than meets these 
design quality requirements.  
Statistical Analysis 
The researcher (PR) was blinded to the treatment conditions throughout data 
analysis. The intent-to-treat (ITT) sample included all participants who consented to 
participate in the study (n=24) regardless of whether they were fully compliant with study 
protocol. No interim analyses were conducted. Frequencies of the categorical variables of 
quit/not quit, dropped-out/continuing, and side-effects/no side effects at specified study 
waypoints were analysed using chi-squared (χ2) tests with odds ratios (OR) and 95% 
Confidence Intervals (CI), using IBM SPSS Statistics version 20. 
Primary Outcome. The primary outcome measure defined a priori was changes in MNWS 
scores at each study waypoint when compared to baseline and pre-quit for those in the ITT 
sample who provided data (i.e., those who did not drop-out), with MNWS median scores, 
range of scores, and sample size calculated for the micronutrient and placebo groups 
separately at each study waypoint. Individual Effect size (ES) measures were calculated 
using Percent Deviating from the Median (PDM), otherwise known as Percent Exceeding the 
Median (i.e., as percent below or above the median depending on the direction of 
therapeutic change) (Parker, Vannest, & Davis, 2011). The PDM approach is appropriate for 
the calculation of effect size of a single-case experimental design to support the analysis of 
visual data (Ma, 2009). The null hypothesis of the PDM approach is that if the treatment has 
no effect, the data points in the treatment phase would fluctuate around the baseline 
median. Ma (2009) suggested that PDM is based on the assumption that if the intervention 
is effective, data points will fall predominately on the therapeutic side of the median. PDM 
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is recommended for use in instances when there is some variability over time or a significant 
outlier is present in the baseline data (Lenz, 2013). Ma (2009) reported that PDM in the 
range 70-90% indicated a moderate treatment effect and PDM >90% a large effect. Since 
median data were used to calculate the ES for individuals, medians were also used as 
measures of central tendency for the groups as well. 
Visual analysis of individual change in MNWS scores were additionally undertaken 
using modified Brinley plots using SigmaPlot 14 Software (Blampied, 2017). Brinley plots 
were originally used to analyse group data from cognitive psychology experiments (Brinley, 
1965). Subsequently, modified Brinley plots have been used to summarize changes over 
time and in identifying systematic effects of an intervention when modified to display each 
individual’s data (Blampied, 2017; Rucklidge & Blampied, 2011). The way modified Brinley 
plots display data is as a scatter-plot that uses orthogonal X-Y coordinates with the same 
origin and scale. Time one (t1; baseline) scores for each participant are normally plotted on 
the X-axis and time two (t2; treatment/intervention phase) scores on the Y-axis. If there are 
no systematic differences between the conditions the individual data points will lie on or 
around the 45-degree diagonal line of no change (i.e., X=Y); however, if there are systematic 
differences between the conditions the points will deviate from the line. When a higher 
score indicates greater impairment/deterioration, points that fall above the line indicate 
greater impairment and scores fall below the line indicate improvement. When a higher 
score indicates improved functioning, points that fall above the line indicate improvement 
and points that fall below the line indicate greater impairment. Where clinical cut-off scores 
for a measure exist, these can be added as horizontal and vertical lines, such that it is 
immediately apparent which individuals have changed from clinical to non-clinical status 
over time (Rucklidge & Blampied, 2011).  
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A key question in interpreting modified Brinley plots is to interpret any change over 
time – how much change is required to be evidence of a clinically or practically meaningful 
change? (Blampied, 2017). A sophisticated measure of change over time uses the Reliable 
Change Index (RCI) (Jacobson & Truax, 1991). The RCI permits the detection of change that 
is reliable (assuming a null hypothesis of zero change) because it exceeds the margin of 
measurement error defined as ±1.96SDiff where SDiff is the standard error of measurement of 
the difference scores (derived from the standard error of measurement; see below). There 
are a number of formulae for calculating the RCI, depending on particular assumptions 
about the psychometric properties of the measure (see; Wise (2004) for a review), but the 
Jacobson and Truax (1991) formula has been widely used:  
RCI = (x1 – x2)/Sdiff 
and RCI(0.05) = Sdiff x 1.96 
where x1 and x2 are an individual’s scores at t1 and t2; Sdiff = √2(SE)2; SE = s1 √1- rxx; s1 is the 
standard deviation of the normal population, a control group, or the pre-treatment group 
(taken from the research studies above from where Cronbach’s alpha was obtained); and rxx 
is the reliability of the measure (preferentially Cronbach’s alpha). Jacobson and Truax (1991) 
showed that the RCI can be used to compute upper and lower bounds demarcating a 
rectangular band of uncertainty about the modified Brinley plot diagonal. Individuals whose 
data points lie within this band have not shown reliable change (i.e., change is unlikely to be 
due to measurement error alone) but those lying outside can be considered as 
demonstrating reliable change, which may be classified as reliable improvement or reliable 




Baseline information and smoking history. Baseline information was reported for all ITT 
participants (n=24) as an average for each group, t-tests and χ2 analyses were conducted to 
identify any significant group differences at baseline, using p ≤0.05. 
MPSS Scores. Median and range was calculated for each daily diary collection study 
waypoint and ES measures were calculated using PDM.  
Drop-out. A drop-out was counted if the researcher could not contact the participant (lost to 
follow-up) or if the participant said they no longer wanted to take part in the trial 
(withdrawal). 
Quit Attempts and quit success. Frequency of quit attempts (≥24 hours continuous 
abstinence), and quit rates at three days (quit success), and weeks 4, 8, and 12 were 
compared between groups by χ2. Percentage of quit success at four-weeks was compared 
with Quitline’s continuous quit rate (Quitline NZ, 2013).  
Cigarettes/day. Cigarettes/day during baseline and pre-quit for participants who made a 
quit attempt were analysed visually using time-series graphs. Median and range was 
calculated at each study waypoint and ES measures were calculated using PDM.  
Psychological symptoms. Median and range was calculated for the DASS-21, ASI, and DEMF 
scores at each study waypoint with PDM effect size in the direction of therapeutic change.  
Side effects and capsule compliance. Differences in capsule compliance and side effects 
were calculated using χ2 tests. 
Data management  
All study data is to be contained in locked storage systems; either a password 
protected computer system at the University of Canterbury or on a web-based data 
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collection system (www.canterbury.qualtrics.com) for electronic documents, while hard 
copies will be kept in secure filing cabinets at the university. 
Renumeration  
Participants received a NZ$10 petrol voucher at every second face-to-face meeting 
to help cover travel costs.  
Ethical Considerations 
The University of Canterbury Human Ethics Committee approved the study (HEC 
2013/55) and the trial was registered with Australia New Zealand Clinical Trials Registry: 
ACTRN12613001188729.  
3.2 Results 
Recruitment for study one was from 01/06/2013 until 22/12/2014. The last data 
collection from a face-to-face interview was 2/06/2014 and data was locked on the 
15/07/2014. The flow of participants through the study is shown in Figure 3.2. Thirty-seven 
participants were assessed for eligibility of which 37 were excluded. Randomisation did not 
achieve comparable groups with regards to baseline length, with more participants in the 
micronutrient group randomised to a two week baseline, and more participants in the 
placebo group to a three week baseline (Figure 3.2). Two participants were lost to follow-up 
during the baseline phase. The placebo group had more participants withdraw during the 
pre-quit phase compared to the micronutrient group. Overall retention rates were 60% (6 

























Assessed for eligibility (n=37) 
Excluded (n=13) 
• Declined to participate (n=3) 
• Did not meet inclusion 
criteria (n=2) 
• On medication (n=7) 
• Moved away (n=1) 
Randomised (n=24) 
Randomised one week baseline 
• Micronutrient group (n=2) (lost 
to follow up n=1) 
• Placebo group (n=3) 
 
Randomised two week baseline 
• Micronutrient (n=8) 
• Placebo (n=2)  
 
Randomised three week 
baseline  
• Micronutrient (n=1) 
• Placebo (n=8) (lost to 
follow up n=1) 
 
Micronutrient formula + Quitline (n=11) 
• Lost to follow up pre-quit (n=1)  
• Quit attempt (n=11) 
• Relapse 1-28 days (n=3), lost to 
follow-up (n=1) 
• Relapse week 4-8 (n=2) 
• Relapse week 8-12 (n=1)  
• Complete full intervention (n=4) 
  
Placebo + Quitline (n=11) 
• Lost to follow-up pre-quit (n=1),  
• Withdrawal due to: side effect(s) (n=1), 
thought on placebo (n=2), did not want 
to quit (n=1)  
• Quit attempt (n=5) 
• Relapse 1-28 days (n=2)  
• Completed full intervention (n=3) 
Data analysed (n=24) 
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Demographic and Smoking information 
In the event that participants reported two ethnicities, ethnicity was randomised 
according to NZ Statistics Guidelines, under this system, Māori had priority coding, 
followed by Pacific, then Asian, then other ethnic groups, with people of only European 
ethnicities last. The average age of participants at baseline in the placebo group was 32.8 
years and 31.5 years in the micronutrient group. A majority of the sample (75.0%) were NZ 
European. Randomization did not achieve comparable study groups for gender ratio, with 
more males in the placebo group (8 versus 4; t(11)=2.35, p=0.04), and nor for baseline 
number of cigarettes/day (14.9 cigarettes/day placebo vs 10.5 cigarettes/day micronutrient; 
t(23)=5.09, p<0.001). Average nicotine dependence (FTCD) was high (≥7) in both groups. 
Participants in the placebo group had previously made an average of 3.2 quit attempts and 
the micronutrient group had made on average 2.3 attempts (Table 3.1.).  
Table 3.1. Demographic characteristics and smoking information of the Intention-to-treat 
sample (n=24).  
 Placebo Group  
(n=12) 












Age (years) (SD) 







Ethnic origin, n, (%) 
     NZ European (%) 
     NZ Māori (%)  













Smoking Information     
Average cigarettes/day (SD)  
     in baseline 










Age first puffed cigarette, 
years (SD) 










Age when started regular 
smoking, years (SD) 
     range 
 








Previous quit attempts (SD)  3.2 (1.2) 2.3 (1.0) 2.7 (2.0) 
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FTCD Score (SD) 7 (3.4) 8 (4.0) 7.8 (2.5) 
FTCD =Fagerstrom Test for Cigarette Dependence; score range 0-10, ≥6 = dependence, ≥7 
high dependence. *significant difference between groups (p<0.05), SD= Standard Deviation  
Primary outcome 
MNWS data (with change in sample size, n, to account for drop-out and relapse) is 
shown in Table 3.2. Symptoms later associated with withdrawal were reported prior to 
quitting (i.e., baseline levels were not zero) and were variable across days and participants, 
with the median baseline score being slightly higher in the micronutrient group (12.5) 
compared to placebo (10.5). At the end of the pre-quit phase (pre-quit week four) and at 
weeks 4, 8, and 12 of the quit phase, the placebo group consistently had higher withdrawal 
median scores and their lowest scores never dropped as low the median for the 
micronutrient group. The PDM ES (% below the median) was consistently larger at each time 
point for the micronutrient group compared to the placebo group, with the overall 
composite ES (the median of the medians) being 73% for the micronutrient group and 35% 
for placebo. 
Table 3.2. Sample size (n) at each phase, median and range for Minnesota Nicotine 
Withdrawal Scale for placebo and micronutrient group with Percent Deviating from the 
Median (PDM) effect sizes.   
 Baseline  Pre-quit week 4 Week 4  Week 8 Week 12  
Placebo  
     n 
 Median  
    Range 
    PDM%  






























     n    
    Median  
    Range  




























Figure 3.3 presents a series of modified Brinley plots presenting comparisons of 
MNWS scores at different time points and displaying the RCI boundaries. As noted above, 
each data point represents the score of a single participant. For each individual data were 
averaged across the start and finish of the first baseline phase (baseline one and two) and 
these average baseline values were carried forward on the X-axis in the next plot (mean 
baseline vs pre-quit baseline). No systematic differences or direction of change was 
identified between mean baseline scores and pre-quit scores, indicating that data were 
stable over these phases, therefore pre-quit scores functioned as Baseline for the 
subsequent quit phase plots. The three modified Brinley plots in the lower row show 
symptoms relative to the pre-quit phase over weeks 4, 8, and 12 of the quit smoking phase.  
In the micronutrient group there was no clear direction of group change for MNWS 
scores at pre-quit. Post-quit, the majority of participants showed a decrease in withdrawal 
at each follow-up, i.e., as time abstinent progressed withdrawal decreased, and participants 
who showed a large increase in MNWS relapsed in the four-weeks thereafter. The majority 
of the placebo group showed an increase in MNWS at pre-quit. At 4, 8, and 12-weeks post-
quit two participants in the placebo group showed a reliable decrease and one participant 
increased in MNWS. Comparison of the two groups at 12-weeks shows that the majority of 





Figure 3.3. Modified Brinley plots displaying change in participant rated Minnesota Nicotine 
Withdrawal Scale scores with arrows indicating the direction of desired change. Parallel lines 
either side of the central diagonal mark the upper and lower boundaries of the Reliable 

























Quit attempts and success 
The micronutrient group was associated with significantly more quit attempts 
compared with placebo (11 vs 5, OR=15.40) and with significantly more quit success overall 
(10 vs 4, OR=10.00; Table 3.3), with NNT=13 (95% CI 24.8, 44.6). The micronutrient group 
consistently had higher quit rates compared to the placebo group, however the contrasts 
between treatment groups were not statistically significant (p≥0.05). [Note:  Due to the 
small sample size not all the assumptions of the chi-square test are meet (number of 
observed cases), therefore, Fisher’s exact test p statistic was calculated.] 
Table 3.3.  Comparison of quit attempts and successes at each follow-up between 













Chi squared  
(p fishers exact test) 
      
Quit 
Attempt 
11 5  15.40* 1.47, 160.98 χ2 (1, n= 24) = 6.75, p=0.01* 
(0.03)* 
Quit Success 10  4  10.00* 1.44, 69.26 χ2 (1, n= 24) = 6.17, p=0.01* 
(0.04)* 










χ2 (1, n= 24) = 2.74, p=0.10 
(0.21) 






















χ2 (1, n= 24) = 0.20, p=0.65 
(1.0) 
      
*p<0.05 statistically significant  
The micronutrient group had a higher continuous four-week quit rate compared to 
the placebo group and Quitline NZ users (43%) reported by Quitline NZ (Quitline NZ, 2013) 




Figure 3.4. Micronutrient and placebo group four-week continuous quit rate relative to the 
four-week quit rate for all Quitline New Zealand users reported by Quitline New Zealand 
(2013).   
MPSS withdrawal scores 
Table 3.4 shows individual MPSS median and range scores, with PDM ES in the 
therapeutic direction (decrease in scores/% below the median) for the micronutrient and 
placebo participants (P = participant). In the micronutrient group P4 showed an increase in 
MPSS median scores during the first four weeks of quitting, and then decreased at week 8 
and 12. P5 increased in MPSS median scores during the first four weeks of quitting, rating no 
days lower than the pre-quit median followed by a relapse. P7 had lower median scores 
during the first four weeks of quitting and week eight; this was followed by a relapse. P8 
rated all MPSS withdrawal symptoms as “not at all” during pre-quit, and this was followed 


































score at pre-quit and during the first four weeks of quitting, followed by a decrease each 
day during week 8 and 12 (PDM=100%). P15, P19, and P21 increased median MPSS scores 
during the first four weeks of quitting and then relapsed. P17 had the same median MPSS 
scores at each study waypoint, showing some variability in the first weeks of quitting 
ranging in total scores from 5-11. P23 rated MPSS lower each day during the first four weeks 
of quitting (PDM=100%) when compared to pre-quit, then relapsed.  
In the placebo group P3 increased in MPSS median scores during the first four weeks 
of quitting and during week 12, and decreased scores at week eight. P11 had an increase in 
median scores during the first four weeks of quitting followed by decreases at weeks 8 and 
12. P14 increased MPSS median scores during the first four weeks of quitting and at week 
eight, this was followed by a decrease at week 12. P20 increased MPSS median score during 
the first four weeks of quitting compared to pre-quit and this was followed by a relapse. The 
overall composite ES (the median of the medians) is 30% for the micronutrient group and 









Table 3.4. Mood and Physical Symptoms Scale total median (M), range, and Percent 
Deviating from the Median (PDM) scores for participants who completed their daily diary 
during the quit phase. 






*relapsed during the phase, incomplete data  
Craving scores. Tables 3.5 and 3.6 shows individual median, range and PDM ES (% below the 
median) of scores for time spent craving cigarettes and the strength of craving for the 






(n=14)   
Week 8 











M (range)  
PDM 
Participant 4 10 (8-14) 
 
11 (5-17)  
30% 
 
9 (7-13)  
57% 
 
5 (5)  
100%  
Participant 5 







Participant 7  
    
10 (10-11) 
 









7 (5-9)  
0% 
6 (5-7)  
0% 
6 (5-7)  
0% 
Participant 13 










     
5 (5)  
 










5 (5-6)  
0% 
5 (5)  
0% 
Participant 19 








    
9 (7-10) 
 





    
9 (6-11) 
 









10 (8-16)  
11% 
9 (8-13)  
50% 
10 (8-13)  
43% 
Participant 11 









Participant 14  
    
10 (8-12) 
 






Participant 20  
    
11 (7-16) 
 






scores post-quit for P4, P7, P8, P13 and P23 decreased or remained stable when compared 
to pre-quit. The individual ES increased for P5, P9, P15, and P21  during the first four weeks 
of quitting and then these participants relapsed. Craving increased for P17 during the first 
four weeks of quitting; scores then decreased during week 8 and 12. In the placebo group 
craving scores for P3 and P11 decreased or remained stable post-quit compared to pre-quit. 
Craving was stable for P14 then increased  during the first four weeks and week eight of 
quitting, then decreased at week 12. The overall composite ES (the median of the 
individual’s ES) for time craving is 57% for the micronutrient group and 25% for the placebo 
group, and for strength of craving 52% for the micronutrient group and 25% for the placebo 
group, i.e., there was a larger effect on craving severity and time spent craving in the 
micronutrient group than for placebo, indicating a benefit of the micronutrient treatment to 










Table 3.5. Mood and Physical Symptom Scale time spent craving and strength of the cravings 
subscales median, range, and Percent Deviating from the Median (PDM) scores for 
participants in the micronutrient group who completed their daily diary during the quit 
phase. 
 Pre-quit  
(n=10)  
Week 4  
(n=10) 
Week 8  
(n=5)  
Week 12  
(n=4) 
 M (range)              M (range)  
PDM 





Participant 4  
   Time craving 
   Strength craving 
 
 
3 (2-3)  
3 (3-4)  
 
 
2 (1-4) 46%  
3 (1-5) 39%  
 
 
2 (1-2) 100%  
2 (1-2) 100%  
 
 
1 (1-2) 100% 
1 (1-2) 100%  
Participant 5 
   Time craving  
   Strength craving  
 
3 (3)  
3 (3-4)  
 
4 (4) 0%* 
4 (4) 0%* 
  
Participant 7 
   Time craving  
   Strength craving  
 
2 (2)  
3 (3-4)  
 
1 (1-2) 86%  
2 (2-3) 64% 
 
1 (1-2) 71%  
2 (2) 100%  
 
Participant 8  
   Time craving  
   Strength craving  
 
1 (1-2)  
1 (1)  
 
0 (0-3) 54%  
0 (0-2) 54%  
 
0 (0) 100%  
0 (0) 100%  
 
0 (0-1) 57% 
1 (0-1) 43% 
Participant 13 
   Time craving  
   Strength craving  
 
2 (1-3)  
2 (1-3)  
 
1 (1-3) 57%  
1 (1-3) 50%  
 
2 (1-2) 29%  
2 (1-2) 29%  
 
1 (1-2) 57%  
1 (102) 71%  
Participant 15  
   Time craving  
   Strength craving 
 
0 (0)  
0 (0)  
 
3 (1-4) 0%  
3 (1-4) 0%  
  
Participant 17 
   Time craving  
   Strength craving 
Participant 19 
   Time craving 
   Strength craving 
 
3 (3)  





4 (0-5) 39%  
4 (0-5) 39%  
 
3 (2-3) 0%* 
3 (2-4) 0%* 
 
1 (0-1) 100% 
0 (0-1) 100%  
 
0 (0) 100%  
0 (0) 100%  
Participant 21  
   Time craving  
   Strength craving  
 
2 (1-2)  
1 (1)  
 
3 (2-4) 0%  
2 (1-3) 0% 
  
Participant 23 
   Time craving  
   Strength craving 
 
3.5 (3-4)  
3 (3-4)  
 
2.5 (2-4) 50%* 
3 (2-4) 33%* 
  
     




Table 3.6. Mood and Physical Symptom Scale time spent craving and strength of the cravings 
subscales median, range, and Percent Deviating from the Median (PDM) scores for 
participants in the micronutrient group who completed their daily diary during the quit 
phase. 
 Pre-quit  
(n=4)  
Week 4  
(n=4) 
Week 8  
(n=3)  
Week 12  
(n=3) 
 M (range) M (range) PDM M (range) PDM M (range) PDM 
Placebo  
Participant 3 
   Time craving 
   Strength craving  
 
 
3 (3-4)  
4 (3-4)  
 
 
1 (0-3) 89%  
1 (0-4) 86%  
 
 
3 (1-3) 33%  
3.5 (1-4) 50%  
 
 
3 (1-4) 17%  
3.5 (1-4) 50%  
Participant 11 
   Time craving  
   Strength craving  
 
2 (2)  
2 (2)  
 
2 (2) 0%  
2 (2) 0%  
 
2 (1-2) 33%  
1 (1-2) 83%  
 
1 (1) 100% 
1 (1) 100% 
Participant 14 
   Time craving  
   Strength craving 
 
2 (2)  
2 (2-4)  
 
2 (2-3) 0%  
3 (3-4) 0%  
 
2 (2-3) 0%  
3 (3) 0%  
 
1 (1-2) 71%  
2 (2) 0%  
Participant 20 
   Time craving  
   Strength craving  
 
2 (1-2)  
2 (1-3)  
 
3.5 (3-4) 0%* 
4 (4) 0%*  
  
*relapsed during the phase, incomplete data. 
Cigarettes/day  
Table 3.7 shows the median, range, and PDM (% below the median) for 
cigarettes/day at baseline, pre-quit week one, and pre-quit week four for those participants 
in the micronutrient and placebo groups who completed their daily diary. In the 
micronutrient group P4, P6, and P7 decreased their median scores at both weeks during 
pre-quit when compared to baseline. P5 and P8 decreased median cigarettes/day at pre-
quit week one followed by an increase in pre-quit week four. Cigarettes/day remained 
stable for P9 at pre-quit week one compared to baseline and decreased at pre-quit week 
four. P17 and P19 increased in median cigarettes/day at pre-quit one and decreased at pre-
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quit week four. P13, 15, and P21 increased cigarette consumption during pre-quit when 
compared to baseline.  
 In the placebo group P1, and P16 increased consumption pre-quit week one and pre-
quit week four when compared to baseline. P2 stayed stable at pre-quit week one, then 
dropped out. Cigarette consumption for P3, P10, P14, P20, and P24 decreased at pre-quit 
week one and four when compared to baseline. P11 reported stable consumption from 
baseline to pre-quit week one followed by a decrease each day at pre-quit week four. P18 
decreased median cigarettes/day at pre-quit week one and increased consumption at pre-
quit week four. The overall composite ES for change in cigarettes/day at pre-quit week four 
is 57% for the micronutrient group and 71% for the placebo group, indicating no benefit to 













Table 3.7. Cigarettes/day median (M), range, and Percent Deviating from the Median (PDM) 
scores for participants who completed their daily diary during baseline and pre-quit. 
 Baseline 
(n=20) 
Pre-quit 1  
(n=20) 
Pre-quit 4  
(n=19) 






Participant 8  
Participant 9  
Participant 13 
Participant 15  









Participant 11  
Participant 14 
Participant 16  







9  (6-12)  
20 (9-24) 
12 (8-14) 








25 (24-29)  
12 (12-15) 
11 (7-15) 
22 (15-26)  
5 (5-9)  
10 (8-17) 
11 (7-15)  
43 (39-59) 
17 (11-24) 
12 (7-15)  
 
14 (8-18) 86%  
9 (3-34) 57%  
6 (3-8) 100% 
12 (9-15) 100%  
9 (7-12)14%  
18 (18-25) 43%  
6 (3-14) 29% 
13 (12-15) 43% 
9 (4-13) 14%  
6 (3-8) 29%  
3 (1-4) 14%  
 
 
25.5 (23-27) 17%  
12 (12-14) 0% 
9 (9-12) 60% 
5 (4-8) 100%   
5 (4-8) 14%  
9 (7-11) 57%  
20 (18-21) 0% 
41 (38-52) 57% 
15 (9-16) 100% 
11 (4-16) 57%  
 
0 (0) 100% 
12.5 (8-16) 46% 
5 (4-6) 100% 
10 (7-13) 71% 
16 (16-25) 57%  
5 (3-10) 43% 
11 (8-17) 57% 
13 (11-17) 0%  
3 (0-6) 71% 
3 (2-3) 29% 
3 (2-3) 0%  
 
 
26 (23-28) 29%   
 
9 (9-10) 100%  
2 (2-4) 100%  
2 (2-4) 100%  
9 (6-10) 71% 
18 (14-23) 0%   
45 (30-50) 43% 
14 (13-17) 71% 
7 (3-23) 43% 
 
Cigarette consumption as reported in daily dairies during baseline and pre-quit 
phase weeks one and four is shown in time-series plots (Figure 3.5 shows micronutrient 
group data and Figure 3.6 placebo data) in order to examine the stability of cigarette 
consumption prior to the quit intervention. Baseline consumption is shown on the left side 
of the solid line, and pre-quit week one and four on the right side of the solid line. For both 
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groups in baseline, while there were differences in overall level of consumption, from 
typically more than 40/day to typically less than ten per day, consumption was mostly 
stable; only a few participants (P4, P18) showing an increase and one (P15) a decrease. 
During the phases prior to quitting, when either micronutrients or placebo were consumed, 
consumption patterns remained generally stable; only one participant (P4) quit in this 
phase, and a couple (P7, P10) considerably reduced consumption. In general, then, 
cigarettes consumption prior to quitting was stable, and not reliably altered by entry into 






Figure 3.5. Cigarettes/day for the micronutrient group during baseline (on the left side of the 
solid line) and pre-quit (for the right side of the solid line) for participants (P) who completed 









Figure 3.6. Cigarettes/day for the placebo group during baseline (on the left side of the solid 
line) and pre-quit (on the right side of the solid line) for participants (P) who completed the 
daily diary.  
Changes in psychological measures 
The median and range of scores and the PDM ES in the therapeutic direction 
(decrease in median) was calculated for the psychological measures at each study waypoint 





Table 3.8. Psychological questionnaire median scores (M), range, and Percent Deviating from 
the Median (PDM) effect sizes, with sample sizes (n) at each study way-point.  
DASS = Depression Anxiety and Stress Scale-21, D (depression), A (anxiety), S (stress) 
subscales, ASI = Anxiety Sensitivity Index, DEMF = Diener and Emmons Mood Form- P 
(positive), N (negative) subscales.  
              Baseline  Pre-quit  Week 4  Week 8 Week 12  
Placebo (n) 12 7 3 3 3 
Micronutrient (n) 12 11 7 5 4 
DASS-D: Placebo          
    M (Range) 3.0 (0-22) 2.0 (1-9) 4.0 (2-14) 16.0 (1-34) 0 (0) 
    PDM%  
 
75% 0% 67% 100% 
Micronutrient       
    M (Range)        6.5 (0-38) 3.0 (0-20) 4.0 (0-8) 2.0 (0-16) 0 (0) 
    PDM%   70% 71% 60% 100% 
DASS-A: Placebo       
    M (Range) 4.0 (0-24) 6.0 (0-16) 4.0 (0-14) 12.0 (1-14) 2.0 (1) 
    PDM%  
 
38% 33% 33% 100% 
Micronutrient       
    M (Range)  8.0 (0-26) 4.0 (0-14) 2.0 (0-12) 4.0 (0-12) 1.0 (0-1) 
    PDM%   90% 86% 80% 100% 
DASS-S: Placebo      
    M (Range) 12.0 (0-28) 11.0(0-22) 14.0 (12-16) 8.0 (4-18) 12.0 (10-14) 
    PDM%  50% 0% 66% 50% 
Micronutrient      
    M (Range) 16.0 (2-18) 10.0 (0-20) 12.0 (8-18) 8.0 (8-20) 3 (2-10) 
    PDM% 
 
80% 71% 80% 100% 
ASI: Placebo       
    M (Range) 10.0 (2-38) 6.5 (3-59) 20.0 (10-47) 19.0 (3-45.0) 23.5 (5-42) 
    PDM%  63% 33% 33% 50% 
Micronutrient      
    M (Range) 17.0 (8-33) 15.0 (3-39) 10.0 (1-49) 13.0 (1-53) 7.5 (2-11) 
    PDM% 
 
50% 71% 80% 100% 
DEMF-P: Placebo       
    M (Range) 16.8 (7-22) 15.0 (6-20) 15.0 (13-22) 12.0 (1-21) 9.5 (6-13) 
    PDM%  50% 33% 33% 0% 
Micronutrient      
    M (Range) 12.8 (4-20) 14.0 (7-20) 12.0 (8-16) 12.0 (5-14) 14.5 (12-24)  
    PDM% 
 
70% 43% 20% 75% 
DEMF-N: Placebo      
    M (Range) 5.8 (0-18) 5.5 (0-17) 5.0 (3-9) 5.0 (3-11) 1.5 (0-3) 
    PDM%  50% 67% 67% 100% 
Micronutrient      
    M (Range) 4.3 (3-16) 6.0 (0-10) 5.0 (1-9) 9.0 (2-19) 0.5 (0-3) 
    PDM% 
 
50% 29% 40% 100% 
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DASS-21 scores. The micronutrient group had higher DASS-21 depression (DASS-D), anxiety 
(DASS-A), and stress (DASS-S) median scores at baseline compared to placebo. At each 
subsequent study waypoint there was no clear direction of change for depression median 
scores and PDM effect sizes, however anxiety and stress PDM effect sizes were larger in the 
micronutrient group compared to placebo, indicating more participants decreased below 
the baseline median (Table 3.8).  
ASI scores. ASI median scores were lower in the placebo group compared to the 
micronutrient group at baseline and pre-quit. Conversely, post-quit the micronutrient group 
had consistently lower median ASI scores and larger effect sizes, i.e., more participants 
decreased ASI scores below the baseline median compared to the placebo group (Table 3.8).  
DEMF scores. The placebo group had higher median DEMF-P scores at baseline, pre-quit, 
and at four-weeks post-quit compared to the micronutrient group, indicating a more 
positive mood. The median scores did not differ at week eight, and the micronutrient group 
had higher DEMF-P at 12-weeks. However, at the end of pre-quit and at 4 and 12-weeks 
post-quit the micronutrient group had larger PDM effect sizes for DEMF-P, i.e. more 
participants in the micronutrient group increased in positive mood above the baseline 
median compared to the placebo group (Table 3.8). 
The placebo group had higher baseline DEMF-N median scores compared to the 
micronutrient group, and conversely, the placebo group’s median DEMF-N score was lower 
at pre-quit, four and eight weeks post-quit with larger effect sizes (i.e., more participants in 
the placebo group decreased negative mood). At 12-weeks post-quit all participants in both 
groups had decreased in DEMF-N below baseline median scores (PDM = 100%; Table 3.8). 
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Compliance. All participants who did not drop-out of the 12-week RCT phase were 
compliant with capsule consumption.  
Side effects. Only one participant in the placebo group dropped out of the study directly 
because of a putative side effect (a rash, see Figure 3.1); otherwise, no common treatment 
emergent side-effects were reported.  
3.4 Discussion 
This pilot study investigated the effect of a micronutrient treatment on withdrawal 
and related symptoms and concurrent success at quitting smoking, in a sample of nicotine-
addicted adults. The purpose of the study was to explore a novel approach to helping those 
who desire to give up smoking to increase two essential aspects of quitting, viz., making a 
quit attempt and remaining abstinent thereafter. The preliminary results from this pilot 
study are discussed for the remainder of this chapter.   
Withdrawal symptoms were assessed by two measures. Our prediction that the 
intensity of withdrawal symptoms following quitting would be lower in the micronutrient 
group was supported, with congruent changes in both relevant measures. First, the median 
and range of withdrawal scores measured with the MNWS were consistently lower and the 
composite PDM ES larger in the micronutrient group compared to the placebo group, after 
metabolic adaptation to the capsules. Second, the micronutrient group had larger 
composite PDM ES for withdrawal and craving scores measured by the MPSS. This reduction 
of withdrawal symptoms and craving may have beneficially contributed to the lower relapse 
rates and higher quit success rates observed in the micronutrient group.     
Micronutrient consumption was also associated with significantly more quit 
attempts and quit success at ≥three days relative to placebo, and participants taking 
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micronutrients had higher abstinence rates at 4, 8, and 12 weeks post-quit. The 
micronutrient group had a higher abstinence rate at four weeks than that reported by 
Quitline (Quitline NZ, 2013), and a higher abstinence rate at three months compared to 
standard Quitline care (including NRT), although this must be interpreted with caution due 
to the small sample/replications (Bullen et al., 2010; Walker et al., 2011; Walker et al., 
2012), and Quit Victoria care (a programme that does not supply NRT) (Borland et al., 2003). 
Further, although the three month OR for the current study was lower than that reported in 
the use of NRT, bupropion, and varenicline (viz., 1.98, 2.13 and 3.75 respectively) (Wu et al., 
2006), there are advantages of micronutrients relative to pharmacotherapy, including 
accessibility and lack of adverse side effects, and it is possible that micronutrients combined 
with pharmacotherapy (or NRT) may be even more effective than each treatment alone. 
These options should be explored by conducting a RCT with a larger sample that compares 
micronutrients and placebo alone and in combination with NRT.  
Another beneficial effect of taking micronutrients was the lower DASS-21 anxiety 
and stress scores observed during the quit phase compared to the placebo group. Such 
lower scores of anxiety and stress in the micronutrient group may have contributed to the 
lower relapse rates, given that smokers often report that they smoke to ease feelings of 
anxiety and stress (Taylor et al., 2014). The micronutrient group also had reduced and 
trending lower ASI scores throughout the quit phase compared to the placebo group. This is 
consistent with research on the beneficial effects of micronutrient for anxiety and stress 
(Carroll et al., 2000; Kaplan, Rucklidge, Romijn, & Dolph, 2015; Rucklidge et al., 2012; 
Rucklidge et al., 2011; Schlebusch et al., 2000). Participants in the micronutrient group also 
increased levels of positive mood throughout the trial and the placebo group decreased 
their positive mood, supporting the finding of Kahler et al. (2015) that low positive affect is 
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associated with poor cessation outcomes and consistent with the beneficial effects of 
micronutrients to improve mood (Benton et al., 1995; Gariballa & Forster, 2007; Gosney et 
al., 2008; Harris et al., 2011; Kennedy et al., 2010; Lewis et al., 2013; Mech & Farah, 2016; 
Sarris et al., 2012). 
This pilot study used a single-case research design (See Appendix I), a design that 
focuses on more heavily on individual differences in data. This allowed for a limited number 
of participants to undertake this new and exploratory research, an ethical and fair approach. 
Single-case research designs also require less professionals, resources, and funding. Single-
case research designs are useful for developing hypotheses for future studies, and to 
examine cause and effect relationships (Rassafiani & Sahaf, 2010). Although group 
comparisons are not the primary goal of single-case research they are often employed in the 
analysis of single-case trials (Rassafiani & Sahaf, 2010). Therefore, the risk of type I or II 
error is increased due to the small sample size (or replications) in single-case designs, and 
between group results should be interpreted with caution. Single-case research may also 
not generalise to larger groups of participants or populations and lack external validity (as 
with the majority of clinical trials). This is particularly important in smoking cessation, given 
the prevalence of smokers.  
The current study did not require participants to pay for the interventions, and 
approximate travel costs were covered with petrol vouchers. This strengthens the current 
study as participants are not paying for an intervention that has not demonstrated efficacy. 
This may also have limitations as the participants may not be able to pay for micronutrient 
treatment (or any smoking cessation treatments) in real-life settings. Furthermore, although 
the petrol vouchers were given as a way to cover travel costs only, they may have provided 
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additional incentives for participants in enrol in the study and attempt to quit smoking. This 
may mean that the reported quit rates are inflated as incentives are a known smoking 
cessation intervention (Cahill, Hartmann-Boyce, & Perera, 2015). However, it would be 
expected that this would be comparable between groups due to the randomised design.  
A major limitation of this study was that randomization did not achieve comparable 
study groups with respect to baseline number of cigarettes/day and gender ratio. The 
unbalanced sex ratio may have had a number of consequences. First, the treatment group 
smoked fewer cigarettes/day on average in baseline compared to placebo, possibly because 
there were more males in the placebo group and men are known to smoke at a higher rate 
than women (Russell, Wilson, Taylor, & Baker, 1980). This may have led to a potential bias 
favouring the treatment group. Second, the micronutrient group was slightly more nicotine-
dependent compared to the placebo group, also consistent with research that women are 
more addicted to nicotine and quit less easily than men (Bohadana et al., 2003; Collins et al., 
2004; Smith et al., 2015; Welsch et al., 1999). It is possible that the higher level of nicotine 
dependence in the micronutrient group might have balanced the lower rate of smoking. In 
any event, those taking micronutrients were significantly more likely to make a successful 
quit attempt, and, compared to prior research, our findings are strengthened by double-
blinded random allocation to treatment and the inclusion of placebo control. Another 
limitation was that randomisation did not achieve comparable baseline length in both 
groups, with the placebo group having longer baselines. This did not appear to effect the 
dropout rate with one person in each group dropping out in baseline. However it may have 
led to bias favouring the treatment group.  
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Dropout rate was higher than expected in the placebo group during the pre-quitting 
phase and larger than reported for similar RCTs conducted in NZ (Bullen et al., 2010; Walker 
et al., 2011; Walker et al., 2012). Despite the high dropout and relapse rate resulting in a 
smaller sample size, the study still had ≥three replications per study arm satisfying the 
standard advanced by Horner et al. (2005). Another limitation of the study was that 
verification of self-reported abstinence was not undertaken, owing to budget constraints. 
Abstinence rates may have therefore been over or under reported; however, there should 
not be a difference in the nature of reporting between groups.  
Further direct and systematic replication studies (Haig, 2014) with larger samples in 
double-blind RCT designs are still needed to determine if micronutrients consistently 
enhance quitting and abstinence for all smokers. As noted above, treatment combinations 
of micronutrients, NRT and Quitline, with placebo control, should also be investigated to 
further examine whether micronutrients are efficacious as a smoking cessation treatment 
on their own or as an adjunct to other treatments.  
3.5 Conclusion 
This pilot study tentatively supports the use of micronutrients as a treatment to 
reduce withdrawal symptoms during smoking cessation and to promote quit attempts and 
quit success. Researchers and, more importantly, consumers, will continue to seek 
alternative treatments for smoking cessation because of the high prevalence of smoking, 
the adverse health effects it causes, and the high relapse rates and side effects of current 
smoking cessation interventions. Treatment options that reduce withdrawal symptoms and 
increase the likelihood of abstinence, especially those that are relatively inexpensive to 
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implement and that have few side effects deserve to be explored further. Based on the 
preliminary results micronutrient treatment is clearly worthy of continuing investigation.   
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Chapter 4. Study Two: Novel Mineral-Vitamin Treatment for Smoking 
Cessation: A Fully-Blinded Randomized Placebo-Controlled Trial 
This chapter contains a modified version of the following published article: Reihana, P. K., 
Blampied, N.M, & Rucklidge, J.J. (2018). Novel Mineral-Vitamin Treatment for Reduction in 
Cigarette Smoking: A Fully-Blinded Randomized Placebo-controlled Trial. Nicotine & Tobacco 
Research. DOI: 10.1093/ntr/nty168. Published online September 2018.  
 
The pilot study (study one) and Harrison et al. (2013) tentatively supported the use 
of a broad-spectrum micronutrient treatment to support smoking cessation, and this novel 
approach deserves further investigation. Study two was, therefore, undertaken as a fully-
blind randomised placebo-controlled trial (RCT), with a sample size larger than that used in 
Study One to further investigate the role of broad-spectrum micronutrients (minerals and 
vitamins) in supporting quit attempts, reductions in cigarettes/day and withdrawal 
symptoms.  
Aim 
The aim of study two was to assess the efficacy and safety of micronutrients 
combined with a free phone and on-line counselling/support service (Quitline NZ) on quit 
rates, withdrawal symptoms, cigarettes/day, and associated psychological measures during 





4.1 Hypotheses  
Based upon the results from the pilot study and the limited research evidence that 
nutritional supplements relieve withdrawal symptoms and assist with quitting smoking, I 
hypothesised:  
1) Quit attempts and rates will be higher in the micronutrient + Quitline group versus 
the placebo + Quitline group at each study waypoint after quit date.    
2) Withdrawal symptoms and craving following a quit attempt will be smaller for the 
micronutrient + Quitline group versus the placebo + Quitline group.  
3) Cigarettes/day after metabolic adaptation to the capsules will be less for the 
micronutrient + Quitline group versus the placebo + Quitline group.  
4) Self-efficacy of quitting and positive mood will be higher, and negative mood will be 
lower in the micronutrient + Quitline group versus placebo + Quitline at each study 
waypoint after quit date.  
5) Dropout rates will be lower in the micronutrient + Quitline group versus the placebo + 
Quitline group.  
4.2 Method 
Design  
In a fully-blinded, randomised, placebo-controlled RCT, participants who met criteria 
for current smoking and other inclusion criteria were randomly assigned to receive either 
placebo or micronutrient capsules for four weeks prior to quitting (pre-quit phase) and then 
attempted to quit smoking on a designated quit day. They were also enrolled with Quitline 
(pre-quit) and during the subsequent quit phase, they continued to consume their assigned 
capsules for 12 weeks. 
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Eligibility criteria  
Eligibility for the trial required participants to be ≥18 years old, a current smoker of 
≥three cigarettes/day for 12 months prior to baseline, have a desire to quit but not be 
engaged in other smoking cessation treatments (e.g., NRT), not taking psychiatric 
medication for at least four-weeks prior to starting the trial (combining the formula with 
psychiatric medications may result in complex interactions and should be monitored closely 
(Simpson et al., 2011; Popper, 2001)), not currently pregnant or breast feeding, able to 
consume up to 12 capsules a day, have no medical conditions that would effect participation 
in the trial, and able to attend hour long monthly meetings at the University. Non-
psychiatric medications (e.g., oral contraceptives, antidiabetic drugs, and statins) were 
allowed case-by-case. Participants were excluded if they had taken part in study one due to 
risk of bias.  
Recruitment 
Participants were recruited between January 2015 and March 2016 via self-referral 
through advertising on posters around the University of Canterbury (Christchurch, NZ), local 
businesses, health centres, and a kaupapa Māori service, through advertising on the Mental 
Health and Nutrition Research Group’s Facebook page, and in community newsletters. 
Advertising referred people to the study website to complete an online questionnaire that 
assessed eligibility, which 374 people completed. Eligible participants (n=118) kept 
appointments for an initial meeting at the University, others were referred to the Quitline 
website (www.quit.org.nz). Methods were improved throughout the study aimed at 
participant retention, including shorter visits at the University, participants did not have to 
join Quitline at the pre-quit meeting, staying in the study despite relapse, and the 
opportunity to try the active micronutrient at the end of the study, and  
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Study Interventions  
At the completion of the one-to-two week baseline phase participants were given a 
four-week supply of placebo or micronutrient capsules, in plain containers with their name, 
participant number, date received, and date to start taking the capsules on the container. 
The micronutrient formula was supplied gratis by NutraTek Health Innovation Inc (Raymond, 
Alberta, Canada). It is a broad-spectrum micronutrient formula for oral administration, 
containing 17 minerals, 13 vitamins, four amino acids, and four antioxidants/botanicals (see 
Appendix II). The contents of the pills were independently tested by SupraNaturals in March 
2016 and all quality control samples processed yielded acceptable results. All capsules were 
used within the expiry date, with no compromise in potency. The placebo formula (also 
supplied gratis by NutraTek Health Innovations Inc) included a small amount of riboflavin to 
mimic the urine colour associated with taking micronutrients (see Appendix II). The placebo 
has demonstrated effective masking in a recent study (Rucklidge, Eggleston, Johnstone, 
Darling, & Frampton, 2018). Both capsules were identical in appearance. Participants 
titrated up to the full dose of 12 capsules/day (in routine use, NutraTek Health Innovation 
Inc recommends consuming between 12-15 capsules/day to enhance mental and physical 
well-being) over seven days, taking four capsules three times daily, with the last dose at 
least two hours before bed (as micronutrients can increase energy (Kennedy et al., 2010)), 
with food and plenty of water for the remainder of the trial. Based on previous clinical 
experience, expectation was that participants would typically experience a slow and gradual 
effect from the capsules within four weeks, therefore the pre-quit phase ensured that the 
metabolic effects of the micronutrients were established before quitting was attempted, 
and permitted any effects of the micronutrients or placebo alone on smoking and related 
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symptoms to be detected. This phase then functioned as a second baseline for the quit 
attempt.  
A printed copy of the Quit Book was supplied to all participants and read through 
with the researcher before their quit attempt. The Quit Book (see; www.quit.org.nz) 
explains each step of Quitline’s five step program; 1) Set a Quit date, 2) Know your reasons 
for quitting, 3) Know your triggers, 5) Stay Quit. Step 4, the use of NRT, was removed for this 
study. The first day of the quit phase was the participant’s target quit day, a day where they 
attempted to stop smoking. Participants continued to consume 12 capsules/day during the 
quit phase, receiving a four-week supply at each study waypoint meeting (weeks 4, 8, and 
12 post-quit day). The participant was instructed to contact Quitline if they had a cigarette 
(lapse), if they had a relapse they were instructed to contact Quitline and set a new quit 
date, no other support was provided. The quit phase intervention for this study was 
micronutrient + Quitline or placebo + Quitline for 12 weeks, however for ease to the reader 
the two groups are referred to as micronutrient and placebo. At the end of the quit phase 
participants came to the laboratory to complete study waypoint (baseline, pre-quit week-
four, and 4, 8, and 12 weeks post quit) questionnaires, hand in left over capsules, discuss 
that Quitline can continue to support them, and receive a four-weeks supply of the 
micronutrient capsules, and advice on how to purchase the capsules commercially should 
they wish to continue taking them. Participants were informed as to their randomly 
allocated condition at the end of data analysis and the plain English summary of the results 
(with further results sent on request).   
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Randomisation, allocation, and blinding 
A research assistant using www.randomization.com (using blocks of four) 
randomised the first 88 participants in a 1:1 ratio to micronutrient or placebo condition, and 
the next 19 male participants in were quasi-randomised 3:1 ratio (using blocks of four) to 
micronutrient or placebo condition. Researchers and participants were blind to the 
allocation of micronutrient or placebo status until data analysis was complete. There was no 
difference between the appearances of the capsules; the placebo contained riboflavin to 
mimic the change in urine colour associated with taking micronutrient capsules. A 
pharmacist received the randomisation sequence, and all capsules were pre-packaged by 
the pharmacist in plain containers and labelled with the participant numbers. A separate 
randomization sheet labelled with A and B groups (micronutrient or placebo) was kept by 
the research assistant and was given to the statistician for analysis of the primary outcome, 
and to the researchers for analysis of the secondary outcomes at the end of data collection.  
Concomitant medication  
 Non-psychiatric medications (e.g., oral contraceptives, antidiabetic drugs, and 
statins) were allowed case-by-case. 
Withdrawal criteria  
Participants were able to withdraw voluntarily from the study or the primary 
investigator could discontinue a participant from the study. The primary investigator may 
discontinue or withdraw a participant from the study for the following reasons: pregnancy, 
an adverse event associated with the intervention, medical condition(s) or other situation(s) 
occur such that continued participation in the study would not be in the best interest of the 
participant, and if the participant meets exclusion criteria (either newly developed or not 
previously recognised). A participant is considered lost to follow-up if he or she fails to 
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return for a scheduled visit and is unable to be contacted by researchers (after three 
attempts on mobile, email, and phone call). If participants wanted to stop their participation 
they were asked to come in to the University to complete study way-point questionnaires. 
Any participants that excluded from the study were recommended to contact Quitline NZ 
for advice. 
Baseline assessments   
Meetings (approximately 45 minutes) with each individual participant were held at 
the University of Canterbury Mental Health and Nutrition Research laboratory in the 
Psychology Department. At the baseline meeting participants were given a full description 
of the study (Appendix VII), and had an opportunity to ask any questions before giving 
written consent (Appendix VI). At the end of consent participants used a computer in the 
laboratory to complete baseline questionnaires through Qualtrics. After the questionnaires 
were completed participants received instructions to complete the daily diary (Figure 4.1) 
every day for the next one to two weeks (the duration determined by their schedule of 
availability for their pre-quit meeting). This phase provided baseline assessments (discussed 
below) of cigarettes/day, withdrawal symptoms, and cigarette dependence.  
Demographic and baseline variables. Demographic variables included sex, age, ethnicity, 
marital status, and combined household yearly income. Participants provided information 
on the age they first tried cigarettes, started regular smoking, previous quit attempts, and 
the quality of their diet. Participants completed a baseline questionnaire on previous and/or 
current mental illness(s), current medication(s), and any previous psychoactive 
medication(s).   
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Fagerstrom Test for Cigarette Dependence (FTCD). The FTCD is a six-item questionnaire that 
assessed baseline levels of cigarette dependence, with scores ranging from 0 (least 
dependent) to 10 (most dependent) (Fagerström, 2011). A score of six or higher is 
recognised as establishing cigarette dependence (Yeomans et al., 2011). Cronbach’s alpha = 
0.64 (Pomerleau & Rosecrans, 1989).  
Daily diary. Participants completed a daily diary (Figure 4.1) during baseline. The daily diary 
was used to record the number of cigarettes/day (even a puff), consumption of alcohol 
(standard drinks/day), and MPSS withdrawal and craving scores. The core items of the MPSS 
consist of five single-item ratings of depressed mood, irritability, restlessness, hunger, and 
poor concentration (West & Hajek, 2004). All items are rated on a five-point scale from one 
(not at all) to five (extremely) with total scores ranging from 0 to 25. In addition to these five 
ratings the MPSS contains two six point sub-scales that rate time spent with the urge to 
smoke (i.e. craving) (Javitz et al., 2012) and the strength of the urges/craving. The MPSS only 
uses one item to assess each withdrawal symptom keeping the scale as brief as possible and 
suitable for a daily self-report diary. Cronbach’s alpha = 0.78 (West & Hajek, 2004).  
 
Date:  
Please record the amount of cigarettes you inhale (even if it is 






Please record  if you have any alcoholic beverages at any time 
point (and how many standards you have - e.g. 2 standards can 
be marked with II )  
 
 
Please show for each of the items how you have been feeling over 
the past 24 hours (circle one number for each item). 
                         Not at all   Slightly   Somewhat  Very  Extremely 
    Depressed              1              2                3            4             5 
    Irritable                  1              2                3            4             5 
    Restless                  1              2                3            4             5  
    Hungry                   1              2                3            4             5 
    Poor concentration 1              2                3            4             5 
    How much of the time have you felt the urge to smoke in the   
    past 24 hours? (circle one number). 
         All the  Almost all  A lot of the    Some of   A little of    Not at  
           time     the time       time               the time    the time      all  
            5             4               3                      2                   1           0 
       How strong have the urges been? (circle one number). 
140 
 
 Extremely strong    Very strong   Strong   Moderate   Slight   No urges 
                   5                      4               3           2             1            0  
Figure 4.1. Daily diary participants received to complete with cigarettes/day and standard 
drinks/day on the left-hand side and Mood and Physical Symptoms Scale on the right-hand 
side. 
Primary Outcome.  
The primary outcome for the trial was continuous abstinence 12-weeks after the 
target quit day (day following the end of the pre-quit phase, ITT analysis), measured by self-
report and biochemically confirmed (i.e, ≤ six parts per million (ppm) as recommended by 
Bedfont (www.bedfont.com) based on data from Jarvis, Belcher, Vesey, & Hutchison, 1986) 
by exhaled carbon monoxide (CO) using a Bedfont piCO+TM  Smokerlyzer®, a portable device 
which measures breath CO levels (Benowitz et al., 2002; Kahler et al., 2015; Macdonald et 
al., 2004). Continuous abstinence was defined as 12-weeks abstinence with no relapse, and 
relapse was defined as returning to smoking for ≥ three consecutive days. 
Secondary Outcomes 
Participants self-reported and biochemically confirmed smoking status at the 
University meetings. They had the opportunity to complete questions ≤24 hours before 
their quit attempt, for shorter meeting times, otherwise measures were completed at 
University meeting.  
Quit attempts, success, and rates. A quit attempt was counted if participants tried to quit 
smoking (≥24 hours) on their target quit day, and was scored as successful if they quit 
smoking for three or more subsequent days (if participants relapsed and made another quit 
attempt this was not counted as a quit attempt in the analysis). Continuous quit rates 
(abstinence with no relapse) versus relapse (defined as above) were counted at 4, 8, and 12 
weeks post quit-day (day after end of pre-quit phase) based on self-report and exhaled CO. 
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Daily diary. Participants completed a daily diary (Figure 4.1) in the first and last week (week-
four) of the pre-quit phase, weeks 1-4, 8 and 12 of the quit phase.  
Minnesota Nicotine Withdrawal Scale - short form (MNWS). Participants rated eight 
withdrawal symptoms (i.e., craving, irritability, anxiety, difficulty concentrating, restlessness, 
increased appetite or weight gain, depression, and insomnia) on an ordinal scale from zero 
(not present) to four (severe) at each study waypoint. The sum of the eight scores gives an 
overall rating of withdrawal symptoms severity (range 0 to 32). The MNWS has been 
validated in multiple smoking cessation studies (Zvolensky et al., 2009). Cronbach’s alpha 
>0.8 (Toll et al., 2007).   
Wisconsin Smoking Withdrawal Scale (WSWS). The WSWS is a 28-item scale that measured 
withdrawal symptoms and severity at each study waypoint (Welsch et al., 1999; West et al., 
2006). It includes seven reliable subscales of withdrawal symptoms: anger/irritability, 
anxiety, concentration, craving, hunger, sadness, and sleep/insomnia. The sum of four items 
rated from zero (strongly disagree) to four (strongly agree), gives an overall withdrawal 
score for each subscale (range 0-16). Cronbach’s = 0.75-0.93 (Welsch et al., 1999).   
Self-efficacy of quitting.  Self-efficacy of quitting and remaining abstinent was completed at 
each study waypoint. The two six-item subscales measure confidence in ability to refrain 
from smoking when facing internal stimuli (e.g., feeling depressed) and external stimuli 
(e.g., being with smokers) with lower scores indicating more confidence (Etter, Bergman, 
Humair, & Perneger, 2000). Internal stimuli Cronbach’s alpha= 0.95; external stimuli 
Cronbach’s alpha= 0.94.  
Depression Anxiety Stress Scale-21 (DASS-21). The DASS-21 is a 21-item questionnaire (a 
shortened version of the DASS-42) consisting of three self-report scales designed to 
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measure negative emotional states of depression, anxiety, and stress (Lovibond & Lovibond, 
1995). Participants used a four-point severity scale to rate the extent to which they have 
experienced each state in the week prior to each study waypoint. Each of the three DASS-21 
sub-scales contain seven items, and scores for depression, anxiety, and stress subscales 
were calculated by summing all the scores for relevant items and doubling the outcome to 
align with the DASS-42 scores (range 0-42). Cronbach’s alpha scores = 0.88 for depression, 
0.82 for anxiety, and 0.90 for stress (Henry & Crawford, 2005). The DASS-21 has clinical cut 
offs (greater than “mild”) at 10, 8, and 15 for depression, anxiety, and stress respectively 
(Lovibond & Lovibond, 1995).  
Diener and Emmons Mood Form (DEMF). The DEMF consists of nine items used to assess 
how participants were feeling at each study waypoint on a seven-point scale from zero (not 
at all) to six (extremely). The sum of four items gives a positive affect score (range 0-24) and 
the sum of the remaining five gives a negative affect score (range 0-30). Cronbach’s alpha = 
0.89 for the positive subscale and 0.84 for the negative scale (Diener & Emmons, 1985).  
Alcohol Use Disorders Identification Test- Consumption (AUDIT-C). Participants completed 
the AUDIT-C at each study waypoint, it is a three-item alcohol screen that can help identify 
persons who are hazardous drinkers or have active alcohol use disorders (including abuse or 
dependence) (Bush, Kivlahan, McDonell, Fihn, & Bradley, 1998). The AUDIT-C is a modified 
version of the 10 question AUDIT instrument. Each item has five answer choices with 
allotted points (range 0 - 4) and scores range from 0 to 12. A score of four or more for men 
and a score of three or more for women is considered positive and optimal for identifying 
heavy/hazardous drinking and alcohol use disorders. The higher the score the more likely 
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the participants drinking is affecting their safety. Sensitivity and specificity scores are 
presented in Table 4.1.  
 
 
Table 4.1. Sensitivity and specificity scores for identifying patients with heavy/hazardous 
drinking and/or Active-Diagnostic and Statistical Manual alcohol abuse or dependence for 
Alcohol Use Disorders Identification Test-Consumption. 
Score Men Women  
≥3 Sens: 0.95 / Spec: 0.60 Sens: 0.66 / Spec: 0.94 
≥4 Sens: 0.86 / Spec: 0.72 Sens: 0.48 / Spec: 0.99 
 
Diet quality questionnaire (DQQ). The DQQ completed at baseline and eight weeks, was 
based on descriptions of a healthy eater by Baker, Little, and Brownell (2003) and adapted 
by Kuijer and Boyce (2014). A healthy eater eats in a balanced way, consumes three meals a 
day, doesn’t eat too much junk food, eats moderate amounts, and stops eating when full. 
Total DQQ scores ranged from 9 to 47; a higher score indicates a healthier diet. Cronbach’s 
alpha = 0.67 (Kuijer & Boyce, 2014).  
Side effects. Participants were asked about presence/absence of side-effects potentially 
associated with the consumption of nutrients (e.g., headache, nausea, stomach aches, dry 
mouth) and to report any other possible effects/concerns. Any reported side effects were 
followed up and monitored by the researcher (PR). If any adverse effects were reported 
they would have been discussed with the consultant psychiatrist (Prof. Mulder) to 
determine whether further investigation was required. Prof. Rucklidge was consulted on all 
aspects of the project, and was aware of any foreseeable risks. The trial would of been 
terminated if serious adverse effects known to be caused by the nutrients occurred.  
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Capsule Compliance, Adherence, and Drop-out. Leftover capsules were counted at the end 
of each study waypoint. If a participant consumed ≥ 80% of their capsules they were 
counted as capsule compliant. Participants were classified as dropped-out if they advised 
that they wished to cease participation (withdrawal) or if they ceased responding to emails 
or texts (lost to follow-up). In the ITT (n=107) and full intervention analysis (n = 77), drop-
outs were counted as still smoking. Adherence was determined at the end of intervention; 
those classified as adherent had continued to attend meetings and supply data, 
independent of whether or not they were also capsule compliant. The full intervention 
sample (n = 77) included those who received both the capsule and Quitline intervention, 
independent of their compliance/adherence. The per-protocol sample (maximum n = 65), 
included only those who completed the intervention and were both compliant and 
adherent. 
Sample size 
A sample size of 80 participants (40 in placebo and 40 in micronutrient) conferred 
more than 80% power, with two tailed α=0.05, to detect an abstinence rate at 12 weeks 
similar to that of study one’s four week abstinence rate (53% versus 25%, micronutrient and 
placebo group respectively) with a large effect size. The four-week quit rate was used to 
calculate sample size, as it was predicted that this study would have lower rates of dropout 
because of planned improvements in methods directed at participant retention. The final 
sample size of participants who received either kind of capsule intervention and were 
included in the ITT analysis was 107 (Figure 4.2). 
Statistical analysis 
At completion of data collection for the first 88 participants (the first year of 
collection) an interim analysis of  demographic data only was conducted by a research 
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assistant to investigate if the baseline characteristics were comparable across the two 
groups (in particular sex). This was conducted due to the significant differences in baseline 
data in Study one and to avoid the need for multiple subgroup analyses which can increase 
the chance false-positive and false-negative results due to chance or lack of power (Schulz & 
Grimes, 2005). An independent statistician blind to treatment conditions conducted the 
analysis of the primary outcome data. Three samples were separately analysed. These were 
(1) the ITT sample, which included all participants who received capsules at any point 
(n=107); (2) the full-intervention sample, which included those who received the 
micronutrient/placebo + Quitline (n=77) regardless of their degree of capsule compliance 
and adherence with study protocol following the quit date; and (3) the per-protocol sample 
(maximum n = 65), which included all those who were fully capsule compliant/adherent at 
each waypoint.  Frequencies of the categorical variables of quit/not quit, dropped-
out/continuing, and side-effects/no side effects at specified study waypoints were analysed 
using chi-squared (χ2) tests with odds ratios (OR) and 95% Confidence Intervals (95% CI) 
using IBM Statistics version 20. OR determines whether the probability of an event (or 
disease), for example quitting, is the same of differs across two groups. The range of OR is 
from O to infinity: A value of 1= no association with the specified event (that is, the event is 
equally likely in both groups); as the value of the OR increases or decreases away from 1, 
the association grows increasingly stronger. As proposed by Chen, Cohen, and Chen (2010) 
we interpreted OR ≤1.68 as small, OR ≤ 3.47 as medium, and ≤6.71 as a large treatment 
effect. All tests of statistical significance were two-tailed; exact p-values are reported, and 
no adjustments were made for multiple comparisons, consistent with recent best-practice 
recommendations (Armstrong, 2014; Nakagawa, 2004; Perneger, 1998). Further, as 
recommended by the American Statistical Association (Wasserstein & Lazar, 2016), and 
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Wilkinson and Task Force on Statistical Inference (Wilkinson, 1999) (and many others 
(Cumming, 2013; Gigerenzer, 2018; Gigerenzer & Marewski, 2015; Hubbard, 2004; Hubbard 
& Lindsay, 2008; Sedlmeier, 2009)) we report effect sizes (ES; Cohen’s d and the Common 
Language ES, calculated using software by Lakens (2013)) and 95% CIs (calculated using 
Exploratory Software for Confidence Intervals; (Cumming, 2013)). Cohen’s d was calculated 
using the pooled SD for between-subjects comparison and the average SD for within-
subjects comparisons (Lakens, 2013). When the 95% CI on d does not cross zero this is 
interpreted as indicating that there is a reliable (significant) treatment effect, i.e., an effect 
that is not zero, with the minimum likely effect being at the lower (if d is positive) or upper 
(if negative) CI. Further, we interpreted d ≤0.3 as small and values ≥0.8 as large to very large 
effects (Sullivan & Feinn, 2012). The between-group CLES expresses the probability (as a %) 
that for any two individuals from the placebo group or treatment group, the treatment 
participant has a therapeutically better score than the control/placebo participant (Lakens, 
2013), while the within-group CLES reports the probability that any randomly chosen 
participant has a therapeutically better score in the treatment phase relative to baseline and 
adjusted for the direction of the therapeutic effect on the particular measure. CLES % scores 
range from 0 (for between-group designs, no treatment participant has a better score than 
the placebo participants, and for within-group designs, no participants have a better score 
compared to t1) to 100 (between-group: all treatment participants have a better score than 
the control participants; within-group: all participants have a better score than at t1).  
Primary outcome. The primary outcome measure defined a priori was continuous 
abstinence at 12 weeks post quit-day (day after pre-quit) for the ITT sample, with 
participants categorized as quit/not quit and quit rate compared between groups using χ2. 
Participants lost to follow-up (i.e., did not reply to texts, emails, and calls) were counted as 
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not quit and included in the analysis. The number needed to treat (NNT) for 1 person to 
achieve smoking abstinence above the placebo effect at 12 weeks with 95% CI was also 
calculated (Biswas, 2017). Consistencies of effects of subgroups (gender [men vs women], 
ethnicity [Māori vs non-Māori]) for the primary outcome were assessed using Cochran-
Mantel-Haenszel tests. 
Other outcomes. Means (n), standard deviations (SD), ranges and percentages (where 
appropriate) were calculated for baseline demographic characteristics, smoking history, and 
diet quality, history of mental illness, and psychoactive medication use, differences between 
groups were calculated using χ2 and t-tests.  
Drop-out. Lost to follow up and withdrawal (drop-out) during each phase was compared 
using categorical outcome for participants who started the phase, and total drop-out was 
compared for those who received the capsule intervention (n=107). A Post hoc analysis was 
conducted to compare baseline measures of those dropped out and completers.  
Quit success and quit rates. Frequency of quit attempts (≥24 hours continuous abstinence), 
and quit rates at 3 days (quit success), at weeks 4, 8, and 12 post quit-day were compared 
between groups by χ2. Participants were counted as still smoking if they were lost to follow-
up (i.e., did not reply to texts, emails, and calls).  
Withdrawal and mood symptoms. Visual analyses of individual change in withdrawal, self-
efficacy of quitting, and mood scores was undertaken using modified Brinley plots 
(Blampied, 2017), as described for Study one.  
For all measures the first plot compares baseline (t1) to pre-quit (t2), to observe any 
change in withdrawal or mood during the capsule only intervention. Thereafter, for the 
withdrawal scales (MNWS and WSWS) pre-quit scores are used as t1 because participants 
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had attempted to cut-down on their cigarette smoking at this point and withdrawal 
symptoms may have been evident, subsequent study way-points are used as t2. For all other 
psychological scales (quitting self-efficacy, DASS-21, and DEMF) baseline is used as t1 for 
each of the plots and study way-points as t2 to observe changes in these measures across 
study way-points. For each measure, the reliable change index (RCI) (Jacobson & Truax, 
1991) as calculated in Study one, is displayed as two lines on each side of the 45-degree 
angle line. Only when a data point lies outside the RCI boundaries is it deemed reliable (i.e., 
larger than likely due to measurement error alone). The percentage of participants 
demonstrating positive reliable change (RC+) was calculated and is displayed on each plot. 
This effect size (ES) is a conservative outcome measure because it requires a shift in both 
the clinical direction and reliable change (Blampied, 2017). The mean of the data at t1 and t2 
are displayed as a pair of lines at right angles, such that the cross-point indicates the co-
ordinates of the respective means and the length of the lines display the 95% CI’s of the 
means. As mentioned, if there is no change in mean scores between t1 and t2 the cross-point 
will lie on the 45 degree line; alternatively the mean therapy effect is shown by vertical 
displacement of the mean cross-point above or below the line (Blampied, 2017). The 
magnitude of this displacement is proportional to Cohen’s d. For measures with clinical cut 
offs, these are displayed on the plots as horizontal and vertical lines; an arrow on the 
vertical line indicates the direction of therapeutic change. For plots where there is no clinical 
cut off, an arrow at the side of the plot indicates the direction of clinically beneficial change.  
Cigarettes/day and MPSS symptoms. Within group changes in cigarettes/day and MPSS 
withdrawal scores were averaged for each week of data collection (baseline, pre-quit week 
1, pre-quit week 4, quit week 1, 2, 3, 4, 8 and 12) and displayed on a spaghetti plot. A 
spaghetti plot graphs an individual’s value for a repeated measure (Y axis) versus time (X 
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axis) and connects the dots chronologically. Within group Cohen’s d ES with 95% CIs and the 
CLES were calculated for t1 versus t2 comparisons. Baseline was used as t1 for cigarettes/day 
plots, but quit week 1 was used as t1 for MPSS plots as participants were at their highest 
withdrawal at this point. Between group effect sizes (Cohen’s d ES and CLES) were also 
calculated for each time point. Linear regression was used to predict the direction of change 
of cigarettes/day and MPSS scores, for both before and after quit day.   
DQQ and AUDIT-C. One-way ANCOVAs were conducted to compare the effectiveness of the 
placebo or micronutrient treatments on change in diet quality (DQQ) and AUDIT-C scores 
whilst controlling for baseline scores. Unpaired t-tests were conducted to compare baseline 
and eight week post-quit scores within groups.  
Data management  
All study data was entered by the writer and contained in locked storage systems; 
either a password protected computer system at the University of Canterbury or on a 
web-based data collection system (www.canterbury.qualtrics.com) for electronic 
documents, while hard copies were kept in secure filing cabinets at the university.  
Ethical Considerations. 
The study was approved by the University of Canterbury Ethics Committee (HEC 
2015/11) and prospectively registered with the Australian and New Zealand Clinical Trial 








 Recruitment went from the 08/03/2015 until the 29/02/2016. The last face-to-face 
interview with a participant was on the 30/7/2016 and data were locked as of 20/08/2016. 
An interim analysis showed that the micronutrient group had significantly fewer men than 
the placebo group (18 versus 9, χ2 (1, n=88) = 4.02, p=0.04), therefore, the sample size was 
increased by 19 men randomized in a 3:1 (micronutrient: placebo) ratio. As shown in Figure 
4.2, from 374 self-referrals, 118 adults were deemed eligible, gave informed consent and 
started baseline. Of these, 107 were randomized to either the active treatment 
(micronutrients; n=57) or the placebo (n=50) for the pre-quit phase (ITT sample) and 77 
(full-intervention sample) participants received the micronutrient/placebo + Quitline 






Figure 4.2. Consolidated Standards of Reporting Trials (CONSORT) diagram. 
Demographic and baseline Information  
Ages ranged from 18.8 to 62.2 years and the majority of the sample were NZ 
European (65%), followed by NZ Māori (22%). In the event that participants reported two 
ethnicities, ethnicity was randomised according to NZ Statistics Guidelines, under this 














374 Assessed for eligibility 
  
Excluded (n=256) 
• Did not meet inclusion criteria 
(n=29, taking psychiatric 
medication), (n=1, drug 
maintenance), (n=1 other) 
• Using smoking cessation 
pharmacotherapy (n=7) 
• No response to emails or texts 




Allocated to baseline 
phase (n=118) 
• Did not complete 
baseline (n=11) 
Allocated to micronutrient (n=57) 
• Completed capsule intervention (n=38) 
• Adherent and compliant (n=33) 
Discontinued intervention (n=21) 
• Moved away (n=3) 
• Surgery (n=3) 
• Pills hard to swallow (n=1) 
• Pregnancy (n=1) 
• Psychiatric medication (n=1) 
• Drop-out due to stressful life event (n=4) 
• No response to emails or texts (n=6) 
 
 
Allocated to Placebo (n=50)   
• Completed capsule intervention (n=39) 
• Adherent and compliant (n=32) 
Discontinued intervention (n=11; 22%) 
• Medical illness (n=2) 
• Surgery (n=1) 
• Drop-out due to stressful life event (n=1) 
• No response to emails or texts (n=7) 
 
Received Quitline + micronutrient intervention (n=38) 
• Compliant and adherent at 12-weeks (n=20) 
• Non-compliant and adherent (n=4) 
• Drop out week 4 (n=5) 
• Drop out week 8 (n=6)  
• Drop out week 12 (n=3) 
 
Received Quitline + placebo intervention (n=39) 
• Compliant and adherent at 12-weeks (n=20) 
• Non-compliant and adherent (n=1) 
• Drop out week 4 (n=3)  
• Drop out week 8 (n=12)  
• Drop out week 12 (n=3)  
Non-compli 
Data analysed (n=57) 
• Male participants analysed (n=23) 
• Excluded from analysis (n=0) 
 
Data analysed (n=50) 
• Male participants analysed (n=23) 







groups, with people of only European ethnicities last. Randomization achieved comparable 
study groups, with no substantive differences between the groups on demographic 
variables (Table 4.2). 
Table 4.2. Demographic characteristics at baseline for the Intention-to-treat sample (n=107).  














Average age (years) (SD)  
     Range 
35.7 (10.9) 
18.8-62.2 





     NZ European, n (%) 
     NZ Māori n (%)  
     Samoan n (%)  
     Chinese n (%) 
     Other, n (%) 
Marital Status 











12 (24%)  
2 (4%) 












     De-Facto 16 (28%) 9 (18%) 25 (23%) 
     Single 







     Separated 0 (0%) 1 (20%) 1 (1%) 
Household Incomea    
     <$20,000 
     $20,000-$40,000 
     $40,000-$60,000 
     $60,000-$80,000 
     $80,000 - $100,000 
     >$100,000    






















aNZ dollars; the poverty line would roughly be <NZ$40,000.  
 
Average baseline consumption (cigarettes/day) was 12.4 (range 3.9-42.8) and 14.0 
(range 3.4-25.9) in the micronutrient and placebo groups respectively. The average FTCD 
score was 4.5 (range 0-9) indicating low to moderate dependence on nicotine. On average, 
participants started regular smoking at 16.8 years (range 11.0-48.0 years), had attempted to 
quit 3.3 times (range 0-10). More participants in the micronutrient group had ever used NRT 
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in the past compared to the placebo group (35.1% vs 12.0%, p=0.005). Overall, 21.5% had 
ever used varenicline tartrate and 12.1% had used bupropion hydrochloride (Table 1). 
Participants reported average consumption of 1.2 standard (std) alcoholic drinks/day and 
negligible use of illicit substances (<once/day) during baseline. Dietary patterns were 
comparable across both groups. More participants in the micronutrient group (39%) had 
previously taken psychoactive medication for the treatment of mental illness compared to 
















Table 4.3. Baseline smoking information, substance use, diet quality, previous/current 







Smoking Information  
Cigarettes/day in baseline, mean (SD) 










Age (years) first puffed cigarette,  
mean (SD) 










Age (years) started regular smoking,  
mean (SD) 










Previous quit attempts, mean (SD)  







FTCD Score, mean (SD) 







Previous use of:  







     Champix, n (%) 9 (16%) 14 (28%) 23 (22%) 
     Zyban, n (%) 7 (12%) 6 (12%) 13 (12%) 
Std drinks/day baseline, mean (SD) 







Days/week illicit substance use baseline, 
mean (SD) 










Diet Questionnaire, mean (SD) 







Previous and/or current  







Psychoactive medication history, n (%) 22 (39%)* 9 (18%)* 31 (30%) 
FTCD =Fagerstrom Test for Cigarette Dependence; score range 0-10, ≥6 = dependence, ≥7 




Drop-out rates (withdrawal and lost to follow-up) are shown in Table 4.4; despite 
methodological improvements relative to Study one, these were somewhat high for both 
withdrawal and lost to follow-up. During the pre-quit phase significantly (p<0.05) more 
participants in the micronutrient withdrew from the study compared to the placebo group 
(26% versus 10%). However at all other study way-points drop-out was much the same for 
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the micronutrient and placebo groups. Post hoc comparisons showed that at baseline, those 
who dropped out or smoked more cigarettes (14.5 versus 11.5 cigarettes/day; p=0.01), 
started regular smoking at a younger age (16.0 versus 17.9; p=0.02), had higher FTCD scores 
(5.0 versus 3.6; p=0.01), and lower diet quality scores (27.8 versus 30.4; p=0.01) relative to 
completers (Table 4.5).  
Table 4.4. Number (n) and percentage (%) of participants who withdraw or were lost to 
follow-up at each study waypoint, with sample size at the start of each phase for 
micronutrient (mn) and placebo (pl) groups.  
Study waypoint 
(sample size at start of 
phase) 
Micronutrient  Placebo  Odds 
Ratio  
95% CI Chi squared 
                                              n (%) n (%)    
Pre-quit   
Withdrawal 















χ2 (1, n= 107) = 4.65, p=0.03 
χ2 (1, n= 107) = 0.30, p=0.58 
Week 4  
Withdrawal  
Lost to follow-up 







Week 8   
Withdrawal  


















Total Withdrawal  





















χ2 (1, n= 107) = 1.03, p=0.30 
χ2 (1, n= 107) = 0.75, p=0.39 
 









Table 4.5. Differences in baseline characteristics for participants who dropped out or were 
lost to follow-up at any study waypoint (DO) compared to those who completed the study.  
 DO (n=64)  Completer (n=43) 
Gender  





Age (years), mean (SD)  






     NZ European, n (%) 
     NZ Māori, n (%)  
     Samoan, n (%)  
     Chinese n (%) 
     Other, n (%) 
 
40 (46.9%) 










Marital Status  
     With Partner 
     Without Partner 
Income 
     <$20,000 
     $20,000-$40,000 
     $40,000-$60,000 
     $60,000-$80,000 
     $60,000 - $80,000 




















10 (23.3%)  
Cigarettes/day baseline,  
mean (SD) 







Age (years) first puffed cigarette, 
mean (SD) 







Age (years) started regular 
smoking, mean (SD) 







Previous quit attempts 
mean (SD)                 













FTCD Score, mean (SD) 





 Std drinks/day in baseline, 
 mean (SD) 







Days/week used illicit substance in 
baseline, mean (SD) 







Diet Questionnaire, mean (SD)  





Previous and/or current mental 





Previous psychoactive medication, n 
(%) 
 
22 (34.4%)  
 
9 (20.9%)  




Primary outcome  
All self-reported quitters biochemically confirmed abstinence with ≤5 ppm. At 12 
weeks (Table 4.6) the ITT quit status was 28% (micronutrient group) versus 18% (placebo 
group), a small positive effect in favour of micronutrients (OR=1.78, 95% CI [0.71, 4.48]), but 
estimated with low precision/high uncertainty. NNT = 10 (95% CI [-5.72, 25.86]), consistent 
with a small, additional treatment effect in the presence of a large placebo effect. 
Table 4.6. Comparison of quit attempts and quit successes at each follow-up between 







95% CI Chi squared 
      
Quit Attempt 36 (63%) 35 (70%) 0.73 0.33-1.65 χ2 (1, n= 107) = 0.56, p=0.46 
Quit Success (≥3 
days) 
31 (54%)  28 (56%) 0.94 0.44-2.01 χ2 (1, n= 107) = 0.03, p=0.87 
4 Week Quit Rate 25 (44%) 16 (32%) 1.66 0.75-3.66 χ2 (1, n= 107) = 1.59, p=0.20 
8 Week Quit Rate 18 (32%) 11 (22%) 1.64 0.68-3.91 χ2 (1, n= 107) = 1.24, p=0.27 
Primary Outcome        
12 Week Quit Rate 16 (28%) 9 (18%) 1.78 0.71-4.48 χ2 (1, n= 107) = 1.51, p=0.22 
 
Full Intervention analysis 
With drop-outs during the pre-quit phase excluded, this analysis (Table 4.7) showed 
that almost all participants successfully made a quit attempt. The micronutrient group 
showed higher quit rates at all subsequent waypoints, especially at week 4 (66% vs 41%; OR 





Table 4.7. Comparison of quit attempts, quit success, and continuous quit rates at follow-up 
between micronutrient and placebo groups for the full-intervention sample (n=77).  





 n (%) 
Odds 
Ratio  
95% CI Chi squared 
     
Quit Attempt 36 (95%) 35 (90%) 2.06 0.35-11.96 χ2 (1, n= 77) = 0.69,  p=0.42 
Quit Success  31 (82%) 28 (72%) 1.74 0.59-5.11 χ2 (1, n= 77) = 1.03, p=0.31 
4 Week Quit Rate 25 (66%) 16 (41%) 2.76 1.10-6.97 χ2 (1, n= 77) = 4.74, p=0.03 
8 Week Quit Rate 18 (47%) 11(28%) 2.29 0.89-5.89 χ2 (1, n= 77) = 3.01, p=0.08 
12 Week Quit Rate 16 (42%) 9 (23%) 2.44 0.91-6.49 χ2 (1, n= 77) = 3.18, p=0.08 
mn= micronutrient group sample size, pl= placebo sample size.  
Per-protocol analysis  
This analysis excluded both drop-outs and the non-compliant/non-adherent at each 
waypoint. Again, the majority made a quit attempt, and those taking micronutrients were 
somewhat more successful (Table 4.8). Those taking micronutrients had a higher quit rate at 
each waypoint, especially weeks 4 (83% vs 57%; OR = 3.60, 95% CI [1.06, 12.20]) and 8 (81% 
vs 50%; OR= 4.25, 95% CI [1.08-16.77]), with OR indicative of a medium treatment effect.  
Table 4.8. Per-protocol sample analyses for quit attempts, success, and continuous 





Placebo  Odds 
Ratio  
95% CI Chi squared 
 n (%) n (%)    
Quit Attempt  
(mn=33, pl=32) 
32 (97%) 30 (94%) 1.03 0.52-2.07 χ2 (1, n=65) = 0.38,  p=0.54 
Quit Success 
(mn=33, pl = 32) 
29 (88%) 25 (78%) 2.13 0.18-24.76 χ2 (1, n=66) = 1.10, p=0.21 
4 Week Quit Rate  
(mn=29, pl=28) 
24 (83%) 16 (57%) 3.60 1.06-12.20 χ2 (1, n= 57) = 4.47, p=0.04 
8 Week Quit Rate  
(mn=21, pl=22) 
17 (81%) 11 (50%) 4.25 1.08-16.77 χ2 (1, n= 43) = 4.53, p=0.03 









2 (1, n= 40) = 2.06, p=0.11 
      




The Cochran-Mantel-Haenszel test was used to analyse any difference in the primary 
outcome for subgroups (gender [male versus female], ethnicity [Māori versus Non-Māori]). 
The results showed no significant differences (p>0.05) in the primary outcome (continuous 
abstinence at 12-weeks) for male versus female (Cochran Q(1)=1.7, p=0.12) , or Māori 
versus Non-Māori (Cochran Q(1)=1.5, p=0.23).   
Other outcomes  
Quit attempts, success, and rates  
ITT analyses showed similar quit attempts and success for micronutrient and placebo 
groups. The placebo group made more quit attempts and was more successful at ≥three 
days. ITT analyses also showed small differences in quit rates in favour of micronutrients, 
with OR >1. The differences in quit attempts, success, and rates were again estimated with 
low precision (Table 4.6).  
Quit vs not-quit at 12-weeks  
Baseline measures were compared for each group for those participants with and 
without 12-week continuous abstinence (the primary outcome) using χ2 and t-test analyses 
(Table 4.9). There was a significant difference (p=0.04) between quitters and non-quitters 
for age they first started regular smoking in the micronutrient group. All other comparisons 






Table 4.9. Baseline measures, smoking information, of the participants who achieved 
continuous abstinence at 12-weeks in each group compared to those who did not achieve 
continuous abstinence.   
 Micronutrient 





















Age (years), mean (SD)  





38.8 (11.4)  
22.4 - 54.3 
36.1 (9.9) 
20.8-59.0 
Ethnic origin,  
     NZ European, n (%) 
     NZ Māori, n (%)  
     Samoan, n (%)  
     Chinese n (%) 
     Other, n (%) 
 
12 (75%) 






















Marital Status  
     With Partner* 
     Without Partner** 
Income  
     <$20,000 
     $20,000-$40,000 
     $40,000-$60,000 
     $60,000-$80,000 
     $60,000 - $80,000 






























4 (44%)  
 
17 (41.5%) 
24 (58.5%)  
 
6 (14.6%) 




5 (12.2%)  
Cigarettes/day baseline,  
mean (SD) 













Age (years) first puffed cigarette, 
mean (SD) 













Age (years) started regular 
smoking, mean (SD) 













Previous quit attempts, 
mean (SD)                 























FTCD Score, mean (SD) 









 Std drinks/day in baseline, 
 mean (SD) 













Days/week used illicit substance 
in baseline, mean (SD) 













Diet Questionnaire, mean (SD)  









Previous and/or current mental 










medication, n (%) 
 
6 (37.5%)  
 




8 (19.5%)  
FTCD =Fagerstrom Test for Cigarette Dependence; score range 0-10, ≥6 = dependence, ≥7 high dependence *with partner 




Modified Brinley plots  
Modified Brinley plots were used to examine individual change over study phases in 
MNWS, WSWS, self-efficacy of quitting, DASS-21, and DEMF scores (Figure 4.3-4.17). The 
bottom three plots for the withdrawal measures (MNWS and WSWS) compare pre-quit 
week four (t1) scores to post-quit follow-up score (t2; 4, 8, and 12-weeks post-quit). Pre-quit 
week-four scores are used as baseline as Quitline suggests participants cut down on 
cigarettes/day before their quit attempt, therefore if participants followed this suggestion 
some withdrawal symptoms would be evident. For the mood measures (quitting self-
efficacy, DASS-21 and DEMF) each figure compares baseline (t1) to post-quit follow-up 
scores (t2). Cohen’s d ES, with 95% CI and CLES are displayed on each plot for t1 versus t2.  
Withdrawal measures  
Changes in individual MNWS scores are displayed in Figure 4.3 for the micronutrient 
and placebo groups. Both groups decreased their mean withdrawal scores (as shown by the 
horizontal line on the cross) as the quit phase progressed. The micronutrient group had 
more participants decrease in MNWS scores pre-quit, with the mean MNWS score 
decreasing when compared to baseline. Cohen’s d ES was large and significant, d=0.80; 95% 
CI [-1.2, -0.3]. Conversely the placebo had more participants decrease post-quit; however 




Figure 4.3. Modified Brinley plots displaying change in participant rated Minnesota Nicotine 
Withdrawal Scale scores, with arrows indicating the direction of desired therapeutic change, 
crosses to show mean scores with 95% Confidence Intervals, and Reliable Change (RC+) 
percentages, Cohen’s d effect sizes (d) with 95% Confidence Intervals, and Common 
Language Effect Sizes (CLES) shown.  
Figure 4.4 shows individual changes in WSWS irritability at each study waypoint. 
More participants in the micronutrient group showed decreases in irritability scores at each 
follow-up when compared to the placebo group, as shown by larger RC+ percentages and 
CLES. At 12 weeks post-quit, irritability scores significantly decreased in the micronutrient 
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group when compared to pre-quit, Cohen’s d ES is large and significant, d=0.93 95% CI [-1.7,-
0.2]. 
   
Figure 4.4. Modified Brinley plots displaying change in participant rated Wisconsin Smoking 
Withdrawal Scale (WSWS)- irritability scores, with arrows indicating the direction of desired 
therapeutic change, crosses to show mean scores with 95% Confidence Intervals, and 
Reliable Change (RC+) percentage, Cohen’s d effect sizes (d) with 95% Confidence Intervals, 
and Common Language Effect Sizes (CLES) shown.  
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Figure 4.5 shows that the micronutrient group had more participants decrease in 
WSWS anxiety scores pre-quit, as supported by larger RC+ and CLES. Post-quit the 
micronutrient and placebo groups showed a decreasing trend in anxiety at each study 
waypoint (Figure 4.5). The placebo group had more participants decrease in anxiety scores 







Figure 4.5. Modified Brinley plots displaying change in participant rated Wisconsin Smoking 
Withdrawal Scale (WSWS) anxiety scores, with arrows indicating the direction of desired 
therapeutic change, crosses to show mean scores with 95% Confidence Intervals, and 
Reliable Change (RC+) percentages, Cohen’s d effect sizes (d) with 95% Confidence Intervals, 
and Common Language Effect Sizes (CLES) shown.  
Figure 4.6 shows individual scores for WSWS concentration, with scores above the 
diagonal line of no change indicating decreases in concentration and scores below the line 
indicating improvements in concentration. Cohen’s d values are mostly small for both 
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groups but the micronutrient group had more participants show improvements in 
concentration at each follow-up, as shown by larger CLES, and had more participants show 
reliable improvement at each follow-up excluding week-12 post-quit where the placebo 








Figure 4.6. Modified Brinley plots displaying change in participant rated Wisconsin Smoking 
Withdrawal Scale (WSWS) decreased concentration scores with arrows indicating the 
direction of desired therapeutic change, crosses to show mean scores with 95% Confidence 
Intervals and Reliable Change (RC+) percentages, Cohen’s d effect sizes (d) and 95% 





Figure 4.7. Modified Brinley plots displaying change in participant rated Wisconsin Smoking 
Withdrawal Scale (WSWS) craving or urge to smoke scores, with arrows indicating the 
direction of desired therapeutic change, crosses to show mean scores with 95% Confidence 
Intervals, and Reliable Change (RC+) percentages, Cohen’s d effect sizes (d) and 95% 
Confidence Intervals, and Common Language Effect Sizes (CLES) shown. 
At pre-quit the micronutrient group had somewhat more participants report 
decreases in the WSWS urge to smoke (>RC+ percentage and CLES) compared to the 
placebo group, and the micronutrient group had a decrease in mean urge to smoke scores 
with a medium and significant effect size (d=0.60, 95% CI [-1.0,-0.2]). Conversely, the 
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placebo group had more participants decrease in urge to smoke at each follow-up post-quit, 
and significantly decreased their urge to smoke mean score at 12 weeks. Cohen’s d was 
large and significant (d=1.24. 95% CI [-2.2, -0.2]). Furthermore, the majority of participants 
in both groups had larger decreases in urge to smoke as time in the quit phase progressed 
(Figure 4.7).  
Figure 4.8 shows individual scores for WSWS increased appetite scores, scores below 
the line show participants who moved in the therapeutic direction (no increased appetite; 
as shown by the arrow). The majority of participants in both groups had an increase in 
appetite at each follow-up, indicated by RC+ and CLES of >50%; however, no significant 





Figure 4.8. Modified Brinley plots displaying change in participant rated Wisconsin Smoking 
Withdrawal Scale (WSWS) increased appetite scores, with arrows indicating the direction of 
desired therapeutic change, crosses to show mean scores with 95% Confidence Intervals, and 
Reliable Change (RC+) percentages, Cohen’s d effect sizes (d) and 95% Confidence Intervals, 
and Common Language Effect Sizes (CLES) shown.  
During the pre-quit phase more participants in the placebo group showed reliable 
decrease in WSWS insomnia scores when compared to the micronutrient group (>RC+ 
percentage), and the same percentage of participants showed a decrease in their scores as 
shown by the CLES’s. At four weeks post-quit more participants decreased in insomnia 
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scores in the micronutrient group compared to the placebo group, with the opposite trend 
shown at 8 and 12-weeks post-quit, i.e., more participants decreased in the placebo group 
(Table 4.9).  
  
Figure 4.9. Modified Brinley plots displaying change in participant rated Wisconsin Smoking 
Withdrawal Scale (WSWS) insomnia scores, with arrows indicating the direction of desired 
therapeutic change, crosses to show mean scores with 95% Confidence Intervals, and 
Reliable Change percentages (RC+), Cohen’s d effect size (d) with 95% Confidence Intervals, 
and Common Language Effect Sizes (CLES) shown.  
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Figure 4.10 shows that mean WSWS low mood scores decreased as the study 
progressed. At the pre-quit follow-up, and four weeks post-quit the micronutrient group 
had more participants report decreases in WSWS low mood compared to the placebo group, 
as indicated by larger RC+ percentages and CLES’s. At 8 and 12 weeks post-quit the 
micronutrient group had more reliable decreases in the therapeutic direction, but the 
placebo group had larger CLES showing more of an overall group decrease. The majority of 
participants who remained abstinent for the 12 weeks decreased in low mood when 



































































































Figure 4.10. Modified Brinley plots displaying change in participant rated Wisconsin Smoking 
Withdrawal Scale (WSWS) low mood scores, with arrows indicating the direction of desired 
therapeutic change, crosses to show mean scores with 95% Confidence Intervals, and 
Reliable Change (RC+) percentages, Cohen’s d effect sizes (d) with 95% Confidence Intervals, 





Self-efficacy of quitting 
Figures 4.11 and 4.12 show modified Brinley plots for internal and external self-
efficacy of quitting (SE) scores at each study waypoint (t2) compared to baseline (t1), with 
lower scores indicating more self-efficacy of quitting. The micronutrient and placebo groups 
showed significant decreases in mean self-efficacy internal scores at each study waypoint, 
with Cohen’s d effect sizes ranging from 0.64-1.30 in the micronutrient group and 0.58-2.14 
for the placebo group. At the pre-quit, the micronutrient group had more participants move 
in the therapeutic direction compared to the placebo group (>CLES), but the placebo group 
had more participants show reliable change (>RC+ percentages). At four weeks post-quit 
more participants in the micronutrient group showed improvement in self-efficacy internal 
scores, and at 8 and 12-weeks the placebo group had more participants show improvement 
compared to the placebo group (Figure 4.11).  
Both the micronutrient and placebo groups showed significant decreases in mean 
self-efficacy external scores at each study waypoint, with Cohen’s d effect sizes ranging from 
0.52-1.46 in the micronutrient group and 0.48-2.20 for the placebo group. At pre-quit and 
week four post-quit the micronutrient group had more participants move in the therapeutic 
direction for self-efficacy external scores (>CLES). At eight weeks post-quit, the 
micronutrient group had more participants show reliable decrease in self-efficacy external 
scores (>RC+ percentage), but the placebo group had more participants show any decrease 
(>CLES). At 12 weeks post quit, the placebo group had more participants decrease in self-
efficacy external scores, as shown by larger RC+ percentage and CLES (Figure 4.12).  




Figure 4.11. Modified Brinley plots displaying change in participant rated smoking self-
efficacy (SE) questionnaire internal stimuli scores, with arrows indicating the direction of 
desired therapeutic change, crosses to show mean scores with 95% Confidence Intervals, and 
Reliable Change percentages (RC+), Cohen’s d effect sizes (d) with 95% Confidence Intervals, 
and Common Language Effect Sizes (CLES) shown.  
 
 




























































































Figure 4.12. Modified Brinley plots displaying change in participant rated smoking self-
efficacy questionnaire (SE) external stimuli scores, with arrows indicating the direction of 
desired therapeutic change, crosses to show mean scores with 95% Confidence Intervals, and 
Reliable Change percentages (RC+), Cohen’s d effect sizes (d) with 95% Confidence Intervals, 
and Common Language Effect Sizes (CLES) shown.  
 



























































































Mood measures  
Figure 4.13 to 4.17 presents modified Brinley plots for mental health/ psychological 
measures of depression, anxiety, and stress (DASS-21) and mood (DEMF) at each study 
waypoint (t2) compared to baseline (t1). Very few participants had scores above the clinical 
cut-off in baseline or at the end of pre-quit, so interpretation of any change by way of 
reduction in scores is affected by a strong floor effect for both groups. Nevertheless, the 
micronutrient group had a significant decrease in mean DASS-21 depression (DASS-D) scores 
at pre-quit (Cohen’s d=0.60, 95% CI -1, -0.1) when compared to baseline and more 
participants showed a decrease in depression scores compared to the placebo group as 
shown by larger RC+ percentages and CLES. Post-quit, the placebo group showed more 
reliable change (>RC+ percentages) compared to the micronutrient group, and at 12-weeks 
post-quit, the placebo group had a significant decrease in mean depression scores (d=1.04, 
95% CI -1.8, -0.2). At 12 weeks post-quit, only one participant in each group was above the 




Figure 4.13. Modified Brinley plots displaying change in participant rated Depression Anxiety 
and Stress Scale-21 depression scores (DASS-D), with clinical cut off scores and arrows 
indicating the direction of desired change, crosses to show mean scores with 95% Confidence 
Intervals, and Reliable Change (RC+) percentages, Cohen’s d effect size (d) with 95% 
Confidence Intervals, and Common Language Effect Sizes (CLES) shown.  
The DASS-21 anxiety scores (DASS-A) are somewhat less constrained by a floor effect 
than are the depression scores. DASS-21 anxiety group mean scores remained relatively 
stable in both groups post-quit. The micronutrient group had a significant decrease in mean 
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anxiety scores at pre-quit and week four and eight post-quit when compared to baseline, 
with Cohen’s d ES’s ranging from 0.30-0.57. The placebo group significantly decreased in 
mean scores at 8 and 12 weeks post-quit when compared to baseline, with Cohen’s d effect 
sizes of 0.78 and 0.80 respectively. At pre-quit and four-weeks post-quit, the micronutrient 
group had more participants decrease in anxiety scores (>CLES), but more participants 
showed a reliable decrease in the placebo group (>RC+ percentages). At 8 and 12-weeks 
post-quit the placebo group had more participants decrease in DASS-21 anxiety scores, as 
shown by the larger RC+% and CLES. The majority of participants from both groups were 
below clinical cut-offs for anxiety scores post-quit (Figure 4.14).  
 Compared to DASS depression scores, DASS-21 stress (DASS-S) scores were more 
widely distributed at baseline and at pre-quit for both groups, with numbers of participants 
scoring above the clinical cut-off. Group mean scores decreased as time went on in the quit 
phase for both groups. The micronutrient group had a significant decrease in mean stress 
scores at the end of pre-quit, Cohen’s d ES= 0.37. At each follow-up the micronutrient group 
had more participants decrease in stress scores, as shown by the larger CLES, and had more 
participants reliably decrease in DASS stress scores, excluding week eight when both groups 









































































































Figure 4.14. Modified Brinley plots displaying change in participant rated Depression Anxiety 
and Stress Scales-21 anxiety (DASS-A) scores, with clinical cut off scores and arrows 
indicating the direction of desired change, crosses to show mean scores with 95% Confidence 
Intervals and Reliable Change (RC+) percentages, Cohen’s d effect sizes (d) with 95% 






   
Both groups increased in mean DEMF positive mood as the quit phase progressed. 
However, the majority of participants did not reliably increase in positive mood at each 
follow-up post-quit when compared to baseline, as indicated by RC+ percentages less than 
50% (Figure 4.16). The micronutrient group had higher CLES scores at each follow-up 



































































































Figure 4.15 Modified Brinley plots displaying change in participant rated Depression Anxiety 
and Stress Scale-21 stress scores (DASS-S), with clinical cut off scores and arrows indicating 
the direction of desired change, crosses to show mean scores with 95% Confidence Intervals, 
and Reliable Change (RC+) percentages, Cohen’s d effect sizes (d) with 95% Confidence 





compared to the placebo group, indicating higher scores of positive mood and more overall 
group movement in the therapeutic direction. At four weeks post-quit, participants in the 
placebo group showed significant decreases in positive mood (deterioration), Cohen’s d 
ES=0.47 [-0.9,-0.1].  
 Figure 4.17 shows that the majority of participants did not reliably decrease in DEMF 
negative mood scores at each follow-up (RC+<50%); however, the horizontal line shows that 
the mean group negative affect score decreased (in the therapeutic direction) at each study 
waypoint post-quit when compared to baseline. At each post-quit follow-up, the 
micronutrient group had higher RC+ percentages than the placebo group, however, the 
placebo group had higher CLES scores at each follow-up compared to the micronutrient 
group, indicating more participants moved in the therapeutic direction and at four-weeks 
post-quit the placebo group significantly increased in negative affect scores (therapeutic 



































































































Figure 4.16. Modified Brinley plots displaying change in participant rated Diener and 
Emmons Mood Form (DEMF) positive affect scores, with arrows indicating the direction of 
desired therapeutic change, crosses to show mean scores with 95% Confidence Intervals, and 
Reliable Change (RC+) percentages, Cohen’s d effect sizes (d) with 95% Confidence Intervals,  





Figure 4.17. Modified Brinley plots displaying change in participant rated Diener and 
Emmons Mood Form (DEMF) negative affect scores, with arrows indicating the direction of 
desired therapeutic change, crosses to show mean scores with 95% Confidence Intervals, and 
Reliable Change (RC+) percentages, Cohen’s d effect sizes (d) with 95% Confidence Intervals,  
and Common Language Effect Sizes (CLES) shown.   
 
 





























































































Daily Diary Measures  
Cigarettes/day  
Cigarettes/day were averaged for each week for participants who completed their 
daily diary and results revealed that there were no substantive differences between 
micronutrient and placebo groups in cigarette consumption (average cigarettes/day) at 
baseline. The micronutrient group reported smoking fewer cigarettes/day compared to the 
placebo group during pre-quit week one (Cohen’s d=0.6, 95% CI [0.1,1.1], CLES=70%) and 
pre-quit week four (Cohen’s d=0.7, 95% CI [0.2,1.2], CLES=70%). For the first four weeks of 
the quit phase the micronutrient group continued to smoke less compared to the placebo 
group (Cohen’s d=0.6, 95% CI [0.0, 1.1], CLES=66%), but at quit weeks 8 and 12 there was no 
longer a meaningful difference in consumption between the two groups, although the 










Table 4.10. Mean and standard deviation (SD) of cigarettes/day at each week of daily diary 
data collection for micronutrient and placebo groups, with between groups Cohen’s d and 













 Mean (SD) Mean (SD)   
Baseline 12.4 (7.0) 14.0 (5.6) 0.3 [-0.1,0.7] 60% 
Pre-quit week 1 9.3 (4.7) 12.5 (5.6) 0.6 [0.1,1.1] 70% 
Pre-quit week 2 6.9 (4.3) 10.2 (5.2) 0.7 [0.2,1.2] 70% 
Quit week 1 0.4 (0.8) 1.9 (3.6) 0.5 [0.0,1.0] 65% 
Quit week 2 0.5 (1.3) 3.1 (4.6) 0.8 [0.2,1.3] 70% 
Quit week 3 0.7 (1.3) 3.5 (4.8) 0.8 [0.3,1.3] 71% 
Quit week 4 1.1 (2.3) 3.1 (4.3) 0.6 [0.0,1.1] 66% 
Quit week 8  1.2 (2.2) 2.1 (3.0) 0.4 [-0.7,0.7] 60% 
Quit week 12 1.1 (2.5) 1.2 (4.0) 0.0 [-0.7,0.7] 51% 
 
Figure 4.18 shows the average number of cigarettes consumed per participant/day 
for participants who completed daily diary measures at each study way-point. While 
trajectories of change in smoking were similar in the micronutrient and placebo groups 
during the pre-quit phase, in that individuals in both groups reduced consumption to a 
relatively similar degree, substantial differences are evident between groups in the quit 
phase. In particular, many more individuals in the placebo group maintained relatively high 
levels of daily consumption, and the variability in consumption was also notably higher in 
the placebo group than in the micronutrient group. As indicated by the relevant ESs, the 
micronutrient group substantially decreased the number of cigarettes/day at each quit 
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phase way-point when compared to baseline, with Cohen’s d ES ranging from 0.3 to 2.6 (i.e., 
from borderline small-medium to large). The CLESs were all >70%, in favour of the 
micronutrient group. The largest decrease in cigarettes/day for the micronutrient group was 
during quit week 1 with a large ES (Cohen’s d=4.0, 95% CI [4.3, 2.3], CLES=99%). The placebo 
group also reported decreases in cigarettes per day at each study way-point excluding pre-
quit 1, with Cohen’s d ranging from 0.2-2.7 (small to large) and CLES >63%. The largest 
decrease in cigarettes/day for the placebo group was during week eight (Cohen’s d=2.9, 95% 
CI [3.8, 1.8], CLES=98%). These findings indicate that both groups experienced a treatment 
effect that at times could be rated as large, but the ESs were larger for the micronutrient 
group – implying a larger treatment effect - and the largest ES in that group happened much 
earlier in the treatment phase than for the placebo group. 
Overall trends displayed in Figure 4.18 were analysed by simple linear regressions 
conducted between each study way-point pre-and post-quit separately for each group. Both 
groups reduced consumption in the pre-quit phase [micronutrient (F(1,56)= 17.8 , p=0.01);  
placebo (F(1,49)=9.8, p=0.01)] with a steeper trend in the micronutrient group (R2 = 0.14 vs 
R2 = 0.02), equivalent overall to a mean reduction of 2.8 cigarettes/day in the micronutrient 
group but only 1.9 in the placebo group. These trends in consumption levelled off in the quit 
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Figure 4.18. A spaghetti plot showing the average number of cigarettes per day for each 
participant at each study waypoint, plotted separately for the micronutrient and placebo 
groups. Also shown are the means for each group at baseline (B), pre-quit week 4 (PQ4), quit 
week 1 (Q1), and quit week 12 (Q12). Other waypoints are pre-quit week 1 (PQ1) and quite 
weeks 2–8 (Q2–Q8). The line above the mean shows +1 SD.
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MPSS daily withdrawal scores  
MPSS scores were averaged for each week for participants who completed their 
daily diary and results revealed that both groups had the highest MPSS scores during quit 
week one then decreasing at each subsequent study waypoint post-quit. The placebo group 
had significantly lower MPSS scores when compared to the micronutrient group at 12-weeks 
post-quit (Cohen’s d=1.2, 95% CI 2.2, 0.2), with no other significant differences observed 
(Table 4.11).  
Table 4.11. Mean and standard deviation (SD) for Mood and Physical Symptoms Scale total 
scores at each week of daily diary data collection for micronutrient and placebo groups, with 
between groups Cohen’s d with 95% Confidence Interval (CI) and Common Language (CLES) 
effect sizes.  















Pre-quit week 1 8.2 (2.4) 7.7 (2.5) 0.2 [-0.8,0.3] 56% 
Pre-quit week 2 8.6 (2.9) 8.6 (3.0) 0.0 [-0.5,0.6] 51% 
Quit week 1 11.1 (4.9) 11.9 (3.7) 0.2 [-0.5,0.8] 55% 
Quit week 2 10.8 (4.9) 9.6 (3.7) 0.3 [-0.9,0.4] 57% 
Quit week 3 10.4 (4.7) 8.3 (3.4) 0.4 [-1.1,0.2] 64% 
Quit week 4 9.9 (5.2) 8.1 (3.3) 0.4 [-1.1,0.3] 61% 
Quit week 8  8.6 (3.7) 7.8 (3.0) 0.2 [-1.0,0.5] 56% 
Quit week 12 9.0 (3.0) 6.0 (1.0) 1.2 [2.2,0.2] 82% 
 
There were no between group differences in mean daily MPSS time spent craving 
and strength of the craving scores. However, both groups showed decreases in craving 
scores at 12-weeks post-quit when compared to baseline, pre-quit, and quit week one 
(Table 4.12).   
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Table 4.12. Mean and standard deviation (SD) for Mood and Physical Symptoms Scale – time 
spent craving and strength of craving scores at each week of daily diary data collection for 
micronutrient and placebo per-protocol sample, with between groups Cohen’s d with 95% 
Confidence Interval (CI) and Common Language (CLES) effect sizes.  




Cohen’s d [95% CI] CLES 
                                 Mean (SD)               Mean (SD)   
Time spent craving     
Baseline 2.3 (0.7) 2.3 (0.8) 0.0 [-0.4, 0.4] 51% 
Pre-quit week 1 2.1 (0.7) 2.4 (0.8) 0.4 [-0.1, 0.9] 62% 
Pre-quit week 2 2.0 (0.8) 2.3 (0.8) 0.3 [-0.2, 0.9] 60% 
Quit week 1 2.3 (0.9) 2.6 (1.0) 0.3 [-0.4, 0.9] 57% 
Quit week 2 2.1 (0.9) 1.9 (1.2) 0.1 [-0.8, 0.5] 54% 
Quit week 3 1.8 (1.0) 1.6 (1.2) 0.1 [-0.8, 0.5] 54% 
Quit week 4 1.7 (1.0) 1.5 (1.1) 0.2 [-0.8, 0.5] 54% 
Quit week 8  1.4 (0.9) 1.8 (1.1) 0.4 [-0.4, 1.1] 59% 
Quit week 12 1.1 (1.0) 0.9 (0.7) 0.3 [-1.2, 0.7] 57% 
Strength of the craving    
Baseline 2.5 (0.8) 2.4 (1.0) 0.0 [-0.4, 0.4] 51% 
Pre-quit week 1 2.1 (0.8) 2.4 (0.9) 0.3 [-0.2, 0.9] 59% 
Pre-quit week 2 2.2 (0.9) 2.3 (1.1) 0.1 [-0.4, 0.6] 52% 
Quit week 1 2.4 (1.0) 3.0 (1.1) 0.5 (-0.1, 1.2) 65% 
Quit week 2 2.2 (1.1) 2.2 (1.3)  0.0 [-0.6, 0.6] 51% 
Quit week 3 1.9 (1.2) 1.8 (1.2) 0.1 [-0.7, 0.6] 52% 
Quit week 4 1.9 (1.2) 1.7 (1.2) 0.1 [-0.8, 0.5] 54% 
Quit week 8  1.6 (0.9) 1.7 (1.2) 0.1 [0, 0.8] 53% 
Quit week 12 1.4 (1.1) 1.1 (0.8) 0.3 [-1.3, 0.7] 59% 
Diet Quality Questionnaire  
Participants completed the DQQ at baseline and eight weeks post-quit. A one-way 
ANCOVA was conducted to compare the effectiveness of the placebo or micronutrient on 
change in diet quality scores whilst controlling for baseline scores. Participants completed 
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the DQQ at baseline and eight weeks post-quit. The ANCOVA showed no significant 
difference between the micronutrient and placebo groups in eight-week scores of diet 
quality when controlling for baseline scores (p=0.57). An unpaired t-test showed no 
differences between pre and post scores for the micronutrient group (p=0.64) and the 
placebo group (p=0.77). 
Alcohol Use Disorders Identification Test- Consumption  
Participants completed the AUDIT-C at baseline and eight weeks post-quit. A one-
way ANCOVA was conducted to compare the effectiveness of the placebo or micronutrients 
on change in AUDIT-C scores whilst controlling for baseline scores. The ANCOVA showed no 
significant difference between the micronutrient and placebo groups in eight-week scores of 
AUDIT-C when controlling for baseline scores (p=0.70). An unpaired t-test showed no 
differences between pre and post scores for the micronutrient group (p=0.22) and the 
placebo group (p=0.45).  
Capsule compliance 
There was no difference between groups for the ITT sample in capsule compliance 
(consuming ≥80% of their capsules; p=0.27), with 35% (n=20) of the micronutrient group 
and 40% (n=20) of the placebo group fully capsule compliant for the full study (12-weeks). 
Analysis of participants who did not drop-out at 12-weeks post-quit (n=43) revealed no 
differences between groups (p=0.20) in capsule compliance, with 83% (n=20) of the 





The frequency of the most common treatment emergent side-effects did not 
significantly differ between micronutrient and placebo groups (p>0.05). Although, more 
participants in the micronutrient group reported blurred vision and constipation, with this 
difference nearing significance. However, no participants dropped out of the study due to 
side effects, reporting them to be no worse than ‘mild’. The most common side effects 
reported for both groups were change in appetite (n=28, 26%) and weight gain (n=25, 23%; 
Table 4.13). 
Table 4.13. Treatment-emergent adverse side effects reported by at least 5% of participants 






Dry mouth 4 (7.0%) 10 (20.0%) 0.40 
Urinary retention  4 (7.0%) 4 (8.0%) 1 
Blurred vision  7 (12.3%) 1 (2.0%) 0.08 
Constipation  8 (14.0%) 3 (6.0%) 0.08 
Sedation  7 (12.3%) 9 (18.0%) 0.60 
Sleep disruption  6 (10.5%) 9 (18.0%) 0.63 
Nightmares 6 (10.5%) 8 (16.0%) 0.77 
Change in appetite  13 (22.8%) 15 (30.0%) 0.70 
Weight gain  13 (22.8%) 12 (24.0%) 0.86 
Headache 8 (14.0%) 9 (18.0%) 0.58 
Nausea 8 (14.0%) 10 (20.0%) 0.61 
Gastrointestinal disturbance 8 (14.0%) 7 (14.0%) 0.13 
Abdominal pain 7 (12.3%) 12 (24.0%) 0.73 
Loss of libido 8 (14.0%) 6 (12.0%) 0.11 
Agitation  8 (14.0%) 9 (18.0%) 0.66 
Anxiety  5 (8.8%) 11 (22.0%) 0.20 
 
The following chapter contains the discussion and conclusions from study two. A summary 






Chapter 5. Discussion Study Two 
Study two extended the serendipitous findings of Harrison et al. (2013) and the 
single-case research of study one as a fully-blinded RCT to investigate the use of a broad-
spectrum micronutrient combined with a free phone and on-line counselling/support 
service (Quitline NZ) for smoking cessation, reduction of cigarettes/day and withdrawal 
symptoms, and improvement of psychological symptoms associated with withdrawal. This 
discussion will highlight the hypotheses of study two, summarise the key findings and 
whether these support the hypotheses, and if they are consistent with previous research 
including study one. Strengths and limitations of study two will be addressed along with 
future research recommendations. The chapter will end with a summary of the current 
thesis.  
5.1 Hypotheses of study two 
 Based on the tentative theory that broad-spectrum micronutrient treatment may 
improve brain function, and the limited research supporting nutrient supplementation to 
relieve stress, withdrawal symptoms, and quitting addictive drugs, the following hypotheses 
were formed for study two (as outlined in section 4.1).  
1) Quit attempts and rates will be higher in the micronutrient + Quitline group versus 
the placebo + Quitline group at each study waypoint after quit date.    
2) Withdrawal symptoms and craving following a quit attempt will be smaller for the 
micronutrient + Quitline group versus the placebo + Quitline group.  
3) Cigarettes/day after metabolic adaptation to the capsules will be less for the 
micronutrient + Quitline group versus the placebo + Quitline group.  
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4) Self-efficacy of quitting and positive mood will be higher, and negative mood will be 
lower in the micronutrient + Quitline group versus placebo + Quitline at each study 
waypoint after quit date.  
5) Dropout rates will be lower in the micronutrient + Quitline group versus the placebo + 
Quitline group.  
5.2 Summary of key findings 
Hypothesis 1: Quit success  
Our primary prediction that taking micronutrients daily before and after a quit 
attempt would assist with continuous abstinence at 12-weeks post-quit for the ITT group, 
was not unequivocally supported, although the direction of the difference in quit rates at 12 
weeks between the groups (micronutrients = 28% versus placebo = 18%; OR=1.78) is 
consistent with beneficial effects of micronutrient treatment and with study one’s 12 week 
quit rates (viz, micronutrients = 33% versus placebo = 25%, OR=1.50). The NNT of 10 and 
quit rate for the micronutrient treatment at 12 weeks was comparable to varenicline 
(NNT=11 and quit rate at 12 weeks 28%) (Cahill et al., 2016; Cahill et al., 2014) and better 
than NRT (NNT=15 and quit rate at 12 weeks 17%) (Cahill et al., 2014; Ministry of Health, 
2007).  
 The hypothesis that the micronutrient group would make more quit attempts (≥24 
hours abstinence) and be more successful (≥three days) was not supported in the ITT 
sample. Although there was no statistically significant difference in the number of quit 
attempts made and their success between groups, the placebo group made more quit 
attempts and had more success at day three when compared to the micronutrient group. 
Conversely, the micronutrient group had higher rates of continuous abstinence at four and 
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eight-weeks post-quit in the ITT sample, although the difference was not statistically 
significant. 
Study two demonstrated in a sub-sample consisting of those who did not drop-out 
before their quit meeting but had varying degrees of compliance/adherence (the full 
intervention sample), that the micronutrient group had higher rates of quit attempts and 
success at each follow-up compared to the placebo group. The micronutrient group also had 
a significantly higher four week quit rate compared to the placebo group (66% versus 41%, 
OR = 2.76) in the full intervention sub-sample, which is comparable to the four week quit 
rate of bupropion hydrochloride (OR=2.13) and varenicline (OR=2.88) reported in a meta-
analyses (Cahill et al., 2014; Wu et al., 2006).  
Participants who followed study protocol and were compliant with taking their 
capsules were counted as being fully compliant, and their quit rates were analysed as a sub-
sample (the per-protocol sample). Analysis of the per-protocol sample showed that the 
micronutrient group had significantly higher quit rates compared to the placebo group at 
four (83% versus 57%; OR=3.60) and eight weeks post-quit (81% versus 50%; OR=4.25). The 
micronutrient group also had higher number of quit attempts, and success at three days and 
12-weeks, but this difference was not statistically significant. The higher quit rates observed 
in the full intervention and per-protocol sub-samples for both groups is consistent with 
empirical evidence that suggests participants who adhere to study protocols and treatment 
tend to do better than those who do not adhere, irrespective of assignment to treatment or 
placebo (Montori & Guyatt, 2001).  
In summary, all significant quit rate results are in the same direction for the sub-
sample analyses, (i.e., participants who reported they took the capsules and attended the 
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quit meeting) and tentatively support that the micronutrient treatment increases the 
chance of abstinence of quitting. Furthermore, significant differences between the 
micronutrient and placebo groups were reported during the first eight weeks of quitting. 
Given what we know of the trajectory of tobacco withdrawal symptoms (American 
Psychiatric Association, 2013; Piasecki, 2006), the micronutrients were most successful in 
supporting quitting and abstinence during the acute withdrawal period, a highly desirable 
finding.  
Hypothesis 2: Withdrawal symptoms  
Modified Brinley plots with effect sizes were used to analyse changes in withdrawal 
symptoms before and after quitting. There was variability in withdrawal scores, both within 
and between groups, with significant results in different directions, consistent with the 
multi-dimensional nature of withdrawal symptoms observed in other research (Javitz et al., 
2012; Piasecki, 2006). However, the results still warrant discussion. Both the micronutrient 
and placebo groups showed the characteristic rise and fall pattern consistent with 
withdrawal symptoms (Piper et al., 2011), i.e., withdrawal symptoms peaked in the acute 
phase and then as time in the quit phase increased, mean withdrawal symptoms decreased. 
The results further support the need for adequate smoking cessation interventions in the 
first four weeks post-cessation when withdrawal symptoms are at their highest (American 
Psychiatric Association, 2013; Piasecki, 2006). 
The MNWS was used to give an overall rating of withdrawal symptom severity. The 
micronutrient and placebo groups significantly decreased in MNWS withdrawal scores at the 
pre-quit meeting, with the micronutrient groups having larger effect sizes. Post-quit, the 
placebo group had more participants decrease in MNWS withdrawal scores at each follow-
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up post-quit when compared to pre-quit scores, with a lower mean MNWS score at 12-
weeks post-quit. The steeper reduction of withdrawal observed in the placebo group post-
quit compared to the micronutrient group is not consistent with study one’s MNWS results 
and does not support our hypothesis that the micronutrient group would experience lower 
withdrawal symptoms measured using the MNWS post-quit compared to the placebo group.  
The WSWS allowed for the analysis of individual withdrawal symptoms using seven 
sub-scales. This is particularly useful given that the tobacco withdrawal syndrome consists of 
several different types of symptoms (Javitz et al., 2012). The results revealed considerable 
intra- and inter-individual variability observed across the different withdrawal symptoms 
comparable with other cigarette withdrawal research (Piasecki, 2006).  
The micronutrient group had lower scores of WSWS irritability at each study way-
point when compared to the placebo group, with a significant decrease in irritability scores 
at 12 weeks post-quit. This may tentatively support the use of a broad-spectrum 
micronutrient formula to reduce irritability, particularly when an individual is experiencing 
withdrawal, and may have contributed to more participants achieving abstinence in this 
group.  
The micronutrient group had more participants decrease in WSWS anxiety scores 
compared to the placebo group at the pre-quit follow-up; however, at each follow-up post-
quit, the placebo group had more participants decrease in anxiety scores when compared to 
pre-quit scores, and lower mean scores when compared to the micronutrient group. The 
decrease in anxiety for the majority of participants in the micronutrient group at pre-quit is 
consistent with the observed beneficial effects of micronutrient formulas to support anxiety 
and stress (Carroll et al., 2000; Kaplan, Rucklidge, Romijn, & Dolph, 2015; Rucklidge et al., 
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2012; Rucklidge et al., 2011; Schlebusch et al., 2000). However, the smaller mean anxiety 
scores observed in the placebo group post-quit may does support the use of micronutrients 
to decrease anxiety during withdrawal.  
More participants in the micronutrient group did not report increases in problems 
with concentration at each study way-point when compared to the placebo group, i.e., the 
placebo group reported higher scores of concentration difficulties associated with 
withdrawal, supporting the use of micronutrient treatment to protect against the 
concentration problems that are often observed during cigarette withdrawal. The results 
are consistent with the body of research supporting the use of micronutrient treatment to 
improve Attention-Deficit Hyperactivity Disorder symptoms (Gordon, Rucklidge, Blampied, 
& Johnstone, 2015; Rucklidge et al., 2018; Rucklidge, Frampton, Gorman, & Boggis, 2017; 
Rucklidge & Kaplan, 2014; Vesco, Young, Arnold, & Fristad, 2018). ADHD is diagnosed when 
a person has difficulty with inattention and/or hyperactivity and impulsivity (American 
Psychiatric Association, 2013), and although there are differences between inattention and 
decreased concentration the two are often referred to interchangeably, as concentration is 
sustained attention (Anderson, 2005).  
Both the micronutrient and placebo groups had a similar pattern of WSWS increased 
appetite scores, with the majority of participants in both groups increasing appetite at each 
study way-point. High levels of increased appetite (as a withdrawal symptom) after smoking 
cessation often lasts longer (more than 10 weeks) when compared to other withdrawal 
symptoms (Gross & Stitzer, 1989), therefore, this withdrawal symptom may require a longer 
treatment. Smoking and nicotine directly affect glucose metabolism and body weight as a 
result of changes in metabolism. Post-cessation weight gain has been reported to be one of 
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the main reason why smokers, especially women, fail to initiate smoking cessation or 
relapse after a quit attempt (Siahpush et al., 2014).  There are no substantial data showing 
that any smoking cessation approach is effective at limiting post-cessation weight gain and 
increase in appetite (Siahpush et al., 2014). Smoking cessation approaches that account for 
increased appetite and weight gain during the first six months of cessation must be 
considered in order to increase the chance of long-term abstinence (Harris, Zopey, & 
Friedman, 2016).     
The placebo group had more participants reliably improve in insomnia at the pre-
quit follow-up when compared to the micronutrient group. At four-weeks post-quit the 
micronutrient group had more participants improve in insomnia; however, at eight and 12-
weeks the placebo group showed more improvement when compared to pre-quit. There 
was no direction of change that consistently favoured either group across each study way-
point, and further research into smoking cessation interventions that support insomnia 
post-quitting is needed. Furthermore, although we asked participants to take the last dose 
of the capsules before bed, we did not monitor this. Micronutrient formulas have been 
reported to improve mood and negatively effect sleep if taken late at night (Kennedy et al., 
2010; Sarris et al., 2012), it is possible that this has occurred.  
The micronutrient group had more participants reliably improve in low mood scores 
at each study way-point compared to the placebo group. This supports the substantial body 
of literature supporting the use of micronutrient supplements to improve mood symptoms 
(Benton et al., 1995; Gariballa & Forster, 2007; Gosney et al., 2008; Harris et al., 2011; 
Kennedy et al., 2010; Lewis et al., 2013; Mech & Farah, 2016; Sarris et al., 2012). Given that 
smokers often report a desire for relief from negative affect as a primary reason for smoking 
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and often attribute relapses to acute negative affect (Kahler et al., 2015; Piasecki, 2006), this 
finding is particularly important. Furthermore, the improvement in low mood may have 
supported the higher abstinence rates in the sub-samples (full intervention and per-
protocol) micronutrient group.  
The micronutrient group had more participants decrease in WSWS urge to smoke 
compared to the placebo group at the pre-quit follow-up. At each follow-up post-quit, the 
placebo group had larger decreases in urge to smoke, with a significant decrease observed 
at 12 weeks post-quit. This does not support the hypothesis that those taking the 
micronutrient formula would have lower cravings (urge to smoke) due to withdrawal post-
quit compared to the placebo group. It is suggested that craving may be one of the most 
sensitive predictors for continued smoking and relapse (Piasecki, 2006; Van Zundert, 
Ferguson, et al., 2012), but the results do not support this as the micronutrient group had 
larger decreases in craving but lower quit rates. However, the majority of the research 
suggests that craving should continue to be an important target for smoking cessation 
treatment (Piasecki, 2006; Van Zundert, Ferguson, et al., 2012), and therapies that assist by 
decreasing craving for cigarettes during a quit attempt need to be explored.  
The MPSS consists of five single-item ratings for depressed mood, irritability, 
restlessness, hunger, and poor concentration. This brief scale was used for the self-report 
daily diary. The placebo group had lower mean MPSS scores at each study-waypoint 
excluding quit week one. This does not support the hypothesis that the micronutrient group 
would have lower daily withdrawal scores. The MPSS includes two six-point sub-scales to 
measure time spent craving cigarettes and strength of the cravings. There were no 
between- group differences in daily MPSS time spent craving and strength of craving 
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cigarettes. Both groups showed a significant increase at quit week one followed by 
decreases at each study way-point thereafter, consistent with  the typical strong increase in 
the first week after quitting and decreases after a lengthy period of abstinence (Piasecki, 
2006; Van Zundert, Ferguson, et al., 2012). Notably, the decreases in MPSS scores at each 
study way-point could also reflect the drop-out of those who were experiencing more 
withdrawal symptoms. 
As mentioned, effective smoking cessation treatments show an advantage over 
control treatments very soon after the quit date, within the 5–10 day window in which the 
relapse risk is highest. After this time, relapse curves from treatments and control groups 
tend to be parallel. This may suggest that the determinants of early and late relapse are 
qualitatively different (Piasecki, 2006). For the majority of the withdrawal measures used, 
the micronutrient treatment had lower daily withdrawal scores in the pre-quit phase and 
the first week of quitting. Given that a majority of participants in the micronutrient group 
(81%) and placebo group (74%) had cut down on cigarettes/day during the pre-quit phase, it 
is likely that they were experiencing withdrawal symptoms prior to the quit phase (Piasecki, 
2006). It is possible, therefore, that the micronutrient treatment may have been protective 
against the acute withdrawal symptoms and contributed to the larger quit rates observed in 
the micronutrient group in the full-intervention and per-protocol samples.  
Hypothesis 3: Cigarettes/day 
 The micronutrient group reported smoking fewer cigarettes/day compared to the 
placebo group at each study way-point. Within group analysis showed that both groups 
reduced consumption to a similar degree; however, there were substantial differences 
during the quit phase with the micronutrient group reporting a larger treatment effect and 
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reduction in overall cigarettes/day, supporting the hypothesis. This finding is particularly 
important, given research that shows reductions in cigarette consumption can increase self-
efficacy about controlling one’s smoking and promote cessation attempts resulting in higher 
chances of abstinence (Begh, Lindson-Hawley, & Aveyard, 2015; Broms et al., 2008; Falba, 
Jofre‐Bonet, Busch, Duchovny, & Sindelar, 2004; Farkas, 1999; Lindson‐Hawley et al., 2012; 
Polosa & Benowitz, 2011). A recent review of intervention trials found that for every 1% 
decrease in cigarettes per day (NRT assisted) there was a 3% to 4% increase in cessation 
success, and in the naturalistic studies quartile decreases in cigarettes per day were 
associated with 50% to 290% increased odds of quitting (Klemperer & Hughes, 2016). 
Furthermore, many smokers are able to maintain smoking reductions after a relapse 
predicting subsequent quit attempts and success (Piasecki, 2006). Additionally it should be 
noted that a systematic review analysed 10 studies, with a total of 3760 participants, 
comparing quitting abruptly versus reducing cigarettes before a quit date, and found 
comparable quit success rates in both conditions (Lindson‐Hawley et al., 2012).  
Several factors may contribute to smoking reduction promoting rather than 
deterring cessation. Reduction in cigarettes/day may be a more attainable and realistic goal 
compared to complete abstinence, and is more desirable than continued smoking at the 
current rate. Once achieved this may encourage efforts to achieve complete abstinence 
(Begh et al., 2015). Attempts to cut down in smoking are also viewed by smokers as steps 
towards quitting (Piasecki, 2006). Further, smoking reduction may reduce the severity of 
withdrawal and cravings when complete abstinence is achieved (Balfour, 2009), these being 
the main barriers to achieving abstinence and contributing to relapse (West et al., 2006). 
Furthermore, the neural processes produced by continued smoking lead to the 
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development of conditioned relationships between environmental stimuli and smoking 
(e.g., stress and smoking) and a reduction in smoking may interrupt these relationships so 
that the desire to smoke is less triggered by the previously conditioned cues (Balfour, 2009). 
Shaping uses differential reinforcement of successive approximation to change behaviour, 
thus gradually strengthening a desired behaviour. In the context of smoking, gradual 
reduction of cigarettes/day may induce intermittent reinforcement, encouraging and 
increasing the likelihood of complete abstinence (Begh et al., 2015).  
One of the primary reasons that smokers want to quit is to mitigate the health harms 
it causes (Bottorff et al., 2014; West, McEwen, Bolling, & Owen, 2001). A reduction in 
cigarettes/day reduces an individual’s risk of adverse health effects and mortality (Banks et 
al., 2015; US Department of Health Human Services, 2004). However, it is important to note 
that the risk of mortality in those who continue to smoke at a reduced rate is still much 
higher than for a non-smoker (Banks et al., 2015), and complete abstinence should still be 
the goal of any smoking reduction/cessation campaign. It is also possible that reductions in 
cigarette consumption are compensated for by changes in cigarette brands and/or smoking 
behaviour that maintain or increase nicotine (and other toxin) consumption (Benowitz, 
Jacob, Kozlowski, & Yu, 1986; Godtfredsen, Prescott, Vestbo, & Osler, 2006; Hurt et al., 
2000), limiting any conclusions about harm reduction and supporting the goal to achieve 
abstinence.   
Hypothesis 4: Psychological symptoms 
Modified Brinley plots demonstrated changes in psychological symptoms pre- and 
post-quit. There was considerable intra and inter-variation in the psychological measures 
assessed for both groups. The micronutrient group did not consistently have reduced levels 
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of measures of psychological state at each study way-point when compared to baseline, and 
therefore the results do not support our hypothesis. However, discussion of psychological 
symptoms may provide direction for future research and/or smoking cessation 
interventions.  
The majority of the participants increased in internal and external self-efficacy, i.e., 
one’s confidence to abstain from smoking at each follow-up when compared to baseline, 
with large (significant) effect sizes. Comparison between groups shows that the 
micronutrient group had larger effect sizes at four weeks post-quit, and the placebo group 
had larger effect sizes at 8 and 12 weeks post-quit. Given that increases in early self-efficacy 
in one’s ability to quit smoking predicts abstinence (Gwaltney, Metrik, Kahler, & Shiffman, 
2009), the large increases in self-efficacy may have contributed to the greater odds of 
quitting observed in the micronutrient group.  
The micronutrient group had a significant decrease in mean DASS-21 depression and 
anxiety scores at the pre-quit follow-up, with no significant reduction observed in the 
placebo group. The majority of participants in both groups did not reliably improve in DASS-
21 depression and anxiety scores at four-weeks post-quit. At 8 and 12 weeks post-quit the 
placebo group had more participants decrease in DASS-21 depression and anxiety scores 
when compared to baseline. This is not consistent with the WSWS low mood scores; 
however, the majority of participants scored below the clinical cut-offs and it is likely that 
there was a floor effect making the detection of change difficult, therefore the measure may 
have not been sensitive enough to detect change in participants state below the clinical cut-
off.   
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Both the micronutrient and placebo groups decreased in DASS-21 stress scores at 
each study way-point, with micronutrient treatment associated with larger decreases in 
stress scores at each follow-up post-quit when compared to baseline. These results are 
consistent with study one’s DASS-21 stress results and the beneficial effects of 
micronutrient treatment reducing stress (Carroll et al., 2000; Kaplan, Rucklidge, Romijn, & 
Dolph, 2015; Rucklidge et al., 2012; Rucklidge et al., 2011; Schlebusch et al., 2000), and may 
support the use of micronutrient treatment to reduce stress after a quit attempt.  
The majority of participants did not show a reliable improvement in DEMF positive 
and negative affect scores. More participants increased in positive affect in the 
micronutrient group when compared to the placebo group, consistent with study one’s 
results. Conversely, more participants decreased in negative affect in the placebo group 
when compared to the micronutrient group. Both groups moved in the direction of 
therapeutic change at each follow-up post-quit (increased positive affect and decreased 
negative affect), consistent with the trajectory of withdrawal symptoms that they are worst 
in the early stages of withdrawal (Piasecki, 2006; Van Zundert, Ferguson, et al., 2012). 
Hypothesis 5: Drop-out 
More participants withdrew from the study during the pre-quit phase in the 
micronutrient group. This was not due to reported side effects, rather, a variety of different 
reasons likely occurring due to chance. Drop-out rates were equivalent for the 
micronutrient and placebo groups after the capsule + Quitline intervention, and, despite 
explicit attempts to reduce drop-out (continued support after a relapse and the offer of a 
four-weeks supply of the micronutrient at the end of the study), nearly 60% of participants 
dropped out during the study. This is considerably more than other smoking cessation RCT 
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conducted in NZ, who report drop-out rates of 22-27% at six-months (Bullen et al., 2010, 
Walker et al., 2011, Walker et al., 2012). Propensity to drop-out was associated with 
smoking more at baseline, taking up regular smoking at a younger age, being more nicotine 
dependent, and having a lower quality diet. Targeting such individuals with more support 
during cessation attempts, such as by combining micronutrients with NRT and or general 
nutritional advice, should be among the issues investigated in future research. 
5.3 Research Strengths  
  The main strength of study two was the rigorous study design, which was placebo-
controlled, fully-blind, and randomised. The study was conducted in line with the CONSORT 
guidelines. The method of the study was prospectively registered on the Australia New 
Zealand Clinical Trials Registry, ensuring that the pre-specified primary outcome measure 
and other key design features of the study were not changed after registration. The efficacy 
analysis of the primary outcome and quit rates were completed by an independent 
statistician, and the secondary measures were analysed while the researcher was blind to 
treatment allocation. These measures were put in place with the aim to remove any 
potential bias.  
The trial had broad eligibility criteria and recruited a diverse sample of smokers, 
helping to ensure to generalizability of findings and adding to the external validity of the 
results. Particularly important in the NZ context was the participation of Māori (22%) at a 
rate higher than in the local (8%) and national (15%) population (New Zealand Statistics, 
2013), given that Māori have high rates of smoking (Ministry of Health, 2014) and suffer 
high rates of smoking-related illnesses (Bramley et al., 2005). The selection criteria may also 
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limit interpretation, given that the results may not generalise to populations such as 
teenage smokers, medically compromised smokers, or smokers on psychiatric medications.  
There were several strengths in the implementation of the current study. Firstly, the 
use of bio-chemical (CO) validation of self-reported abstinence provided additional 
assurance that the participants’ self-reports were accurate and is recommended by the 
Society For Research on Nicotine and Tobacco Subcommittee on Biochemical Verification 
(Benowitz et al., 2002). Analysis of the primary outcome was an intent-to-treat analysis 
where all participants lost to follow-up were considered to be smoking, thus making it a 
highly conservative analysis. Withdrawal symptoms, craving, and associated psychological 
symptoms were measured both at baseline, with treatment alone, and during quitting, and 
the modified Brinley plots allowed analyses of these scores both within and between 
groups. Assessment of pre- and post-quit change helps to determine both the withdrawal 
profile and whether a score reflects nicotine withdrawal symptoms, versus pre-existing 
traits and response styles (Piper 2011). Reported side effects were mild and might well have 
been associated with reductions in smoking (American Psychiatric Association, 2013; 
Hatsukami et al., 1984), and not systematically associated with group membership. This 
suggests that micronutrient treatment is a safe and readily available alternative for those 
who have experienced common side effects associated with smoking pharmacotherapy 
(Cahill et al., 2014; McRobbie et al., 2008; Polosa & Benowitz, 2011; Singh et al., 2011; 
Thomas et al., 2015; Wu et al., 2006). Participants were not successful at detecting their 
allocated treatment condition, which increases confidence that the results are not biased by 
participants detecting that they were not receiving the active treatment.  
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As with study one, the current study did not require participants to pay for the 
interventions, and approximate travel costs were covered with petrol vouchers, 
strengthening the current study as participants were not paying for an intervention that has 
not demonstrated efficacy in a large RCT study. This may also have limitations as the 
participants may not be able to pay for micronutrient treatment (or any smoking cessation 
treatments) in real-life settings. Furthermore, although the petrol vouchers were given as a 
way to cover travel costs only, they may have provided additional incentives for participants 
in enrol in the study and attempt to quit smoking. This may mean that the reported quit 
rates are inflated as incentives are a known smoking cessation intervention (Cahill, 
Hartmann-Boyce, & Perera, 2015). However, it would be expected that this would be 
comparable between groups due to the randomised design.  
5.4 Research Limitations and Directions for Future Research 
Although this research employed a rigorous design, with numerous measures taken 
to reduce bias and ensure reliable results, some limitations are inevitable in research, 
particularly when the research is exploratory and the aim is behaviour change. Some of the 
limitations of study two are discussed below, along with how these limitations of the study 
could be addressed in future research.   
A major limitation of the current research was that it didn’t follow all of the criteria 
proposed by the ‘Russell Standard’. The Russell standard are six standard criteria applied to 
trials of cessation aids where participants have a target quit date and there is face-to-face 
contact with researchers or clinic staff as proposed by West, Hajek, Stead, & Stapleton, 
2005. The six criteria are: (1) Follow-up for 6 or 12 months from the target quit date or the 
end of a predefined ‘grace period’, for example, a 2 week period at the start of the quit 
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attempt, after which the cessation period begins; (2) self-report of smoking abstinence over 
the whole follow-up period allowing up to five cigarettes in total; (3) biochemical 
verification of abstinence at least at the 6 or 12-month follow-up period; (4) use of an 
intention-to-treat approach, where data from all randomized smokers are included in the 
analysis, unless they are deceased or moved from an untraceable address; (5) following up 
protocol violators and using their true smoking status in the analysis; and (6) collecting 
follow-up data blind to smokers’ allocation to trial group (West et al., 2005). The current 
trials only followed up participants for three months post-quit attempt and did not allow for 
a grace period; however, biochemical validation was used. Participants were counted as not 
quit if they self-reported smoking cigarettes for ≥three days in a row, instead of the Russell 
standard of ≤five cigarettes in total. Intention-to-treat analysis was used for the primary 
outcome, and protocol violators (that were not lost to follow-up) true smoking status was 
used. Follow-up data (up to three months) were collected while researchers and 
participants remained blind to smokers’ allocation; however, there was no follow-up once 
participants completed the randomized phase. Furthermore, the current study had a 
biochemical validation of abstinence cut off set at ≤6ppm, as recommended by Bedfont (see 
www.bedfont.com). However, the Society for Research on Nicotine and Tobacco suggests a 
cut off of 8ppm (Benowitz et al., 2002). Although no participants who self-reported 
abstinence were between the 6-to-8ppm cut off, this could have contributed to a major 
limitation in the current study.  
The current study used 0.8 (80%) power to calculate sample size. The reason for 
selecting 0.8 and not 0.9 power was due to this research being exploratory (i.e., the first RCT 
using micronutrients in smoking cessation). A high power, and therefore larger sample size, 
can be unethical in exploratory research as it may waste participants’ time and subject them 
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to a non-efficacious intervention. Also, with larger sample sizes more resources are needed, 
and these may also be wasted. However, using a smaller power may have subjected the 
current research to be more prone to Type I or II error.  
A serious limitation of this study was the result of the higher than expected drop-out 
rate (60%), which reduced the sample size for full (12-week) participation, increased the 
width of the CIs, and reduced power to detect within and between-group differences. In 
addition to dropping out, participants might also not be compliant with the requirements to 
consume 12 capsules/day (a considerable challenge), and might also fail to comply with 
other study requirements such as keeping appointments and maintaining diary records. As 
Figure 4.2 shows, those who failed to consume their capsules also tended to drop-out. The 
three analyses reported – ITT, full intervention, and per-protocol – were thus differentially 
affected by drop-out, non-compliance, and non-adherence, with the ITT analysis the most 
and the per-protocol analysis the least affected. As Tables 4.6-4.8 shows, there is a fairly 
systematic trend for the OR for each comparison to increase from the ITT analysis to the 
per-protocol analysis, reflecting the systematic reduction in the influence of these factors on 
the outcomes reported.  
In addition to frank dropping out, compliance with the requirements to consume 12 
capsules/day was low for both the micronutrient (35%) and placebo (40%) groups, and 
compared with previous smoking cessation RCTs, which have reported adherence with 
instructions of approximately 80% (Anthenelli et al., 2016; Koegelenberg et al., 2014; Rose & 
Behm, 2016). Analysis of those participants who did not drop-out at 12-weeks post-quit 
revealed comparable rates of compliance with 83% of the micronutrient group and 90% of 
the placebo group capsule consumption compliant for the full intervention. Unfortunately, 
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due to the majority of participants who dropped out not replying to contact attempts, it is 
impossible to ascertain the reasons for drop-out. The consumption of 12 capsules a day, 
keeping up with study requirements such as keeping appointments and completion of the 
daily diary may have become tedious for some participants and only those with a high level 
of commitment to the micronutrient treatment may have been able to follow the full 
treatment regime.  
Since the study completion, the bioavailability of the formula has been improved, 
reducing the dose down to eight capsules per day which could be taken as two doses. This 
change could address adherence in future studies, as adherence is inversely proportional to 
frequency of the dose, and simpler dosing helps to maximise adherence to drug therapy 
(Osterberg & Blaschke, 2005). Furthermore, complex capsule taking regimens and failing to 
explain benefits and side effects of a treatment adequately contributes to poor adherence 
(Osterberg & Blaschke, 2005) and this was present in the current study due to the 
experimental nature of the trial and its fully-blinded nature. Future research should 
investigate the reasons for drop-out and efforts to reduce the drop-out should be taken. 
Future research should also aim to support participants to be compliant and adherent to 
study protocols.   
Having multiple dependent variables and measuring them at multiple study way-
points increased the chance of making a Type 1 error; however, all the significant efficacy 
results in the sub-sample analyses were in the same direction, namely, favouring 
micronutrient treatment over placebo, indicating that it is unlikely our findings were 
compromised by false positives (Bender & Lange, 2001). The presentation of effect sizes, 
confidence intervals, and clinical and practical significance (e.g., how many responded to 
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treatment) provides additional assurance regarding the clinical interpretation of our findings 
and follows an approach that is increasingly being encouraged (Cumming, 2013; Haig, 2014; 
Mark, Lee, & Harrell, 2016). Given that many of the observed efficacy effect sizes were small 
to medium, results should be considered encouraging, but preliminary, as is consistent with 
findings from exploratory studies. Further direct and systematic replication studies (Haig, 
2014) with larger samples (>600 participants), consistent with other recent smoking 
cessation RCTs conducted in NZ (Bullen et al., 2013; Walker et al., 2011; Walker et al., 2012), 
in double-blind randomised controlled designs are needed to determine if micronutrients 
consistently enhance quitting and abstinence for all smokers and to explore their full 
potential as a smoking cessation intervention.  
Some individuals who are trying to achieve abstinence may also benefit from 
combination therapy, e.g., the simultaneous use of different micronutrient and nicotine 
replacement therapies (NRT). Combination therapy can capitalize on the synergy obtained 
from two different mechanisms of actions (Ramon, Morchon, Baena, & Masuet-Aumatell, 
2014). Researchers also need to establish the optimal duration of treatment. Perhaps an 
intervention that is longer than 12 weeks would be of greater benefit for long-term 
abstinence. Both study one and two would have been strengthened by the analysis of 
Quitline use information. Although this analysis was outside of the scope of the current 
thesis it cannot be ruled out that the micronutrient and placebo groups had different 
amounts of Quitline use (an active intervention) and this may have skewed the outcome of 
the results.  
The approach used in the current study was to analyse withdrawal symptoms of the 
randomised sample, regardless of their smoking status. This has the advantage of increasing 
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the generalizability of the findings; however, the results may become contaminated because 
participants who smoke/lapse during withdrawal possibly have a decrease in their 
symptoms (Jorenby et al., 2006). Given that the placebo group smoked significantly more 
cigarettes than the micronutrient group during the first six weeks of treatment, this 
contamination may have varied across groups. Fiore, Smith, Jorenby, and Baker (1994) 
found that those who lapsed during a quit attempt reported weaker withdrawal symptoms 
than those who did not relapse. Future research could be supported by only assessing 
tobacco withdrawal in those who are completely abstinent after quit date, thereby 
eliminating the possibility of confounding effects from contamination due to smoking. 
However, this will also decrease the sample size and generalizability of the results, and the 
participants’ receiving placebo may be more likely to smoke and therefore excluded from 
the analyses, and this might result in the treatment condition being confounded with 
participant type.  
5.5 Conclusion 
 The current thesis presents two studies that are the first randomised controlled trials 
to investigate a broad-spectrum micronutrient formula to support smoking cessation, 
reduction of cigarettes/day, and decrease withdrawal symptoms. Over the two studies 
reported and the research by Harrison et al. (2013), the results tentatively support the use 
of micronutrients as a treatment to assist smoking cessation and reduce cigarette 
consumption. Researchers will continue to seek treatments for smoking cessation because 
of the high prevalence of smoking, its adverse health effects, side effects, and high relapse 
rates experienced by those using current quit-smoking methods. Treatment options that 
increase quitting rates, reduce cigarette consumption, and decrease withdrawal symptoms, 
214 
 
especially those treatments that are relatively inexpensive to implement and that have few 
side effects clearly deserve further exploration and research.  
Thesis Summary 
 
Over the two studies completed and the research by Harrison et al. (2013) into the 
effects of micronutrients on smoking, the results support a tentative conclusion that there is 
a replicated, small, positive treatment effect, favouring micronutrient treatment over 
baseline or placebo. The use of several effect sizes measures, and the agreement between 
them for quit rates and cigarette/day reduction, provides meaningful information regarding 
the clinical interpretation of our findings and follows an approach that is now strongly 
recommended (Biswas, 2017; Cumming, 2013; Gigerenzer, 2018; Gigerenzer & Marewski, 
2015; Hubbard, 2004; Hubbard & Lindsay, 2008; Kline, 2013; Lakens, 2013; Sedlmeier, 2009; 
Sullivan & Feinn, 2012; Wasserstein & Lazar, 2016). Given that many of the observed effect 
sizes were small to medium, the results should be considered encouraging, but preliminary, 
as is consistent with findings from an exploratory research such as this. Although there was 
considerable intra- and inter-variability in withdrawal symptoms, the results consistently 
show that the micronutrient supplement supported larger reductions in the majority of 
withdrawal and psychological symptoms during the pre-quit phase, when participants were 
attempting to reduce cigarettes/day. Further direct and systematic independent replication 
studies (Haig, 2014) with larger samples in fully-blind RCTs are needed to determine if 
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Appendix I. An Introduction to Single-case Research Design 
Single-case research designs (SCRD) are a family of research designs that specify the 
design, conduct, and analysis of true experiments (i.e., experiments that permit the drawing 
of causal inferences) where the focus is on single cases not group aggregates. Broadly 
speaking, SCRD can be characterised as quantitative ideographic designs, in contrast to the 
quantitative nomothetic designs used within the group-based Null Hypothesis Statistical 
Test (NHST) tradition or the qualitative ideographic designs used in qualitative social science 
research.  In this context, nomothetic refers to research that is focussed on group average 
results obtained from samples for the purpose of making inferences at the population level 
in order to support some highly general statement or law. Ideographic research is directed 
at understanding individuals in context (Lamiell, 1998). Formal SCRD emerged in the middle 
of the 20th C, based on principles articulated by late 19th and early 20th C physiologists, 
notably Claude Bernard and Ivan Pavlov. Bernard’s Introduction `a l’étude de la medicine 
expérimentale (Bernard, 1985; translated into English as An Introduction to the study of 
experimental medicine in 1927; Dover edition 1957) is often taken as the first systematic 
exposition of the principles of SCRD. Pavlov’s Conditioned Reflexes (Pavlov, 1927) is in the 
same tradition. 
Although single-case methods were widely used in psychology prior to World War II 
(Smith, Best, Cylke, & Stubbs, 2000), group research and group statistical inference became 
dominant in the course of what has been called the inference revolution of the 1950’s (Rucci 
& Tweney, 1980). This saw the wholesale adoption in psychology research of the factorial 
designs and inferential NHST analyses developed by R.A. Fisher, all of which required group 
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aggregate data (Blampied, 2013). Only recently has the hegemony of this tradition been 
challenged (Balluerka, Gomez, & Hidalgo, 2005; Nickerson, 2000; Wilkinson & Task Force on 
Statistical Inference, 1999) along with allegations of it being associated with many 
questionable research practices (see 
https://replicationindex.wordpress.com/2015/01/24/questionable-research-practices-
definition-detect-and-recommendations-for-better-practices/ ) and a replication crisis 
adversely affecting research in psychology and the health sciences (Gigerenzer, 2018). 
 Despite the dominance of NHST following the inference revolution of the 1950’s, 
SCRD continued to be developed and used, but only by a small minority of researchers. 
Skinner (1938), in founding the area known as the experimental analysis of behaviour (also 
known as the study of operant behaviour), espoused SCRD, and these were formalized for 
use in laboratory research by Sidman (1960). In time, applied researchers began to extend 
the principles of SCRD for use in applied settings, particularly in the assessment of therapy 
outcomes. The first systematic statement of applied SCRD was by Hersen and Barlow (1976; 
3rd Ed 2009), with other important contributions by Barlow, Hayes, and Nelson (1984) and 
(for health research) by Morgan and Morgan (2009). 
 The core element of SCRD is a single case. This is very frequently a single individual, 
but may be a unit composed of individuals sharing some common attribute, such as a 
family, class, team, or work group, etc (Valsiner, 1986). Once a target response/behaviour 
has been identified repeated measurement of the target as performed by the case can 
begin. Measures (ideally, many measures) are made under constant conditions to form a 
data time series in an experimental phase called baseline. The baseline phase serves to 
establish, for the particular case, the level of the response, any trends (increasing, 
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decreasing, cyclical), and the variability typical of the case. It is important for the integrity of 
SCRD that the baseline be stable (within limits), since the baseline time series serves as the 
comparison phase against which any change occurring in the subsequent treatment phase 
(the phase where the independent variable, IV, is experienced by the case) is assessed. 
Differences in the data paths between baseline and treatment phases permits the detection 
of any change occurring coincident with the application of the IV. All SCRD are composed of 
baseline-treatment phase pairs (cf the basic element of any group design, which is the 
control and the treatment group). For information about the full range of SCRD the reader is 
referred to Cooper, Heron, and Heward (2007) and/or to Barlow, Nock, and Hersen (2009). 
What follows is a brief statement of key features of two common SCRD. 
 The detection of change (if any) is the first essential step in any SCRD, but it is not 
sufficient to justify a conclusion that the IV caused the observed change; this requires 
replication. Replication may be achieved in different ways; these give rise to different forms 
of SCRD (Cooper, et al, 2009). Some replications may be accomplished within-case. For 
instance, in reversal (also known as withdrawal) designs, the IV is withdrawn after the initial 
baseline phase (said to be a reversal to baseline conditions) and then after a time (a second 
baseline phase) reintroduced in a second treatment phase. If the change observed initially 
then disappears, with the data returning to baseline levels coincident with the removal of 
the IV and then re-appears with the reintroduction of the IV, a causal inference that the IV 
caused the change is tentatively drawn. This conclusion may be made less tentative by way 
of additional direct replications with the same or other cases. Only when there is evidence 
of consistent replication of treatment effects is there some confidence established in the 
reliability of the IV as a cause of the observed behavioural changes. Reversal designs require 
that any desirable changes observed in the initial treatment phase be permitted to reverse 
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in the reversal phase, which may be impractical or even unethical. For that reason such 
SCRD are not commonly used to assess treatments of damaging behaviour, such as smoking 
or illicit drug consumption.  
Between-case replications are illustrated by one form of multiple-baseline design, 
namely the multiple-baseline across participants/cases design. This design is now the 
workhorse design for applied behaviour analysis and is suitable for investigating treatments 
for smoking and drug addiction because no treatment withdrawal occurs. In the design, 
several cases participate in the research, either recruited concurrently or sequentially (non-
concurrently). All cases enter the study in the baseline phase. When baseline stability is 
achieved for one case, the IV (treatment) is introduced for that case and a further time-
series of data in the treatment phase is recorded; all other cases remain in baseline. After 
some further baseline data has been recorded for the other cases, one further case is 
exposed to the IV, and so forth until all cases have experienced treatment. There are as 
many opportunities to observe change coincident with the introduction of the IV as there 
are case in the design (a minimum of three is required); consistent replication of change 
when and only when the IV is introduced is the basis for drawing the tentative inference 
that the IV caused the change, with the additional proviso that the different baseline phase 
lengths rule out some potential confounding variables, such as the change being due to 
regression to the mean, or to non-specific effects of participation in the study and/or 
exposure to measurement.  Again, further direct replication with additional cases helps 
strengthen the conclusion that the treatment reliably caused the change. 
The logic of SCRD is thus profoundly different from that of group designs with NHST. 
Participants are not simply regarded as samples from some putative population, serving 
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only to supply sample statistics for the estimation of population parameters. SCRD 
researchers are not interested in inferences about abstract population parameters, but 
about the extent, reliability and consistency of treatment-induced changes in target 
responses by individual cases. Replication, via direct, systematic, and clinical replication 
(Barlow, et al., 1984), is the key for drawing inferences. There is no equivalent of the 
computation of a p-value or its comparison to some criterion for statistical “significance”. 
There is, therefore, no equivalent in SCRD to the common confusion in group NHST research 
of statistical with clinical significance Wasserstein & Lazar, 2016), nor is there any direct 
equivalent to power calculations in SCRD, although the number and consistency of 
replications somewhat serves as a measure of power in SCRD.  
SCRD are rarely taught as part of the curriculum of research methods in psychology 
or the health sciences (Aiken, West, & Millsap, 2008; Friedrich, Childress, & Cheng, 2018). 
Nevertheless, they have received increasing recognition as valid ways to identify evidence-
based treatments in psychology and the health sciences. Twenty years ago Chambless and 
Hollon (1998) stated that properly conducted SCRD with sufficient independent replications 
were the equivalent of randomised-controlled trials (RCT) for determining the efficacy of 
psychological treatments.  Very recently, the American Psychological Association 
Publications and Communications Board Taskforce reported on standards for reporting 
qualitative research (Appelbaum, Cooper, Kline, Mayo-Wilson, Nezu, & Rao, 2018) and 
specified standards for SCRD along with those for other qualitative approaches such as RCTs 
and other clinical trials, and meta-analyses, supplementing work by Smith (2012) and the 
CONSORT statement of N=1 designs (Shamseer, et al., 2015). These several statements can 
be taken as evidence that, although generally poorly understood and seriously underutilised 
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Boron (as chelate) 0.2 mg 1.9 mg - - 
Vanadium (as chelate) 0.1 mg 1.0 mg - - 
Lithium orotate (as chelate) 0.07 mg 0.8 mg - - 
Nickel (as chelate) 0.002 mg 0.024 mg - - 
*reference values are given as Adequate Intake not RDA as RDA not available, †RDA varies 
with age 
Placebo Ingredients 15 capsules(mg) 
Fiber Acacia Gum  4500.00 
Maltodextrin  5938.50 
Cocoa Powder  60.0 















Appendix III. Information sheet Study one 
Nutritional supplements and withdrawal symptoms in smoking cessation 
Information Sheet for Participants 
 
Principal Investigator: Phillipa Newton (phillipa.newton@pg.canterbury.ac.nz) 
 
Other investigators: Assoc Prof Neville Blampied (Neville.blampied@canterbury.ac.nz), Assoc Prof 
Julia Rucklidge (Julia.Rucklidge@canterbury.ac.nz), 
 
What is the purpose of the study?  
This study is interested in investigating the impact of a micronutrient formula on symptoms 
of withdrawal and negative affect related to the withdrawal from nicotine dependence 
because of cigarette smoking.  The supplement we are studying is called Daily Essential 
Nutrients (revised version of EMPowerplus).  You are invited to participate in this study as 
you are a current smoker with no acute or chronic illness and are not currently on 
psychoactive medication.  
 
What would I have to do?  
If you agree to take part you will be asked to do the following: 
Over an eight month period you will be required to come in to the laboratory at the 
University of Canterbury 6 times, during these meetings you will fill out questionnaires to 
measure mood, withdrawal, anxiety sensitivity, and nicotine dependence. 
Monitor number of cigarettes smoked, and withdrawal and mood symptoms for 1, 2, or 3 
weeks while continuing with a normal smoking pattern.   
After the 1, 2, or 3 weeks take four capsules three times a day of a micronutrient or a 
placebo for four weeks.  On specific days during these four weeks you will monitor for 
cigarette smoking, withdrawal and mood.   
After the four weeks of taking the capsules you will attempt to quit smoking.  
For a six month period you will abstain from smoking while continuing to take four capsules 
three times a day. During the first month you will be required to monitor cigarette smoking, 
withdrawal and mood measures, after this you will only monitor the measures on the last 
week of each month.  
If you relapse in to a normal smoking routine before the end of the six months it will signal 
the end of your involvement in the study. 
What are the risks?  
You may experience some physical effects of withdrawal and/or become stressed during 
smoking cessation.  You may also experience some emotional distress of increased stress 
and negative affect during smoking cessation.  Quitline has many resources to minimize this 
risk.   
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Although we have no reason to suspect that this supplement can harm a physically healthy 
individual in any way, we will monitor you throughout the trial by asking you whether you 
are experiencing side effects or other changes to your physical or mental health.  
This type of supplement has been used by many people for many years without any 
unpleasant results reported. More recently, investigators in Canada have published a 
research paper outlining the safety of the micronutrients being studied. Data were 
assembled from all the known published and unpublished studies for the complex formula 
with the largest amount of published research in mental health. Biological safety data from 
144 children and adults were available from six sources: there were no occurrences of 
clinically meaningful negative outcomes/effects or abnormal blood tests that could be 
attributed to toxicity.  In our trials conducted here at Canterbury, we have assessed to date 
over 100 participants taking micronutrients for up to 4 months. There were no abnormal 
blood results that concluded that these micronutrients were having an adverse effect on 
liver and kidney function. Further, any side effects reported by this sample were temporary 
and mild. 
The most common ‘side effects’ are that previously-experienced constipation has been 
relieved and that the patient is sleeping better; i.e., positive side effects rather than adverse 
events. Other side effects that are reported by people taking micronutrients are headaches 
and stomach aches, although they are typically mild and transitory. These difficulties can be 
avoided by taking capsules on a full stomach, and so we suggest you always take your 
capsules with food and plenty of water. We will review side effects fortnightly and make a 
referral to a medical practitioner if necessary. We are happy to provide you with copies of 
the studies that have been done to date on EMP+. 
Micronutrients have the potential to interact with other medicines or drugs so you should 
avoid taking other medicines whilst on this treatment. For this reason, we are only including 
individuals in the study who are not being concurrently treated for their illness using 
prescribed medications. With respect to whether to take other medications, such as over-
the-counter medications to treat colds, flu, stomach upset and sleep problems, because 
they may interact with the micronutrients, you should first discuss with us or your 
pharmacist before use. Pain killers such as Aspirin, Nurofen, Brufen or Voltaren (the NSAIDs 
or non-steroidal anti-inflammatory drugs) should be avoided whilst on the micronutrients as 
they can affect the ability of your blood to clot, and hence stop bleeding from a cut, in a 
similar way to some of the ingredients of DSD. So for example, if you needed a pain killer for 
a headache, it would be safer for you to take Paracetamol or Panadol than Nurofen whilst 
on DSD.  
For safety reasons if you are, or become pregnant, you will have to withdraw from the study. 
Pregnancy should be avoided while taking the supplements. Further, we advise that during 
the trial, if relevant, you use appropriate contraception. 
Will I benefit if I take part? 
There may or may not be a direct medical benefit to you. Your withdrawal symptoms may 
be improved during the study, and negative affect levels may decrease, but there is no 
guarantee that this research will help you. The information we obtain from this study may 
help us to provide better interventions in the future for patients suffering from nicotine 
dependence.   
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Do I have to participate? 
If you decide not to participate in this study, or if you decide part-way through that you 
want to stop, you are certainly free to do so. This decision will not influence your ongoing 
health care in any way. Similarly, the study’s investigators might choose to end your 
participation in the study at any time for any reason. If new information becomes available 
that might affect your willingness to participate in the study, you will be informed as soon as 
possible.  
Will I be paid for participating, or do I have to pay for anything? 
Arrangements will be made with each individual participant to ensure that your 
transportation costs to the university (to meet with the investigator) and parking are 
covered. The capsules that you will take during the study will be provided at no cost.  
Will my records be kept private?  
I will take particular care to ensure the confidentiality of all data gathered for the study.  I 
will also take care to ensure anonymity in publications of the findings.   Neville Blampied 
and Julia Rucklidge will also have access to the data obtained during the study.  Data will be 
stored on password protected computer files on the UC system with paper records held in 
locked storage in the Psychology Department for 10 years.  It will then be destroyed.     
What happens after the study? 
If you feel you have benefited at the end of the trial, and want to continue taking the 
supplement, it is commercially available. We can provide you with the contact information 
so that you can continue to obtain it. Quitline will also be available after the end of the 
study.   
The results of this research will be reported in a thesis held digitally in the UC library, 
reported at professional and scientific conferences, submitted for publication in peer 
reviewed scientific articles, and may be publicized in the media.  You may request the 
reports from this study.  
Who can I contact during the study if I have a question?  
If you have any questions throughout the study you can contact me (details above) or the 
supervisors of this research by email Neville.blampied@canterbury.ac.nz and 
Julia.rucklidge@canterbury.ac.nz.  This project has received ethical approval from the 
University of Canterbury Educational Research Human Ethics Committee, and you should 
address any complaints to The Chair, Educational Research Human Ethics Committee, 
University of Canterbury, Private Bag 4800, Christchurch (human-ethics@canterbury.ac.nz)  
If you understand and agree to take part in the study please complete the attached consent 
form.    







Appendix IV. Consent form Study one  
Using Micronutrients in smoking cessation  
Consent form for participants 
 
Principle Investigator: Phillipa Newton  
 
Other Investigators: Profs Neville Blampied & Julia Rucklidge 
 
I have read and I understand the information sheet dated 10/06/2013 for volunteers taking 
part in the study designed to assess the impact of a micronutrient formula on quit success 
and the associated withdrawal symptoms and psychological measures during a smoking 
cessation intervention. I have had the opportunity to discuss this study. I am satisfied with 
the answers I have been given. I understand that taking part in this study is voluntary (my 
choice) and that I may withdraw from the study at any time and this will in no way affect my 
continuing health care. I also understand that I may withdraw any information already 
provided. 
 
I understand that my participation in this study is confidential and that no material which 
could identify me will be used in any reports on this study. I understand that the treatment, 
or investigation, will be stopped if it should appear harmful to me. I understand the 
compensation provisions for this study. I have had time to consider whether to take part. I 
know who to contact if I have any side effects to the study, or if anything occurs which I would 
consider a reason to withdraw from the study. I know who to contact if I have any questions 
about the study. 
 
I wish to receive a copy of the results                                                     YES/NO 
 
Participants should be advised that a significant delay may occur between data collection and 
publication of the results. 
 
I consent to being contacted 3 months after completion of the study regardless of whether I 
chose to continue to take the micronutrients and at that point I can choose whether to 
complete questionnaires.                                                                               YES/NO 
 
I consent to my name being placed in a separate database so that I can be contacted in the 
future should there be other studies for me to participate in with the understanding that I can 
choose whether to participate in such studies or not. 
YES/NO 




I consent to the use of my data for future related studies, which have been given ethical 
approval from a Health and Disability Ethics Committee                                        YES/NO 
 
 
I hereby consent to participate. 
 
  







Printed name:  
  
Signature of person 
who gained consent: 
 
  
Address for results:  
 
The person who may be contacted about the research is: 
 
Principle Investigator: Phillipa Newton, phillipa.newton@pg.canterbury.ac.nz 
 
Or: Julia Rucklidge & Neville Blampied  
 
A signed copy of this consent form has been given to you to keep for your records and 





















Appendix VI. Consent form Study two.  
 





Title of the research project: Using micronutrients in smoking cessation: A randomised 
controlled trial.  
 
Principal Investigator: Phillipa Newton 
 
Other Investigators: Profs Neville Blampied & Julia Rucklidge 
 
I have read and I understand the information sheet dated 5 February 2015 for volunteers 
taking part in the study designed to assess the impact of a micronutrient formula on quit 
success and symptoms of withdrawal from nicotine dependence. I have had the opportunity 
to discuss all four phases of the study and any questions I had have been answered. I am 
happy with the answers I have been given. I understand that taking part in this study is 
voluntary (my choice) and that I may stop taking part in the study at any time and this will in 
no way affect my continuing health care. I also understand that I may remove any information 
already provided. 
 
I understand that my participation in this study is private and confidential and that no material 
that could identify me will be used in any reports on this study. I understand that the 
treatment, or investigation, will be stopped if it should appear harmful to me. I understand 
the payment for this study and that all costs to me are covered. I have had time to consider 
whether to take part. I know who to contact if I have any side effects to the study, or if 
anything occurs which I would consider a reason to withdraw from the study. I know who to 




I agree to take part in phase one (baseline phase) of the study:     
YES/NO 
 
I agree to take part in phase two (pre-quit) of the study:     
YES/NO 
 
I agree to take part in phase three of this study, the quit phase where I will attempt to quit 
smoking to the best of my ability:         
YES/NO 
 
I agree to the phase four of this study, and open-label phase where I know I will be taking the 
active micronutrient, Daily Essential Nutrients       
YES/NO 
 
I wish to receive a copy of the results                                                     YES/NO 
 
Participants should be advised that a significant delay may occur between data collection and 
publication of the results. 
 
I consent to being contacted 3 months after completion of the study regardless of whether I 
chose to continue to take the micronutrients and at that point I can choose whether to 
complete questionnaires.                                                                               
YES/NO 
 
I consent to my name being placed in a separate database so that I can be contacted in the 
future should there be other studies for me to participate in with the understanding that I can 
choose whether to participate in such studies or not. 
YES/NO 
 
I consent to the use of my data for future related studies, which have been given ethical 








Signed:  Date:  
  
Printed name:  
  







The person who may be contacted about the research is: 
 
Principal Investigator: phillipa.newton@pg.canterbury.ac.nz 
 
Or: Julia Rucklidge and Neville Blampied 
 
A signed copy of this consent form has been given to you to keep for your records and 














Information Sheet for Participants 
 
Principal Investigator: Phillipa Newton (phillipa.newton@pg.canterbury.ac.nz) 
Mobile: 0273909422 
 
Other investigators: Professor Neville Blampied (Neville.blampied@canterbury.ac.nz), 
Professor Julia Rucklidge (Julia.Rucklidge@canterbury.ac.nz), 
 
What is the purpose of the study?  
This study is interested in investigating the impact of a micronutrient formula (vitamins and 
minerals) on quit success, symptoms of withdrawal and low mood related to the withdrawal 
from nicotine dependence because of cigarette smoking.  The supplement we are studying is 
called Daily Essential Nutrients. You are invited to participate in this study as you are a 
current smoker with no acute or chronic illness and are not currently on psychoactive 
medication (e.g. anti-depressants).  
 
What would I have to do?  
The study has four phases and if you agree to take part you will be asked to do the following 
during each phase (each visit to the University will take approximately an hour and free 
parking is provided): 
Baseline (1-2 weeks): You will be asked to come in to the University of Canterbury to 
complete baseline questionnaires on smoking history, nicotine dependence and withdrawal, 
and associated psychological measures. After the first meeting you will complete a daily 
diary for one-two weeks that asks questions on smoking habits and withdrawal.  Please do not 




Pre-quit (4 weeks): After the 2 baseline phase you will be asked to come back to the 
University and complete questionnaires again. The pre-quit phase is a four-week phase of 
taking the capsules (non-active placebo or active micronutrient) to prepare you for quitting 
smoking. You will titrate up to your full dose of 12 capsules per day over seven days, once 
you are at the full dose you take four capsules three times daily until the end of the four 
weeks. In the first and last week of this phase you will monitor for cigarette smoking and 
withdrawal using the daily diary. At the end of this phase you will receive an email of things 
to do to prepare you to quit smoking. 
Quit Phase (12 weeks*): After the four weeks of taking the capsules you will attempt to quit 
smoking on a target quit date.You will follow Quitline New Zealand’s structured program to 
help you quit as well as continuing to consume 12 capsules every day. The researcher will 
help you to set up with Quitline. For the first month of phase three you will complete a daily 
diary of smoking habits and withdrawal, every two weeks you will receive an email and text 
reminder to complete online questionnaires. At weeks four and eight of this phase you come 
back in to the University to complete questionnaires, receive more capsules, and have a talk 
with the researcher about your smoking cessation plan. During week 7 and week 11 of this 
phase you will complete the daily dairy asking about smoking and withdrawal, you will be 
reminded of this by a text message and email. If you smoke at any time please text, call, or 
email the researcher. If you smoke for 3 days in a row this is counted as having a relapse and 
the researcher will call you to make another quit date.  
What are the risks?  
You may experience some physical effects of withdrawal and/or become stressed during 
smoking cessation.  You may also experience some emotional distress of increased stress 
and negative affect (low mood) during from attempting to quit smoking.  Quitline has many 
resources to minimize this risk.   
 
Although we have no reason to suspect that this supplement can harm a physically healthy 
individual in any way, we will monitor you throughout the trial by asking you whether you 
are experiencing side effects or other changes to your physical or mental health. 
 
This type of supplement has been used by many people for many years without any 
unpleasant results reported. More recently, investigators in Canada have published a 
research paper outlining the safety of the micronutrients being studied. Data were 
assembled from all the known published and unpublished studies for the complex formula 
with the largest amount of published research in mental health. Biological safety data from 
144 children and adults were available from six sources: there were no occurrences of 
clinically meaningful negative outcomes/effects or abnormal blood tests that could be 
attributed to toxicity.  The company ‘Nutratek’ provides nutrients for other studies in the 
department of psychology at the University of Canterbury under the supervision of Julia 
Rucklidge and Neville Blampied. These studies have all received ethical approval through 
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either HEC or HDEC. In our trials conducted here at Canterbury, we have assessed to date 
over 100 participants taking micronutrients for up to 4 months. There were no abnormal 
blood results that concluded that these micronutrients were having an adverse effect on 
liver and kidney function. Further, any side effects reported by this sample were temporary 
and mild. 
 
The most common ‘side effects’ are that previously-experienced constipation has been 
relieved and that the patient is sleeping better; i.e., positive side effects rather than adverse 
events. Other side effects that are reported by people taking micronutrients are headaches 
and stomach aches, although they are typically mild and transitory. These difficulties can be 
avoided by taking capsules on a full stomach, and so we suggest you always take your 
capsules with food and plenty of water. We will review side effects fortnightly and make a 
referral to a medical practitioner if necessary. We are happy to provide you with copies of 
the studies that have been done to date on EMP+. 
 
Micronutrients have the potential to interact with other medicines or drugs so you should 
avoid taking other medicines whilst on this treatment. For this reason, we are only including 
individuals in the study who are not being concurrently treated for their illness using 
prescribed medications. With respect to whether to take other medications, such as over-
the-counter medications to treat colds, flu, stomach upset and sleep problems, because 
they may interact with the micronutrients, you should first discuss with us or your 
pharmacist before use. Pain killers such as Aspirin, Nurofen, Brufen or Voltaren (the NSAIDs 
or non-steroidal anti-inflammatory drugs) should be limited whilst on the micronutrients as 
they can affect the ability of your blood to clot, and hence stop bleeding from a cut, in a 
similar way to some of the ingredients of DEN. So for example, if you needed a pain killer for 
a headache, it would be safer for you to take Paracetamol or Panadol than Nurofen whilst 
on DEN.  
 
If you need to take an antibiotic or antifungal agent orally at any time during the trial, please 
let us know. We ask this because antibiotics and antifungal drugs may interfere with the 
absorption of the micronutrients. You will be asked to not try any alternative medicines or 
other forms of therapy until after completing this study. 
 
For safety reasons if you are, or become pregnant, you will have to withdraw from the study. 
Pregnancy should be avoided while taking the supplements. Further, we advise that during 




Will I benefit if I take part? 
There may or may not be a direct medical benefit to you. Your withdrawal symptoms may 
be improved during the study, and your mood may improve during your quit attempt, but 
there is no guarantee that this research will help you. There is a chance you may receive a 
placebo (a non-active capsule), this is a double blind study so both you and the researcher 
will not know whether you receive DEN or placebo.  All other aspects of the study will be 
identical for all participants and you may still benefit from Quitline New Zealand’s five-step 
program and being actively involved in a study.  The information we obtain from this study 
may help us to provide better interventions in the future for patients suffering from tobacco 
smoking addiction. 
Do I have to participate? 
Participation is your choice and you can stop at any time. 
If you decide not to participate in this study, or if you decide part-way through that you 
want to stop, you are certainly free to do so. This decision will not influence your ongoing 
health care in any way. Similarly, the study’s investigators might choose to end your 
participation in the study at any time for any reason. If new information becomes available 
that might affect your willingness to participate in the study, you will be informed as soon as 
possible.  
 
Will I be paid for participating, or do I have to pay for anything? 
Arrangements will be made with each individual participant to ensure that your 
transportation costs to the university (to meet with the investigator) and parking are 
covered. The capsules that you will take during the study will be provided at no cost.  
 
Will my records be kept private?  
I will take particular care to ensure the confidentiality of all data gathered for the study.  I 
will also take care to ensure anonymity in publications of the findings.   Neville Blampied 
and Julia Rucklidge will also have access to the data obtained during the study.  Data will be 
stored on password protected computer files on the UC system with paper records held in 
locked storage in the Psychology Department for 10 years.  It will then be destroyed.     
 
What happens after the study? 
If you feel you have benefited at the end of the trial, and want to continue taking the 
supplement, it is commercially available. The researcher will ask at the end of the study if 
you would like to purchase DEN and contact information so that you can obtain it will be 
given at this time. Quitline New Zealand (www.quit.org.nz) is a free service that will be 
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available after the end of the study if you would like to continue using their services.  The 
researcher will ask at the end of the study if you would like to come in to the laboratory to 
further discuss the five-step program and the services that Quitline offers. The username 
and password for Quitline made with the help of the researcher will not expire at the end of 
the study and you can continue to use this for support for smoking cessation.   
 
The results of this research will be reported in a thesis held digitally in the UC library, 
reported at professional and scientific conferences, submitted for publication in peer 
reviewed scientific articles, and may be publicized in the media.  You may request the 
reports from this study.  
 
Who can I contact during the study if I have a question?  
If you have any questions throughout the study you can contact me (details above) or the 
supervisors of this research by email Neville.blampied@canterbury.ac.nz and 
Julia.rucklidge@canterbury.ac.nz.  This project has received ethical approval from the 
University of Canterbury Human Ethics Committee and you should address any complaints 
to The Chair, Human Ethics Committee, University of Canterbury, Private Bag 4800, 
Christchurch (human-ethics@canterbury.ac.nz). 
 
If you understand and agree to take part in the study please complete the attached consent 
form.    
I am looking forward to working with you and thank you in advance for your contributions.  





























Appendix VIII Study Questionnaires  
 












Are you:  
Married 
     De-Facto 
     Single 
     Divorced 
     Separated 
 
 
Address: (please include suburb)  
 
Do you have an email address?       Yes / No                 Email address: 
 
Home phone number:  
 
Mobile phone number:  
 
Are you taking any medication on a regular basis?  
Yes / No  















Smoking History Questionnaire  
Please answer the following questions to the best of your ability.  
Age when you had your first puff of a cigarette? 
 
When did you begin regular smoking? (3 cigarettes a day for three consecutive days) 
 
How many cigarettes on average have you smoked per day over the last month?  
 
How many SERIOUS quit attempts have you made in your life? Note: a serious quit attempt 
lasted more than three days. 
 

























Study two baseline questionnaires 
First Name:  
Last Name:  
Middle name(s):  
What is your date of birth?  




What is your ethnicity?  
New Zealand European  
Maori  
Samoan  






What is your residential address?  
What is your email address?  
Please write down the number you prefer to be contacted on: 
Please write down another contact number:   
Are you:  
Married 
     De-Facto 
     Single 
     Divorced 
280 
 
     Separated 
  
What is your combined house hold income?  
If you have ANY acute or chronic illness(es) please list them below (this includes any mental 
illness) 
If you are taking ANY medication(s) on a regular basis please list them below (including 
psychoactive medication e.g. antidepressants or anti anxiety) 
Have you ever been on any psychoactive medication (antidepressants, anti-anxiety etc)  
At what age did you have your first cigarette?  
At what age did you begin regular smoking? (3 cigarettes a day for three consecutive days) 
How many cigarettes have you smoked per day over the last month?  
How many SERIOUS quit attempt have you made in your life? (lasted more than three 
days)?  
How many of these quit attempts last SIX months or over?  
Are you currently taking any medications for smoking cessation or on nicotine replacement 
therapy (nicotine patches, e -cigarettes or lozenges)?  















Side Effects Questionnaire  
Please indicate if, in the last 2 weeks, you have experienced any of the following symptoms. 
 
Dry mouth   
 
Urinary retention  
 










Change in appetite 
 
Skin rash  
 








Abdominal pain  
 
Inability to achieve an erection  
 
Inability to achieve an orgasm  
 








If you have experienced any of these symptoms, what action did you take to remedy them?  
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